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The Genetics and Biochemistry 
of DNA Mismatch Repair 
and Implications for Carcinogenesis

Genome Stability
DNA repair pathways protect cells from genomic instability, and the organism from aging 
and cancer. To preserve the information encoded by the DNA of a cell it is essential to 
prevent mutations. Mutations can arise as a consequence of unrepaired exogenous and 
endogenous damage to DNA. A plethora of mechanisms is available to cells to either 
repair or tolerate DNA damages  (reviewed in [Hoeijmakers, 2009; Jackson and Bartek, 
2009; Ciccia and Elledge, 2010]. Though DNA damage is a major threat to the genome, 
its integrity can also be threatened by DNA replication. The fidelity of DNA replication is 
ensured by several factors. First, the main replicative polymerases δ and ε display a high 
degree of nucleotide selectivity, misincorporating at a frequency of only approximately 10-4 
to 10-5 [Iyer et al., 2006; Arana and Kunkel, 2010].  Then, the proofreading activities of 
polymerases δ and ε can remove most misincorporations, increasing replication fidelity 
to 10-7 per basepair per replication round. Residual misincorporations are detected and 
corrected by the DNA mismatch repair (MMR) system. The orchestrated action of these 
pathways ensures extremely accurate replication fidelity [Arana and Kunkel, 2010], and 
protects organisms from cancer development [Hanahan and Weinberg, 2000, 2011].
DNA Mismatch Repair
MMR is an evolutionary conserved postreplicative DNA repair system that corrects (spontaneous) 
replication errors, such as base-base mispairs and insertion/deletion loops (IDLs; reviewed in 
[Hsieh and Yamane, 2008; Li, 2008; Jiricny, 2013]). Besides its role in replication fidelity, MMR 
has also been implicated in homologous recombination, in somatic hyper mutation, in triplet 
repeat expansion, crosslink repair and in the response to various DNA damaging agents such 
as methylating agents, oxidative agents, ionizing radiation and nucleotide analogs [Stojic et al., 
2004; McMurray, 2010; Deans and West, 2011; Jiricny, 2013 and references therein]. 
During the repair of replication errors in eukaryotes, the MMR pathway is initiated 
by the recognition of a mismatch or IDL by either the heterodimeric MutSα, consisting 
of the homologous MSH2 and MSH6 proteins, or the MutSβ heterodimer consisting of 
MSH2 and MSH3. These early factors in MMR are named after their bacterial homolog 
MutS (MSH=MutS Homolog) that was first described over 40 years ago [Cox et al., 1972]. 
The MutSα complex is responsible for the recognition of base-base mispairs and small 
IDLs, whereas MutSβ is responsible for the redundant repair mainly of larger IDLs. Each 
subunit of MutSα and MutSβ consists of five major domains, which have been referred 
to as a mismatch binding domain, a connector domain, a lever domain, a clamp domain 
and an ATPase domain (Figure 1A and B; [Warren et al., 2007; Gupta et al., 2012]). These 
domain names are analogous to the domains described in the bacterial MutS [Lamers et al., 
2000; Obmolova et al., 2000]. The term ”mismatch binding domain” is, in fact, a misnomer 
for MSH2 and MSH3, as only the mismatch binding in MSH6 actually binds mismatches. 
Both the MutSα and the MutSβ complex very much resembe a Θ-like structure.  The (mis)
matched DNA is in the upper channel, the lower channel is empty, and MSH2 and MSH6 













The MutSα heterodimer is recruited onto chromatin through a PWWP motif in the 
N-terminus of MSH6, by interacting with the histone mark H3K56me3 [Li et al., 2013]. In 
addition, MutSα complexes are targeted to newly synthesized DNA by being a constitutive 
part of replication factories in a manner depending on an interaction with PCNA (Figure 
2; [Iyer et al., 2008; Hombauer et al., 2011a]). Also, MMR proteins only function when 
expressed during replication and not after, in support of the coupling between replication 
and MMR [Hombauer et al., 2011b]. Upon mismatch binding, MSH6 makes contact with 
the mismatch through a conserved Phe-X-Glu motif in the mismatch binding domain in 
its N-terminus. The phenylalanine residue is inserted into the DNA helix and stacks against 
the mispaired nucleotide, which results in kinking of the DNA by 60o [Lamers et al., 2000; 
Obmolova et al., 2000; Warren et al., 2007]. MSH3 lacks a Phe-X-Glu motif but it contacts 
the backbone of the DNA through several amino acids its N-terminus [Gupta et al., 2012]. 
All MutS homologs are ATPases that carry a Walker ATP motif, a common motif among 
DNA repair proteins, in their C-terminal ATPase domains. They are members of the ATP 
Binding Cassette (ABC) transporter ATPase superfamily (Figure 1A; reviewed in [Holland 
and Blight, 1999]). Each MutS homolog heterodimer has two composite nucleotide binding 
sites, one on each subunit. Both contain a Walker A and Walker B motif from one subunit, and 
an ABC signature motif from the other subunit. The binding sites are nonidentical: in MutSα, 
MSH6 has high affinity for ATP, whereas MSH2 has a higher affinity for ADP [Antony and 
Hingorani, 2003; Antony et al., 2006]. After the MutSα complex binds a mismatch through 
its mismatch binding domain, the complex exchanges ADP for ATP and undergoes an ATP-
induced conformational change, converting the heterodimer into a sliding clamp [Gradia et 
al., 1999], which can freely move along the DNA helix contour [Gorman et al., 2007].
After DNA mismatch binding MutSα (or MutSβ) recruits the MutLα heterodimer 
(consisting of MLH1-PMS2; Figure 2). This complex is thought to act as a matchmaker 
protein between the MutSα mismatch recognizing complex and the downstream 
exonuclease. Both MLH1 and PMS2 contain an N-terminal ATPase domain and a 
C-terminal dimerization domain, connected by a linker (Figure 1C). MLH1 (Mut L 
Homolog 1) belongs to the superfamily of GKHL (gyrase II/Hsp90/histidine kinase/MutL) 
ATPases (Figure 1C and D). MutLα is partially redundant with another heterodimer, MutLγ 
(consisting of MLH1-MLH3). However, MutLγ cannot fully substitute for MutLα, at least in 
vitro [Cannavo et al., 2005; Korhonen et al., 2008]. The MutLα complex helps to stabilize the 
ternary DNA·MutSα·MutLα complex. Like MutSα, MutLα has (weak) ATPase activity and 
undergoes sequential conformational changes after ATP binding (Figure 1C; [Sacho et al., 
2008]), but the relevance of these changes is still very poorly understood. 
Besides functioning as a matchmaker, MutLα is very important because of the endonuclease 
activity within the C-terminus of the PMS2 (Postmeiotic segregation increased 2) subunit. 
To direct MMR-mediated excision to the newly synthesized strand, MMR requires a strand 
discrimination signal that in vitro is a nick [Lahue et al., 1989; Constantin et al., 2005]. It 
has been proposed that lagging strand MMR is directed, at least in part, by 3’ or 5’ ends of 
Okazaki fragments [Pavlov et al., 2003]. MMR at the leading strand, in turn, partly depends 
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on small gaps induced after the removal of ribonucleotides from the nascent strand by RNase 
H2, which are fortuitously incorporated during replication by the leading strand polymerase 
ε [Ghodgaonkar et al., 2013; Lujan et al., 2013]. In addition to these RNase H2-induced 
gaps, additional signals may serve as strand a discrimination, such as the 3’ terminus of a 
leading strand. The 3’ terminus at the nascent strand dictates the polarity of the processivity 
factor Proliferating Cell Nuclear Antigen (PCNA) on DNA, which in turn determines the 
directionality of the nicking activity of MutLα on DNA [Peña-Diaz and Jiricny, 2010; Pluciennik 
Figure 1. Domains and crystal structures of mismatch repair proteins and complexes. (A) Schematic representation of 
domains in the primary protein structures of MSH2 and MSH6. Numbering reflects amino acid numbering. Domains 
are as published [Warren et al., 2007]. Of note, the mismatch binding domain in MSH2 does not bind mismatches 
(see main text). PCNA binding: PCNA binding motif [Hombauer et al., 2011a]. Phe-X-Glu: Mismatch binding motif. 
(B) As A, but for MLH1 and PMS2. Domains have been described in [Raevaara et al., 2005; Gueneau et al., 2013]. 
Endonuclease: Endonuclease motif [Kadyrov et al., 2006]. (C) Crystal structures of the human MutSα (MSH2/
MSH6; [Warren et al., 2007]), human MutSβ (MSH2/MSH3; [Gupta et al., 2012]) and S. cerevisiae MutLα (MLH1/













et al., 2010]. The endonuclease activity of the PMS2 subunit introduces new nicks on the 
nascent strand, 5’ of the mismatch [Kadyrov et al., 2006]. Such nicks serve as entry point for 
Exonuclease 1 (EXO1), a 5’-3’ exonuclease that carries out excision of the misincorporation-
containing DNA strand. In vitro reconstitution of MMR depends on EXO1 [Dzantiev et al., 
2004; Constantin et al., 2005] but, oddly enough, Exo1-/- cells have a less severe phenotype 
than Msh2-/- cells [Wei et al., 2003], suggesting that other exonucleases or mechanisms may 
substitute for EXO1 function. It has recently been shown that MMR, at least in vitro, can also 
occur independently from EXO1 through strand displacement by Polδ (Figure 2; [Kadyrov 
et al., 2009]). In addition, EXO1 is preferentially required for lagging strand MMR and not 
for leading strand MMR [Hombauer et al., 2011a], suggesting mechanistically distinct MMR 
events that differentially require EXO1. As the lagging strand provides an ideal substrate both 
for strand displacement and EXO1-mediated degradation, this latter finding is surprising.
Once the misincorporation-containing DNA strand is excised, the single stranded DNA 
patch is protected by the single-strand DNA binding protein Replication Protein A (RPA) 
and the strand is resynthesized by Polδ in the presence the clamp loader Replication Factor 
Figure 2. Sequential steps of canonical MMR. (A) MutSα is a constitutive part of replication factories through an 
interaction between the N-terminus of MSH6 and PCNA. (B) Mismatches are recognized by MutSα (left panel), 
while IDLs are recognized mostly by MutSβ. (C) Once a substrate is bound, the MutLα heterodimer is recruited. 
(D) The PMS2 subunit introduces nicks 5’ to the mismatch, creating a substrate for either strand displacement by 
POLδ or for EXO1-mediated strand removal. After the former, the flap is removed by a flap endonuclease. (E) After 
the latter, the resulting gap is filled by RFC, PCNA and POLδ, the nick is ligated, and repair is completed.
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C (RFC) that loads PCNA (Figure 2; [Longley et al., 1997; Dzantiev et al., 2004; Constantin 
et al., 2005]). Additional proteins possibly involved in MMR are HMGB1 [Yuan et al., 2004; 
Genschel and Modrich, 2009], RFX [Zhang et al., 2008] and PARP1 [Liu et al., 2011], but 
their roles are more elusive.
Discrimination by MutSα between matched and mismatched DNA in vitro is only ~5-30 
fold [Hays et al., 2005] and of all mismatches, only the G∙T mismatch is bound well by 
MutSα in Electrophoretic Mobility Shift Assays [Jiricny et al., 1988]. However, in in vitro 
MMR assays, all mismatches are repaired when embedded in perfectly paired DNA [Hays et 
al., 2005]. Repair of the C∙C mismatch is less efficient, but this mismatch is very efficiently 
removed by the proofreading activity of the replicative polymerases. Overall, the mechanistic 
basis of detecting mismatches in a large excess of matched DNA is still poorly understood. 
Mismatch discrimination may be a very complex process, ensured by several (kinetic) 
mechanisms and/or additional MMR factors [Labazi et al., 2009]. Multiple (ATP-controlled) 
conformational changes in MutSα may contribute to specificity. Also, the ATP-induced 
sliding along the DNA may provide only a short time window for MutLα to bind, providing 
a “kinetic control” of heteroduplex binding. Furthermore, ATP-induced conformational 
changes in MutLα may also contribute to mismatch specificity [Sacho et al., 2008].
Mutator Phenotype and Microsatellite Instability 
MMR increases replication fidelity by 100 to 1000 fold to one replication error per 109-1010 
nucleotides, and in this way protects cells from spontaneous mutations [Iyer et al., 2006]. 
Vice versa, the inactivation of MMR leads to a mutator phenotype in which spontaneous 
mutation rates are highly elevated. These elevated mutation rates affect the whole genome, 
including protein-encoding genes. 
MMR deficiency also results in microsatellite instability (MSI). MSI refers to size changes, 
often shrinkage, of genomic repetitive sequences (such as [CA]N, or [A]N; reviewed in [Boland 
and Goel, 2010]). This hyper mutable phenotype is caused by low processivity of the replicative 
polymerases on microsatellites. During replication of these loci, polymerases often have to be 
reloaded, a process that frequently induces IDLs. These IDLs are a substrate for MMR, which 
aids in the maintenance of the stability of microsatellites [Strand et al., 1993]. 
Tolerance of Genotoxic Agents
Besides recognizing mismatches and IDLs, MutSα is also capable of detecting and binding 
modified DNA bases, such as those induced by oxygen radicals [Mazurek et al., 2002; 
Macpherson et al., 2005], methylating agents [Duckett et al., 1996; Rasmussen and Samson, 
1996] or UV (but only when mispaired [Hoffman et al., 2005]). Cells deficient for MMR are 
tolerant to various genotoxic agents, such as the methylating agents N-Methyl-N-nitroso-
N′-nitroguanidine (MNNG) and Temozolomide, but also to nucleotide analogs such as 
6-thioguanine (6-TG; [Swann et al., 1996]) and Fluorouracil (5-FU; [Meyers et al., 2003]).
Of these drugs, the response of MMR proficient and deficient cells to the methylating agent 













others), a highly mutagenic lesion due to its efficient basepairing with thymine [Warren et 
al., 2006]. The finding that O6-methylguanines are the toxic lesions is substantiated by the 
fact that the detoxifying protein methylguanine-DNA methyltransferase (MGMT) protects 
the cells against MNNG-induced apoptosis [Kaina et al., 2007]. MMR deficient cells are up 
to a 100 fold more tolerant to MNNG compared with MMR proficient cells [Goldmacher 
et al., 1986; Kat et al., 1993; Stojic et al., 2005]. The investigation of the MMR-mediated 
response to MNNG has yielded two major models, that are not mutually exclusive, to explain 
these phenotypes. In the first model, generally referred to as the direct signaling model, the 
MMR-mediated response to methylating agents may be regulated in a direct manner, in the 
absence of MMR-mediated excision. In vitro the signaling kinase ATR/ATRIP, but not RPA, 
is preferentially recruited to O6meG·T mismatches on a covalently closed circular substrate 
in a MutSα and MutLα dependent manner. Also, ATR is activated to phosphorylate its target 
CHK1 in the presence of O6-meG·T mismatches and MMR proteins in vitro in the absence of 
excision, suggesting direct activation of signaling proteins (Figure 3, right panel; [Yoshioka 
et al., 2006]). This may be further supported by cellular data showing interactions between 
MutSα and ATR [Liu et al., 2009; Pabla et al., 2011], TopBP1, Claspin and CHK1, and between 
MutLα and TopBP1 and Claspin [Liu et al., 2009]. Liu et. al also showed binding of ATR, 
TopBP1 and CHK1, but not RPA, to chromatin after MNNG treatment in a MutSα and MutLα 
dependent manner. Oddly enough, this paper only shows recruitment of these factors but not 
their activation nor contribution in cell cycle responses. An interesting experiment would 
be to find/generate mutant MMR proteins that do not bind the signaling proteins, and see 
whether these interactions are required to induce apoptosis in response to MNNG. 
In case the direct signaling model is true, one would predict that DNA damage signaling 
and apoptosis are induced in the first cell cycle after treatment. In contrast to this, DNA damage 
signaling, G2 arrest and apoptosis are induced in the second cell cycle after treatment [Stojic et 
al., 2004; Mojas et al., 2007]. This finding is the basis of a second model, referred to as the futile 
cycling model. Since the O6-meG cannot properly form a Watson-Crick basepair with any other 
nucleotide, basepairing of O6-meG will often yield an MMR substrate. However, since MMR 
is directed only towards the newly synthesized strand, not the O6-meG in the parental strand, 
but its mispairing partner in the nascent strand is removed. Polymerase-mediated gap filling of 
this structure yields yet another MMR substrate, inducing multiple rounds of MMR [York and 
Modrich, 2006]. The notion that actual excision of the mismatch is required is supported by the 
fact that O6-meG induced cell death requires (the catalytic function of) EXO1 [Klapacz et al., 
2009; Schaetzlein et al., 2013]. After several attempts of futile repair, iterative MMR-induced 
gaps opposite the O6-meG are believed to be carried over to a subsequent S-phase, in which 
they becomes toxic DNA intermediates that will induce double-strand breaks when replicated 
(Figure 3, left panel; [Stojic et al., 2005; Mojas et al., 2007]). The idea that double strand breaks 
are the inducer of cell death in response to methylating agents is supported by the finding that 
both ATM [Debiak et al., 2004]  and BRCA1 [Yamane et al., 2007] are involved in the cellular 
response to methylation damage and that S. cerevisiae is relatively tolerant to MNNG-induced 




The accumulation of mutations in DNA is proposed to be a driving force for cancer 
development [Hanahan and Weinberg, 2000, 2011], and this is reflected in mouse models 
of MMR. These models have directly linked loss of MMR to cancer predisposition, and help 
to understand the etiology and tissue distribution of tumours (reviewed in [Wei et al., 2002; 
Edelmann and Edelmann, 2004; Taketo and Edelmann, 2009]).
In terms of cancer predisposition, the divergent phenotypes of Msh2-/-, Msh3-/- and 
Msh6-/- mice reflect the functional redundancy between MutSα and MutSβ. Msh2-/- mice die 
within a year due to strong cancer predisposition [de Wind et al., 1995, 1999]. The majority 
of these mice develop T-cell lymphomas. Msh6-/- mice are also tumor prone, but less than 
their Msh2-/- counterparts, as 75% of mice succumb within a year [Edelmann et al., 1997; de 
Wind et al., 1999]. Msh3-/- mice have no apparent phenotype, but in an Msh6-/- background, 
Msh3 loss accelerates tumorigenesis [de Wind et al., 1999]. 
Interestingly, inactivation of either Mlh1 or Pms2 leads to infertility [Baker et al., 1996; 
Edelmann et al., 1996]. Mlh1-deficient spermatocytes exhibit high levels of prematurely 
separated chromosomes and arrest in the first division of meiosis, suggesting involvement 
of Mlh1 in meiotic crossing over. Mlh1-/- animals are, like the Msh2-/- mice, highly cancer 
prone. Pms2-/- mice succumb to cancer later in life, suggesting functional redundancy of 
Figure 3. Possible mechanisms of the MMR-mediated response to methylating agents. Left panel: MutSα binds 
the mismatched, methylated basepair and triggers excision. Since the methylated nucleotide is in the parental 
strand, it is not excised and gap-filling creates a novel MMR substrate, which induces rounds of futile cycling. 
Gapped intermediates are transferred to the next cell cycle, in which they are replicated and generate a double-
strand break, which triggers apoptosis. Right panel: MutSα binds the mismatched, methylated basepair and 













Pms2 with other heterodimeric Mlh1 partners [Prolla et al., 1998]. Mouse knockouts of the 
exonuclease involved in MMR, Exo1, are predisposed to cancer but not as strong as Msh2-/- 
or Mlh1-/- mice. As mentioned before, this suggests that other exonucleases or mechanisms 
may substitute for Exo1 function [Wei et al., 2003].
The mouse and human MMR systems are very similar. This is reflected by the fact that 
the human MLH1 cDNA is able to complement MMR defects in mouse Mlh1-/- fibroblasts 
[Buermeyer et al., 1999]. While MMR deficient mice rapidly develop cancer, mice heterozygous 
for an MMR gene do not. Such mice are MMR proficient and have to stochastically lose 
their remaining wild type allele through Loss of Heterozygosity (LOH), and subsequently 
accumulate mutations for mutation-driven carcinogenesis. Due to the relatively short lifespan 
of mice, there likely is insufficient time for these events. In contrast, humans heterozygous for 
an MMR gene suffer from a cancer susceptibility, called Lynch syndrome.
Lynch Syndrome
Lynch syndrome (LS) is a hereditary cancer predisposition syndrome characterized by an 
increased risk of cancers, mainly of the gastrointestinal and genitourinary tracts (reviewed in 
[Lynch and de la Chapelle, 2003; Lagerstedt Robinson et al., 2007; Boland and Lynch, 2013]). 
LS is caused by inherited heterozygous mutations in one of the MMR genes (see below). Since 
the acquisition of a single affected allele through the germline is considered to cause LS, it is 
inherited in an autosomal dominant fashion. However, since LS patients require a second hit at a 
cellular level to induce a phenotype, LS is considered recessive cellularly.  It is the stochastic loss 
of the second, wild type, allele (Loss of Heterozygosity, LOH) that inactivates MMR in a subset 
of cells. This leads to an accumulation of mutations and the accelerated onset of cancer. 
Genetics of Lynch Syndrome
Lynch syndrome is typically caused by mutations in MSH2, MLH1, MSH6 or PMS2 [Fishel et 
al., 1993; Leach et al., 1993; Bronner et al., 1994; Nicolaides et al., 1994; Edelmann et al., 1997]. 
Mutations in MLH1 and MSH2 account for the majority of Lynch syndrome (42% and 33%, 
respectively; [Plazzer et al., 2013]). This is in line with the genetics of MMR, where MSH2 
and MLH1 are major players in the pathway. MSH6 and PMS2 are less important players in 
LS due to their redundancy with other MMR factors, and cover 18 and 7% of the MMR gene 
mutations, respectively [Gruber, 2006, Plazzer et al., 2013]. This distribution of mutations is 
probably subject to an ascertainment bias, as historically, highly penetrant families have been 
diagnosed first, leading to an overrepresentation of mutations in MSH2 and MLH1.
Besides the four core MMR genes, other genes such as MLH3 and EXO1 have also been 
implicated in LS, but their roles are less clear or controversial [Wu et al., 2001b; Peltomäki and 
Vasen, 2004]. Some MLH3 mutations are found in families with atypical LS features [Liu et al., 
2003], while other studies were unable to identify a correlation between LS and MLH3 [Lipkin 
et al., 2000]. EXO1 mutations were also found in families with atypical LS [Wu et al., 2001a]. 
In the last few years, evidence for epimutations as a cause of LS has emerged. The MSH2 gene 
can be inactivated in cis due to deletions of the 3’ region of its upstream gene TACSTD1, which 
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encodes the EpCAM protein. In tissues expressing the mutated TACSTD1 gene, transcription 
extends into MSH2, thereby resulting in methylation and silencing of the MSH2 promoter 
[Ligtenberg et al., 2009]. Carriers of such a mutation have an LS-like phenotype since they 
are heterozygous for an MMR gene-inactivating mutation. However, since MMR deficiency 
is limited to EpCAM expressing tissues, their tumor spectrum tends to be different (Table 1). 
As for MLH1, Mendelian inheritance of a constitutional MLH1 epimutation was shown to be 
induced by a c.-27C>A nucleotide variant within the 5’ UTR [Hitchins et al., 2011].
Characteristics of Lynch Syndrome
Lynch syndrome is noteworthy for its tumor spectrum, including cancers of the 
gastrointestinal tract such as colorectal, stomach, pancreas, biliary tract and small bowel 
cancer, but also endometrial, ovarian, ureter/renal pelvis, brain and/or sebaceous gland 
cancers. The risk of developing such tumors depends on both the tumor type as well as the 
affected gene (Table 1; [Stoffel et al., 2009; Bonadona et al., 2011; Engel et al., 2012]). The 
age of onset of colorectal cancer (CRC) for LS patients is on average 45 years old (versus 63 
years in the general population).
A hallmark of MMR deficient cancer is MSI, which is found in more than 80% of all 
Lynch syndrome-related tumors [de la Chapelle and Hampel, 2010]. MSI is typically found 
in tumors deficient for MSH2 or MLH1. MSH6 deficient tumors typically show lower levels 
of MSI, due to the functional redundancy of MutSα with MutSβ. Though most microsatellites 
are found within noncoding regions, some are found within tumor-suppressor genes such 
as TGFβRII and IGF2R, involved in growth, BAX, involved in apoptosis, and the DNA 
repair genes BLM, MRE11, RAD50, MSH3 and MSH6 [Giráldez et al., 2008]. TGFβRII 
for example, is inactivated in ~80% of MMR-deficient tumors [Markowitz et al., 1995; 
Table 1. Risk at Lynch syndrome-related tumors per genotype, as decribed in several studies.
Cumulative Risk, % (95% Conf. Interval)a
Gene
Cancer subtype MLH1 MSH2 MSH6 PMS2 EPCAM
Colorectal 41 (25-70) b 48 (30-77) b 12 (8-22) b 20 (11-34) d 75 (65-85) c
79 (68-90) c 77 (64-90) c 50 (38-62) c






15 (6-35) d 12 (0-27) c
Ovarian 20 (1-65) b 24 (3-52) b 1 (0-3) b NA NA
Stomach 6 (0.2-17) b 0.2 (0-10) b 0 b NA NA
Urothelium 0.2 (0-2.6) b 2.2 (0.6-8) b 0.7 (0-2.1) b NA NA
Small bowel 0.4 (0.1-3) b 1.1 (0-5) b 0 b NA NA
Biliary tract 1.9 (0-15) b 0.02 (0-0.2) b 0 b NA NA
NA: No data available. a Cumulative cancer risk at 70 years of Lynch syndrome associated cancers according 













Alhopuro et al., 2012]. MSI in these genes may be a bystander effect of MMR deficiency, 
but may also contribute to carcinogenesis. The MSI phenotype is also considered typical for 
the development of LS tumors, which are usually (near) diploid [Boland and Goel, 2010; 
de la Chapelle and Hampel, 2010]. This is in contrast with most sporadic CRCs that are 
aneuploid, and consistent with the hypothesis that MMR-deficient tumors are not driven by 
gross chromosomal instability (called the CIN phenotype; [Hanahan and Weinberg, 2000, 
2011]) but by their intrinsic mutator phenotype. 
In contrast to the knockout mice LS patients do not develop lymphomas, and develop 
tumors only in a subset of tissues. This seems a paradox, since MMR is active in all dividing 
cells. Several properties of MMR-deficient cells, together with the microenvironment of the 
colon, may explain the tumor tropism in LS patients [Chao and Lipkin, 2006; Hofstra et al., 
2008]. First, the exposure to mutagens from bile and food in the proximal colon [Medina-
Arana et al., 2012] may increase the mutation or LOH rate of the remaining wild type MMR 
allele in cells heterozygous for an MMR gene [Borgdorff et al., 2005]. In light of this, LS (or 
MSI) tumors are often found in the right-sided (proximal) colon, while CIN tumors are 
found more distally/left sided [Jass, 2004]. This can be explained by the mutagenicity of 
products secreted by the gallbladder, which is proximal of the colon. Second, MMR deficient 
cells are tolerant to various DNA damaging agents, giving these cells a survival advantage 
over neighboring cells that allows their clonal outgrowth [Toft et al., 1999]. In addition, the 
mutator phenotype of these MMR deficient cells is boosted by the hypermutability to the 
mutagens they are exposed to [Glaab et al., 1998; Toft et al., 1999].  The high proliferation 
rate of the epithelial cells of the colon provides an opportunity for mutations to accumulate. 
All of these factors may contribute to the tumor spectrum of LS patients [Kloor et al., 2012]. 
Diagnosis of Lynch Syndrome
Recognition of genetic susceptibility in suspected LS patients is critical for the clinical 
management of these patients [Vasen et. al, 2013]. LS patients comply to one of a specified 
set of criteria named the Revised Bethesda Criteria (Figure 4). These criteria are:
•	 CRC before 50 years of age.
•	 Presence of synchronous, metachronous colorectal or another LS-associated tumor 
(colorectal, endometrial, stomach, ovarian, pancreas, ureter/renal pelvis, biliary tract, 
small bowel, brain and/or sebaceous gland), regardless of age.
•	 CRC with MSI-H histology in a patient below 60 years of age.
•	 CRC diagnosed in one or more first-degree relatives with an LS-related tumor, one of 
which is diagnosed before the age of 50.
•	 CRC diagnosed in two or more first or second-degree relatives with LS-related tumors, 
regardless of age.
Once an individual complies to one of these criteria, that individual is clinically diagnosed 
as an LS patient. Even though the Revised Bethesda criteria are still commonly used, they 
lack sensitivity to diagnose less penetrant alleles, especially in genes such as MSH6 and 
18
CHAPTER 1
PMS2 [Sjursen et al., 2010; Moreira et al., 2012]. Besides the Besthesda criteria, alternative 
prediction models for MMR gene mutations have been described but these seem to perform 
similarly [Win et. al, 2013]. Several studies have shown that sensitivity can be increased by 
screening all CRC cases (independent of the Bethesda criteria) for MMR gene mutations, 
but this is not yet cost-effective [Hampel et al., 2005; Moreira et al., 2012]. 
Diagnosis of LS is completed only by pinpointing a genetic defect in an MMR gene in 
these patients, therefore, a clinical diagnosis per se does not formally confirm the syndrome. 
Even so, once LS is clinically diagnosed in the index patient, the index patient and all direct 
relatives enroll in interval screening procedures. These include colonoscopies every one to 
two years, to be able to detect colorectal carcinomas or their precursor lesions at an early 
stage. Such surveillance effectively reduces morbidity and mortality [Lagerstedt Robinson 
et al., 2007]. In addition, annual gynecological examination, vaginal ultrasound and testing 
for the tumor biomarker CA-125 in blood is recommended for women, due to the increased 
risk of endometrial carcinomas [Chen et al., 2007]. It is only a genetic diagnosis which 
enables the presymptomatic diagnosis of LS, and will enable the differentiation between 
family members with normal or increased cancer risk. As a consequence, unaffected 
relatives can be liberated from the burden associated with screening. 
Genetic testing in suspected LS patients is a stepwise process, which starts by testing the 
proband for MMR gene mutations. This is usually preceded by prescreening methods such as 
MSI testing and immunohistochemistry (IHC; Figure 4). As a pre-screening before genetic 
testing, nuclear expression of MMR proteins in tumors is visualized by antibody staining. IHC 
has the advantage that it indicates the MMR gene most eligible for sequencing analysis. The 
absence of expression of one of the MMR proteins is suggestive for a germline mutation within 
its corresponding gene and will indicate its sequencing. Only the loss of MSH6 or PMS2 can be 
visualized by itself, whereas loss MSH2 is always accompanied by MSH6 loss, and MLH1 loss 
is always accompanied by PMS2 loss [Hendriks et al., 2006]. This feature has been attributed to 
the loss of protein stability due to loss of dimer formation [de Wind et al., 1999; Hendriks et al., 
2006]. Therefore, loss of either MSH6 or PMS2 implies a mutation in its respective gene, loss of 
both MSH2 and MSH6 implies an MSH2 gene defect and loss of both MLH1 and PMS2 implies 
an MLH1 defect (Figure 4). IHC is considered a superior predictor of MMR gene mutations, 
with a sensitivity of 88-90% and a specificity of 84-99% [Niessen et al., 2006].
In case IHC is inconclusive, MSI is considered a good secondary selection criterion 
for MMR gene mutation screening, as MSI is seen in most of the LS-associated tumors [de 
la Chapelle and Hampel, 2010]. The sensitivity of MSI for an MMR gene mutation is 82% 
and the specificity is 70% [Niessen et al., 2006]. MSI is typically tested by PCR-amplifying 
five microsatellites: mononucleotide repeats BAT-25 and BAT-26 and dinucleotide repeats 
D2S123, D5S346 and D17S250 [Umar et al., 2004; Boland and Goel, 2010; de la Chapelle and 
Hampel, 2010]. Recently, though, a panel of the mononucleotide repeats BAT-25, BAT-26, 
NR-21, NR-24 and NR-27 was put forward as an alternative, as testing for dinucleotide 
repeats is relatively insensitive [Goel et al., 2010]. The size of these microsatellites is assessed 













Since not only LS tumors, but also 10-15% of all sporadic tumors express MSI, MSI is not 
highly specific for LS. MSI in sporadic cases is mostly a consequence of hypermethylation of 
the 5’CpG island of the MLH1 promoter, leading to transcriptional silencing [Herman et al., 
1998]. To screen against such tumors, MSI testing is often accompanied by testing for the 
BRAF V600E mutation. The presence of this mutation is associated with MLH1 silencing 
but not with LS, therefore, wild type BRAF together with MSI suggests a germline MMR 
defect (Figure 4; [Domingo et al., 2005]).
Implications of Lynch Syndrome Diagnosis
As described, confirmed LS patients benefit from tight surveillance programs. In addition, 
LS patients benefit from chemoprevention, such as daily aspirin intake which significantly 
reduces the incidence of cancer [Burn et al., 2011].  Both smoking and a high body-mass 
index (BMI) increase CRC risk in LS patients [van Duijnhoven et al., 2013]. Even though 
consumption of red meat and alcohol increase the risk of sporadic CRC, such an association 
has not been shown for LS patients [van Duijnhoven et al., 2013]. 
LS patients benefit from stratified therapy [Hewish et al., 2010]. For instance, CRC 
is treated with adjuvant chemotherapy that includes 5-FU, amongst others [Devaud and 
Gallinger, 2013]. Unfortunately, 5-FU only improves survival of microsatellite-stable tumors 
and not of MSI tumors [Ribic et al., 2003], in agreement with functional data that shows that 
MMR-deficient cells are tolerant to 5-FU [Meyers et al., 2003; Liu et al., 2008]. Therefore, 
LS patients do not benefit from standard treatment regimens. Novel approaches to treat 
MMR deficient cancers are mostly based on synthetic lethality. Silencing of PTEN-induced 
putative kinase 1 (PINK1) [Martin et al., 2011] or polymerase β (POLβ) [Martin et al., 2010] is 
synthetically lethal with MMR deficiency, as is treatment with the drug methotrexate [Martin 
Figure 4. The Lynch syndrome diagnosic tree. Adapted from [Coetzee et al., 2013].
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et al., 2009]. All of these treatments lead to an increase in oxidative stress, suggesting that 
oxidative DNA-damaging agents may be utilized to selectively target MMR-deficient cancers 
[Brierley and Martin, 2013]. Of note, methotrexate induces amplification of the DHFR locus 
and of the adjacent MSH3. This increases MSH3 protein levels, which sequesters MSH2 into 
MutSβ and decreases MutSα levels, impairing MMR [Marra et al., 1998; Chang et al., 2002]. 
Methotrexate selectively retards MMR deficient (tumor) cells, but as an adverse effect may 
also induce MMR deficiency in normal somatic cells. In addition, the high levels of oxidative 
stress in these cells may be toxic, but could also further boost the mutator phenotype in the 
absence of MMR. Additional (mouse) experiments are required to validate the therapeutic 
potential of PINK1/POLß silencing and/or methotrexate treatment.
In addition to the mentioned therapies, MMR-deficient tumors may be treated by a 
selective gene therapy. This method is based on combining a harmless prodrug with a gene 
encoding a suicide enzyme. The gene is out-of-frame, resulting from a microsatellite within 
the gene. Only in MMR-deficient (tumor) cells the microsatellite size decreases, the suicide 
gene is rendered in frame and the suicide enzyme is produced, converting the prodrug into 
a toxic metabolite that kills the cells [Ferrás et al., 2009].
Variants of Uncertain Significance
Once a variant MMR allele has been identified, its relevance to the disease phenotype 
needs to be determined. In several classes of mutations, such as deletions, frameshifts or 
truncating mutations, this is achieved relatively easy. These mutant proteins usually lose 
their function and/or are degraded by the proteasome. For mutations that do not lead to 
protein truncations, such as silent mutations, missense mutations, intron variants or small 
in-frame insertion/deletions, classification is not straightforward. These variants are often 
referred to as Variants of Uncertain Significance (VUS). The lack of classification of these 
VUS precludes diagnosis for carriers and their relatives. Therefore, when a suspected Lynch 
syndrome patient carries a VUS, all first-degree relatives currently enroll lifelong periodic 
screening, irrespective of their mutation status [Castells et al., 2009]. Due to the inability 
to diagnose such variants, genetic testing is often not offered to the proband’s relatives. The 
uncertainty of their disease status and the screening itself pose a physical and psychological 
burden on these families, but also a burden on the preventive health care apparatus. 
Currently, 34% of all variants in MMR genes comprise missense mutations [Plazzer 
et al., 2013]. Inactivating missense mutations may currently remain under detected. The 
current LS diagnosis protocol only implies an MMR gene for genetic testing once loss of 
expression of the respective protein is shown in IHC, even though inactivating missense 
mutations do not necessarily destabilize a protein [Drost et al., 2013]. Now that DNA 
sequencing technologies are becoming cheaper and more widely applied, the stringency at 
which MMR genes are selected for sequencing may lower, and the incidence of MMR gene 
VUS is believed to further increase [Heinen, 2010; Rasmussen et al., 2012]. The development 
and use of robust and accessible approaches to identify pathogenic VUS will enable the 













MMR gene VUS. Meanwhile, unaffected relatives of such carriers can be liberated from the 
burden associated with the uncertain pathogenicity of the VUS while unwarranted inflow 
into preventive healthcare systems is reduced [Hennink et al., 2013].
Classification of VUS
VUS may be classified using a large set of criteria, such as:
•	 Segregation of the VUS with disease within affected families, 
•	 De novo appearance of a VUS, 
•	 Presence of the VUS in individuals with a second, obviously pathogenic, MMR gene 
defect arguing against the pathogenicity of the VUS,
•	 Absence of the VUS in control sets, 
•	 Change in amino acid polarity or size,
•	 Presence of the VUS at a predicted splice site.
Unfortunately, such criteria cannot always be applied, since family- or segregation data are 
often absent, or families are too small to calculate segregation. Even if such correlations can 
be made, they do not provide definitive proof of pathogenicity. Segregation of a VUS, for 
example, only suggests that the allele segregates with disease. Therefore, additional genetic 
factors on that allele, other than the VUS, may cause cancer predisposition. Definite proof 
of pathogenicity can be provided by assays that test the functional activity of the VUS.
AIM OF THIS THESIS
The inability to assess the pathogenicity of VUS in DNA Mismatch Repair genes is a 
bottleneck in LS diagnosis. Lack of pathogenic assessment precludes diagnosis for carriers 
and their relatives, precludes targeted preventive and curative healthcare for carriers of 
pathogenic VUS and clutters preventive healthcare systems. For these reasons, there is a 
need for convenient functional assays for the diagnostic assessment of MMR gene VUS. 
This thesis focuses on the development such assays, while making use of the well-established 
genetics and biochemistry of the MMR pathway.
The thesis starts with a discussion of recent advances in functional analysis of Variants of 
Uncertain Significance in DNA Mismatch Repair genes (Chapter 2; [Rasmussen et al., 2012]). In 
Chapter 3, I describe the development of a functional assay based on measuring MMR activity 
of MSH2 and MSH6 VUS in vitro that allows for a rapid assessment of pathogenicity [Drost et 
al., 2012]. A similar assay is applied for VUS in MLH1 [Drost et al., 2010] and PMS2, which is 
discussed in Chapters 4 and 5, respectively. Chapter 6 describes a different approach for the 
functional analysis of MMR gene VUS. Here, a genetic screen is developed and experimentally 
validated that systematically identifies residues essential for in vivo function of Msh2 [Drost et 
al., 2013]. Finally, in Chapter 7 a similar genetic screen  is applied to Msh6, and the generated 




Alhopuro P, Sammalkorpi H, Niittymäki I, Biström 
M, Raitila A, Saharinen J, Nousiainen K, 
Lehtonen HJ, Heliövaara E, Puhakka J, 
Tuupanen S, Sousa S et al. 2012. Candidate 
driver genes in microsatellite-unstable 
colorectal cancer. Int J Cancer 130: 1558-1566.
Antony E, Hingorani MM. 2003. Mismatch 
recognition-coupled stabilization of Msh2-
Msh6 in an ATP-bound state at the initiation of 
DNA repair. Biochemistry 42: 7682-7693.
Antony E, Khubchandani S, Chen S, Hingorani MM. 
2006. Contribution of Msh2 and Msh6 subunits 
to the asymmetric ATPase and DNA mismatch 
binding activities of Saccharomyces cerevisiae 
Msh2-Msh6 mismatch repair protein. DNA 
Repair 5: 153-162.
Arana ME, Kunkel TA. 2010. Mutator phenotypes 
due to DNA replication infidelity. Semin 
Cancer Biol 20: 304-311.
Baker SM, Plug AW, Prolla TA, Bronner CE, Harris AC, 
Yao X, Christie DM, Monell C, Arnheim N, Bradley 
A, Ashley T, Liskay RM. 1996. Involvement of 
mouse Mlh1 in DNA mismatch repair and meiotic 
crossing over. Nat Genet 13: 336-342.
Boland CR, Goel A. 2010. Microsatellite instability 
in colorectal cancer. Gastroenterology 138: 
2073-2087.e3.
Boland CR, Lynch HT. 2013. The History of Lynch 
Syndrome. Fam Cancer 12:147-157.
Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, 
Huiart L, Longy M, Guimbaud R, Buecher B, 
Bignon YJ, Caron O, Colas C, Noguès C et al. 
2011. Cancer risks associated with germline 
mutations in MLH1, MSH2, and MSH6 genes 
in Lynch syndrome. JAMA 305: 2304-2310.
Borgdorff V, van Hees-Stuivenberg S, Meijers CM, 
de Wind N. 2005. Spontaneous and mutagen-
induced loss of DNA mismatch repair in Msh2-
heterozygous mammalian cells. Mutat Res 574: 
50-57.
Brierley DJ, Martin SA. 2013. Oxidative stress and 
the DNA mismatch repair pathway. Antioxid 
Redox Signal 18: 2420-2428.
Bronner CE, Baker SM, Morrison PT, Warren G, 
Smith LG, Lescoe MK, Kane M, Earabino 
C, Lipford J, Lindblom A. 1994. Mutation in 
the DNA mismatch repair gene homologue 
hMLH1 is associated with hereditary non-
polyposis colon cancer. Nature 368: 258-261.
Buermeyer AB, Wilson-Van Patten C, Baker SM, 
Liskay RM. 1999. The human MLH1 cDNA 
complements DNA mismatch repair defects in 
Mlh1-deficient mouse embryonic fibroblasts. 
Cancer Res 59: 538-541.
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein 
G, Olschwang S, Eccles D, Evans DG, Maher 
ER, Bertario L, Bisgaard ML, Dunlop MG et 
al. 2011. Long-term effect of aspirin on cancer 
risk in carriers of hereditary colorectal cancer: 
an analysis from the CAPP2 randomised 
controlled trial. Lancet 378: 2081-2087.
Cannavo E, Marra G, Sabates-Bellver J, Menigatti 
M, Lipin SM, Fischer F, Cejka P, Jiricny J. 2005. 
Expression of the MutL Homologue hMLH3 in 
Human Cells and its Role in DNA Mismatch 
Repair. Cancer Res 65: 10759-10766
Castells A, Castellví-Bel S, Balaguer F. 2009. Concepts 
in familial colorectal cancer: where do we stand 
and what is the future? Gastroenterology 137: 
404-409.
Cejka P, Mojas N, Gillet L, Schär P, Jiricny J. 
2005. Homologous recombination rescues 
mismatch-repair-dependent cytotoxicity of 
S(N)1-type methylating agents in S. cerevisiae. 
Curr Biol 15: 1395-1400.
Chang CL, Marra G, Chauhan DP, Ha HT, Chang 
DK, Ricciardiello L, Randolph A, Carethers JM, 
Boland CR. 2002. Oxidative stress inactivates 
the human DNA mismatch repair system. Am J 
Physiol, Cell Physiol 283: C148-54.
Chao EC, Lipkin SM. 2006. Molecular models for 
the tissue specificity of DNA mismatch repair-
deficient carcinogenesis. Nucleic Acids Res 34: 
840-852.
Chen LM, Yang KY, Little SE, Cheung MK, Caughey 
AB. 2007. Gynecologic cancer prevention in 
Lynch syndrome/hereditary nonpolyposis 
colorectal cancer families. Obstet Gynecol 110: 
18-25.
Ciccia A, Elledge SJ. 2010. The DNA damage 
response: making it safe to play with knives. 
Mol Cell 40: 179-204.
Coetzee E, Algar U, Goldberg P. 2013. New Insights 
into Lynch Syndrome Diagnosis. DNA 
Alterations in Lynch Syndrome (Book).
Constantin N, Dzantiev L, Kadyrov FA, Modrich PL. 
2005. Human mismatch repair: reconstitution 
of a nick-directed bidirectional reaction. J Biol 
Chem 280: 39752-39761.
Cox EC, Degnen GE, Scheppe ML. 1972. Mutator 














de la Chapelle A, Hampel H. 2010. Clinical relevance 
of microsatellite instability in colorectal cancer. 
J Clin Oncol 28: 3380-3387.
de Wind N, Dekker M, Berns A, Radman M, te 
Riele H. 1995. Inactivation of the mouse Msh2 
gene results in mismatch repair deficiency, 
methylation tolerance, hyperrecombination, 
and predisposition to cancer. Cell 82: 321-330.
de Wind N, Dekker M, Claij N, Jansen L, van Klink 
Y, Radman M, Riggins G, van der Valk M, van’t 
Wout K, te Riele H. 1999. HNPCC-like cancer 
predisposition in mice through simultaneous 
loss of Msh3 and Msh6 mismatch-repair 
protein functions. Nat Genet 23: 359-362.
Deans AJ, West SC. 2011. DNA interstrand crosslink 
repair and cancer. Nat Rev Cancer 11: 467-480.
Debiak M, Nikolova T, Kaina B. 2004. Loss of ATM 
sensitizes against O6-methylguanine triggered 
apoptosis, SCEs and chromosomal aberrations. 
DNA Repair 3: 359-368.
Devaud N, Gallinger S. 2013. Chemotherapy of 
MMR-deficient colorectal cancer. Fam Cancer 
12: 301-306.
Domingo E, Niessen RC, Oliveira C, Alhopuro P, 
Moutinho C, Espín E, Armengol M, Sijmons 
RH, Kleibeuker JH, Seruca R, Aaltonen LA, 
Imai K et al. 2005. BRAF-V600E is not involved 
in the colorectal tumorigenesis of HNPCC in 
patients with functional MLH1 and MSH2 
genes. Oncogene 24: 3995-3998.
Drost M, Lutzen A, Van Hees S, Ferreira D, Calleja 
F, Zonneveld J, Nielsen F, Rasmussen L, de 
Wind N. 2013. Genetic screens to identify 
pathogenic gene variants in the common 
cancer predisposition Lynch syndrome. Proc 
Natl Acad Sci USA 110: 9403-9408.
Drost M, Zonneveld JB, Van Dijk L, Morreau H, Tops 
CM, Vasen HFA, Wijnen J, De Wind N. 2010. 
A cell-free assay for the functional analysis of 
variants of the mismatch repair protein MLH1. 
Hum Mutat 31: 247-253.
Drost M, Zonneveld JB, van Hees S, Rasmussen LJ, 
Hofstra RM, De Wind N. 2012. A rapid and cell-
free assay to test the activity of lynch syndrome-
associated MSH2 and MSH6 missense variants. 
Hum Mutat 33: 488-494.
Duckett DR, Drummond JT, Murchie AI, Reardon 
JT, Sancar A, Lilley DM, Modrich P. 1996. 
Human MutSalpha recognizes damaged DNA 
base pairs containing O6-methylguanine, 
O4-methylthymine, or the cisplatin-d(GpG) 
adduct. Proc Natl Acad Sci USA 93: 6443-6447.
Dzantiev L, Constantin N, Genschel J, Iyer RR, Burgers 
PM, Modrich PL. 2004. A defined human system 
that supports bidirectional mismatch-provoked 
excision. Mol Cell 15: 31-41.
Edelmann L, Edelmann W. 2004. Loss of DNA 
mismatch repair function and cancer 
predisposition in the mouse: animal models 
for human hereditary nonpolyposis colorectal 
cancer. American journal of medical genetics 
Part C, Seminars in medical genetics 129: 91-99.
Edelmann W, Cohen PE, Kane M, Lau K, Morrow 
B, Bennett S, Umar A, Kunkel T, Cattoretti 
G, Chaganti R, Pollard JW, Kolodner RD et 
al. 1996. Meiotic pachytene arrest in MLH1-
deficient mice. Cell 85: 1125-1134.
Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan 
K, Liedtke W, Cohen PE, Kane MF, Lipford 
JR, Yu N, Crouse GF et al. 1997. Mutation in 
the mismatch repair gene Msh6 causes cancer 
susceptibility. Cell 91: 467-477.
Engel C, Loeffler M, Steinke V, Rahner N, Holinski-
Feder E, Dietmaier W, Schackert HK, Goergens 
H, von Knebel Doeberitz M, Goecke TO, 
Schmiegel W, Buettner R et al. 2012. Risks of less 
common cancers in proven mutation carriers 
with lynch syndrome. J Clin Oncol 30: 4409-4415.
Ferrás C, Oude Vrielink JA, Verspuy JW, te Riele 
H, Tsaalbi-Shtylik A, de Wind N. 2009. 
Abrogation of Microsatellite-instable Tumors 
Using a Highly Selective Suicide Gene/Prodrug 
Combination. Mol Ther 17: 1373-1380
Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins 
NA, Garber J, Kane M, Kolodner R. 1993. The 
human mutator gene homolog MSH2 and 
its association with hereditary nonpolyposis 
colon cancer. Cell 75: 1027-1038.
Genschel J, Modrich P. 2009. Functions of 
MutLalpha, replication protein A (RPA), and 
HMGB1 in 5’-directed mismatch repair. J Biol 
Chem 284: 21536-21544.
Ghodgaonkar MM, Lazzaro F, Olivera-Pimentel M, 
Artola-Borán M, Cejka P, Reijns MA, Jackson 
AP, Plevani P, Muzi-Falconi M, Jiricny J. 2013. 
Ribonucleotides misincorporated into DNA act 
as strand-discrimination signals in eukaryotic 
mismatch repair. Mol Cell 50: 323-332.
Giráldez MD, Castellví-Bel S, Balaguer F, Gonzalo 
V, Ocaña T, Castells A. 2008. Lynch syndrome 
in colorectal cancer patients. Expert Rev 
Anticancer Ther 8: 573-583.
Glaab WE, Risinger JI, Umar A, Barrett JC, Kunkel TA, 
Tindall KR. 1998. Resistance to 6-thioguanine in 
mismatch repair-deficient human cancer cell lines 
24
CHAPTER 1
correlates with an increase in induced mutations 
at the HPRT locus. Carcinogenesis 19: 1931-1937.
Goel A, Nagasaka T, Hamelin R, Boland CR. 2010. 
An optimized pentaplex PCR for detecting 
DNA mismatch repair-deficient colorectal 
cancers. PLoS ONE 5: e9393.
Goldmacher VS, Cuzick RA, Thilly WG. 1986. Isolation 
and partial characterization of human cell mutants 
differing in sensitivity to killing and mutation by 
methylnitrosourea and N-methyl-N’-nitro-N-
nitrosoguanidine. J Biol Chem 261: 12462-12471.
Gorman J, Chowdhury A, Surtees JA, Shimada J. 
2007. Dynamic Basis for One-Dimensional 
DNA Scanning by the Mismatch Repair 
Complex Msh2-Msh6. Mol Cell 28: 359-370
Gradia S, Subramanian D, Wilson T, Acharya S, 
Makhov A, Griffith J, Fishel R. 1999. hMSH2-
hMSH6 forms a hydrolysis-independent sliding 
clamp on mismatched DNA. Mol Cell 3: 255-261.
Gruber S. 2006. New Developments in Lynch 
Syndrome (Hereditary Nonpolyposis Colorectal 
Cancer) and Mismatch Repair Gene Testing. 
Gastroenterology 130: 577-587.
Gueneau E, Dherin C, Legrand P, Tellier-Lebegue C, 
Gilquin B, Bonnesoeur P, Londino F, Quemener 
C, Le Du MH, Márquez JA, Moutiez M, Gondry 
M et al. 2013. Structure of the MutLα C-
terminal domain reveals how Mlh1 contributes 
to Pms1 endonuclease site. Nat Struct Mol Biol 
20: 461-468.
Gupta S, Gellert M, Yang W. 2012. Mechanism of 
mismatch recognition revealed by human 
MutSβ bound to unpaired DNA loops. Nat 
Struct Mol Biol 19: 72-78.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja 
K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, 
Westman J, Panescu J, Fix D et al. 2005. Screening 
for the Lynch syndrome (hereditary nonpolyposis 
colorectal cancer). N Engl J Med 352: 1851-1860.
Hanahan D, Weinberg RA. 2000. The hallmarks of 
cancer. Cell 100: 57-70.
Hanahan D, Weinberg RA. 2011. Hallmarks of 
cancer: the next generation. Cell 144: 646-674.
Hays JB, Hoffman PD, Wang H. 2005. Discrimination 
and versatility in mismatch repair. DNA Repair 
4: 1463-1474.
Heinen CD. 2010. Genotype to phenotype: analyzing 
the effects of inherited mutations in colorectal 
cancer families. Mutat Res 693: 32-45.
Hendriks Y, De Jong A, Morreau H, Tops CM, 
Vasen HFA, Wijnen J, Breuning M, Brocker-
Vriends A. 2006. Diagnostic Approach and 
Management of Lynch Syndrome (Hereditary 
Nonpolyposis Colorectal Carcinoma): A 
Guide for Clinicians. CA: A Cancer Journal for 
Clinicians 56: 213-225.
Hennink SD, Hofland N, Gopie JP, van der Kaa C, de 
Koning K, Nielsen M, Tops C, Morreau H, de 
Vos Tot Nederveen Cappel WH, Langers AM, 
Hardwick JC, Gaarenstroom KN et al. 2013. 
Value-based healthcare in Lynch syndrome. 
Fam Cancer 12: 347-354.
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa 
JP, Markowitz S, Willson JK, Hamilton SR, Kinzler 
KW, Kane MF, Kolodner RD et al. 1998. Incidence 
and functional consequences of hMLH1 promoter 
hypermethylation in colorectal carcinoma. Proc 
Natl Acad Sci USA 95: 6870-6875.
Hewish M, Lord CJ, Martin SA, Cunningham D, 
Ashworth A. 2010. Mismatch repair deficient 
colorectal cancer in the era of personalized 
treatment. Nat Rev Clin Oncol 7: 197-208.
Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong 
JJ, Khachigian LM, Polly P, Goldblatt J, Ward 
RL. 2011. Dominantly inherited constitutional 
epigenetic silencing of MLH1 in a cancer-affected 
family is linked to a single nucleotide variant 
within the 5’UTR. Cancer Cell 20: 200-213.
Hoeijmakers JH. 2009. DNA damage, aging, and 
cancer. N Engl J Med 361: 1475-1485.
Hoffman PD, Wang H, Lawrence CW, Iwai S, 
Hanaoka F, Hays JB. 2005. Binding of MutS 
mismatch repair protein to DNA containing UV 
photoproducts, “mismatched” opposite Watson-
-Crick and novel nucleotides, in different DNA 
sequence contexts. DNA Repair 4: 983-993.
Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, 
De Wind N, Hoogerbrugge N, Hogervorst 
FB, Group IARCUGVW. 2008. Tumor 
characteristics as an analytic tool for classifying 
genetic variants of uncertain clinical 
significance. Hum Mutat 29: 1292-1303.
Holland IB, Blight MA. 1999. ABC-ATPases, adaptable 
energy generators fuelling transmembrane 
movement of a variety of molecules in organisms 
from bacteria to humans. J Mol Biol 293: 381-399.
Hombauer H, Campbell C, Smith C, Desai A, 
Kolodner R. 2011a. Visualization of Eukaryotic 
DNA Mismatch Repair Reveals Distinct 
Recognition and Repair Intermediates. Cell 
147: 1040-1053.
Hombauer H, Srivatsan A, Putnam C, Kolodner R. 
2011b. Mismatch Repair, But Not Heteroduplex 
Rejection, Is Temporally Coupled to DNA 













Hsieh P, Yamane K. 2008. DNA mismatch repair: 
molecular mechanism, cancer, and ageing. 
Mech Ageing Dev 129: 391-407.
Iyer RR, Pluciennik A, Burdett V, Modrich PL. 
2006. DNA mismatch repair: functions and 
mechanisms. Chem Rev 106: 302-323.
Iyer RR, Pohlhaus TJ, Chen S, Hura GL, Dzantiev L, 
Beese LS, Modrich PL. 2008. The MutSalpha-
proliferating cell nuclear antigen interaction in 
human DNA mismatch repair. J Biol Chem 283: 
13310-13319.
Jackson SP, Bartek J. 2009. The DNA-damage 
response in human biology and disease. Nature 
461: 1071-1078.
Jass JR. 2004. Role of the pathologist in the diagnosis 
of hereditary non-polyposis colorectal cancer. 
Dis Markers 20: 215-224.
Jiricny J. 2013. Postreplicative mismatch repair. Cold 
Spring Harbor Perspectives in Biology 5.
Jiricny J, Su SS, Wood SG, Modrich P. 1988. 
Mismatch-containing oligonucleotide 
duplexes bound by the E. coli mutS-encoded 
protein. Nucleic Acids Res 16: 7843-7853.
Kadyrov FA, Dzantiev L, Constantin N, Modrich PL. 
2006. Endonucleolytic function of MutLalpha 
in human mismatch repair. Cell 126: 297-308.
Kadyrov FA, Genschel J, Fang Y, Penland E, 
Edelmann W, Modrich P. 2009. A possible 
mechanism for exonuclease 1-independent 
eukaryotic mismatch repair. Proc Natl Acad Sci 
USA 106: 8495-8500.
Kaina B, Christmann M, Naumann S, Roos WP. 
2007. MGMT: key node in the battle against 
genotoxicity, carcinogenicity and apoptosis 
induced by alkylating agents. DNA Repair 6: 
1079-1099.
Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, 
Modrich P. 1993. An alkylation-tolerant, 
mutator human cell line is deficient in strand-
specific mismatch repair. Proc Natl Acad Sci 
USA 90: 6424-6428.
Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, 
Hutter P, Rahner N, Schackert HK, Steinke V, 
Holinski-Feder E, Morak M, Kloor M, Büttner 
R et al. 2011. Risk of colorectal and endometrial 
cancers in EPCAM deletion-positive Lynch 
syndrome: a cohort study. Lancet Oncol 12: 49-55.
Klapacz J, Meira LB, Luchetti DG, Calvo JA, Bronson 
RT, Edelmann W, Samson LD. 2009. O6-
methylguanine-induced cell death involves 
exonuclease 1 as well as DNA mismatch 
recognition in vivo. Proc Natl Acad Sci USA 
106: 576-581
Kloor M, Huth C, Voigt AY, Benner A, Schirmacher 
P, von Knebel Doeberitz M, Bläker H. 2012. 
Prevalence of mismatch repair-deficient crypt 
foci in Lynch syndrome: a pathological study. 
Lancet Oncol 13: 598-606.
Korhonen MK, Vuorenmaa E, Nyström M. 2008. 
The first functional study of MLH3 mutations 
found in cancer patients. Genes Chromosomes 
Cancer 47: 803-809.
Labazi M, Jaafar L, Flores-Rozas H. 2009. Modulation 
of the DNA-binding activity of Saccharomyces 
cerevisiae MSH2-MSH6 complex by the high-
mobility group protein NHP6A, in vitro. 
Nucleic Acids Res 37 :7581-7589
Lagerstedt Robinson K, Liu T, Vandrovcova J, 
Halvarsson B, Clendenning M, Frebourg T, 
Papadopoulos N, Kinzler KW, Vogelstein B, 
Peltomäki P, Kolodner RD, Nilbert M et al. 2007. 
Lynch syndrome (hereditary nonpolyposis 
colorectal cancer) diagnostics. J Natl Cancer 
Inst 99: 291-299.
Lahue RS, Au KG, Modrich PL. 1989. DNA mismatch 
correction in a defined system. Science 245: 
160-164.
Lamers MH, Perrakis A, Enzlin JH, Winterwerp HH, 
de Wind N, Sixma TK. 2000. The crystal structure 
of DNA mismatch repair protein MutS binding to 
a G x T mismatch. Nature 407: 711-717.
Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen 
J, Parsons R, Peltomäki P, Sistonen P, Aaltonen 
LA, Nyström-Lahti M. 1993. Mutations of a 
mutS homolog in hereditary nonpolyposis 
colorectal cancer. Cell 75: 1215-1225.
Li F, Mao G, Tong D, Huang J, Gu L, Yang W, Li GM. 
2013. The Histone Mark H3K36me3 Regulates 
Human DNA Mismatch Repair through Its 
Interaction with MutSα. Cell 153: 590-600.
Li GM. 2008. Mechanisms and functions of DNA 
mismatch repair. Cell Res 18: 85-98.
Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, 
Hebeda KM, Voorendt M, Lee TY, Bodmer D, 
Hoenselaar E, Hendriks-Cornelissen SJ, Tsui 
WY, Kong CK et al. 2009. Heritable somatic 
methylation and inactivation of MSH2 in families 
with Lynch syndrome due to deletion of the 3’ 
exons of TACSTD1. Nat Genet 41: 112-117.
Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, 
Baxevanis AD, Lynch HT, Elliott RM, Collins 
FS. 2000. MLH3: a DNA mismatch repair gene 
associated with mammalian microsatellite 
instability. Nat Genet 24: 27-35.
Liu A, Yoshioka K, Salerno V, Hsieh P. 2008. 
The mismatch repair-mediated cell cycle 
26
CHAPTER 1
checkpoint response to fluorodeoxyuridine. J 
Cell Biol 105: 245-254.
Liu HX, Zhou XL, Liu T, Werelius B, Lindmark G, 
Dahl N, Lindblom A. 2003. The role of hMLH3 
in familial colorectal cancer. Cancer Res 63: 
1894-1899.
Liu Y, Fang Y, Shao H, Lindsey-Boltz L, Sancar 
A, Modrich P. 2009. Interactions of human 
mismatch repair proteins MutS   and MutL   
with proteins of the ATR-Chk1 pathway. J Biol 
Chem 285: 5974-5982
Liu Y, Kadyrov FA, Modrich P. 2011. PARP-1 
enhances the mismatch-dependence of 
5’-directed excision in human mismatch repair 
in vitro. DNA Repair 10: 1145-1153.
Longley MJ, Pierce AJ, Modrich PL. 1997. DNA 
Polymerase δ Is Required for Human Mismatch 
Repair in Vitro. J Biol Chem 272: 10917-10921
Lujan SA, Williams JS, Clausen AR, Clark AB, Kunkel 
TA. 2013. Ribonucleotides are signals for 
mismatch repair of leading-strand replication 
errors. Mol Cell 50: 437-443.
Lynch HT, de la Chapelle A. 2003. Hereditary 
colorectal cancer. N Engl J Med 348: 919-932.
Macpherson P, Barone F, Maga G, Mazzei F, Karran P, 
Bignami M. 2005. 8-oxoguanine incorporation 
into DNA repeats in vitro and mismatch 
recognition by MutSalpha. Nucleic Acids Res 
33: 5094-5105.
Markowitz S, Wang JY, Myeroff L, Parsons R, Sun L, 
Lutterbaugh J, Fan RS, Zborowska E, Kinzler 
KW, Vogelstein B. 1995. Inactivation of the type 
II TGF-beta receptor in colon cancer cells with 
microsatellite instability. Science 268: 1336-1338.
Marra G, Iaccarino I, Lettieri T, Roscilli G, Delmastro 
P, Jiricny J. 1998. Mismatch repair deficiency 
associated with overexpression of the MSH3 
gene. Proc Natl Acad Sci USA 95: 8568-8573.
Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A. 
2011. Parallel high-throughput RNA interference 
screens identify PINK1 as a potential therapeutic 
target for the treatment of DNA mismatch repair-
deficient cancers. Cancer Res 71: 1836-1848.
Martin SA, Mccabe N, Mullarkey M, Cummins R, 
Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord 
CJ, Ashworth A. 2010. DNA polymerases 
as potential therapeutic targets for cancers 
deficient in the DNA mismatch repair proteins 
MSH2 or MLH1. Cancer Cell 17: 235-248.
Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry 
S, Lord CJ, Ashworth A. 2009. Methotrexate 
induces oxidative DNA damage and is 
selectively lethal to tumour cells with defects in 
the DNA mismatch repair gene MSH2. EMBO 
Mol Med 1: 323-337.
Mazurek A, Berardini M, Fishel R. 2002. Activation 
of human MutS homologs by 8-oxo-guanine 
DNA damage. J Biol Chem 277: 8260-8266.
McMurray CT. 2010. Mechanisms of trinucleotide 
repeat instability during human development. 
Nat Rev Genet 11: 786-799.
Medina-Arana V, Delgado L, Bravo A, Martín J, 
Fernández-Peralta AM, González-Aguilera 
JJ. 2012. Tumor spectrum in lynch syndrome, 
DNA mismatch repair system and endogenous 
carcinogens. J Surg Oncol 106: 10-16.
Meyers M, Hwang A, Wagner MW, Bruening AJ, 
Veigl ML, Sedwick WD, Boothman DA. 2003. 
A role for DNA mismatch repair in sensing 
and responding to fluoropyrimidine damage. 
Oncogene 22: 7376-7388.
Mojas N, Lopes M, Jiricny J. 2007. Mismatch repair-
dependent processing of methylation damage 
gives rise to persistent single-stranded gaps in 
newly replicated DNA. Genes Dev 21: 3342-3355.
Moreira L, Balaguer F, Lindor N, de la Chapelle 
A, Hampel H, Aaltonen LA, Hopper JL, Le 
Marchand L, Gallinger S, Newcomb P, Haile 
R, Thibodeau SN et al. 2012. Identification 
of Lynch syndrome among patients with 
colorectal cancer. JAMA 308: 1555-1565.
Nicolaides NC, Papadopoulos N, Liu B, Wei YF, 
Carter KC, Ruben SM, Rosen CA, Haseltine WA, 
Fleischmann RD, Fraser CM. 1994. Mutations 
of two PMS homologues in hereditary 
nonpolyposis colon cancer. Nature 371: 75-80.
Niessen RC, Berends MJ, Wu Y, Sijmons RH, Hollema 
H, Ligtenberg MJ, de Walle HE, de Vries EG, 
Karrenbeld A, Buys CH, van der Zee AG, Hofstra 
RM et al. 2006. Identification of mismatch repair 
gene mutations in young patients with colorectal 
cancer and in patients with multiple tumours 
associated with hereditary non-polyposis 
colorectal cancer. Gut 55: 1781-1788.
Obmolova G, Ban C, Hsieh P, Yang W. 2000. Crystal 
structures of mismatch repair protein MutS 
and its complex with a substrate DNA. Nature 
407: 703-710.
Pabla N, Ma Z, Mcilhatton M, Fishel R, Dong Z. 2011. 
hMSH2 Recruits ATR to DNA Damage Sites 
for Activation during DNA Damage-induced 
Apoptosis. J Biol Chem 286: 10411-10418.
Pavlov YI, Mian IM, Kunkel TA. 2003. Evidence for 
preferential mismatch repair of lagging strand 














Peltomäki P, Vasen HFA. 2004. Mutations associated 
with HNPCC predisposition -- Update of ICG-
HNPCC/INSiGHT mutation database. Dis 
Markers 20: 269-276.
Peña-Diaz J, Jiricny J. 2010. PCNA and MutLα: 
partners in crime in triplet repeat expansion? 
Proc Natl Acad Sci USA 107: 16409-16410.
Plazzer JP, Sijmons RH, Woods MO, Peltomäki P, 
Thompson B, Den Dunnen JT, Macrae F. 2013. 
The InSiGHT database: utilizing 100  years of 
insights into Lynch Syndrome. Fam Cancer 12: 
175-180.
Pluciennik A, Dzantiev L, Iyer RR, Constantin N, 
Kadyrov FA, Modrich P. 2010. PCNA function 
in the activation and strand direction of MutLα 
endonuclease in mismatch repair. Proc Natl 
Acad Sci USA 107: 16066-16071.
Prolla TA, Baker SM, Harris AC, Tsao JL, Yao X, 
Bronner CE, Zheng B, Gordon M, Reneker J, 
Arnheim N, Shibata D, Bradley A et al. 1998. 
Tumour susceptibility and spontaneous mutation 
in mice deficient in Mlh1, Pms1 and Pms2 DNA 
mismatch repair. Nat Genet 18: 276-279.
Raevaara TE, Korhonen MK, Lohi H, Hampel H, 
Lynch E, Lönnqvist KE, Holinski-Feder E, Sutter 
C, McKinnon W, Duraisamy S, Gerdes AM, 
Peltomäki P et al. 2005. Functional significance and 
clinical phenotype of nontruncating mismatch 
repair variants of MLH1. Gastroenterology 129: 
537-549.
Rasmussen LJ, Heinen CD, Royer-Pokora B, Drost 
M, Tavtigian S, Hofstra RM, De Wind N. 2012. 
Pathological assessment of mismatch repair 
gene variants in Lynch syndrome: Past, present, 
and future. Hum Mutat 33: 1617-1625.
Rasmussen LJ, Samson LD. 1996. The Escherichia 
coli MutS DNA mismatch binding protein 
specifically binds O(6)-methylguanine DNA 
lesions. Carcinogenesis 17: 2085-2088.
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, 
French AJ, Goldberg RM, Hamilton SR, 
Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, 
Redston M et al. 2003. Tumor microsatellite-
instability status as a predictor of benefit from 
fluorouracil-based adjuvant chemotherapy for 
colon cancer. N Engl J Med 349: 247-257.
Sacho EJ, Kadyrov FA, Modrich PL, Kunkel TA, Erie 
DA. 2008. Direct Visualization of Asymmetric 
Adenine Nucleotide-Induced Conformational 
Changes in MutLalpha. Mol Cell 29: 112-121.
Schaetzlein S, Chahwan R, Avdievich E, Roa S, Wei K, 
Eoff RL, Sellers RS, Clark AB, Kunkel TA, Scharff 
MD, Edelmann W. 2013. Mammalian Exo1 
encodes both structural and catalytic functions 
that play distinct roles in essential biological 
processes. Proc Natl Acad Sci USA 110: E2470-9.
Senter L, Clendenning M, Sotamaa K, Hampel H, 
Green J, Potter JD, Lindblom A, Lagerstedt K, 
Thibodeau SN, Lindor NM, Young J, Winship 
I et al. 2008. The clinical phenotype of Lynch 
syndrome due to germ-line PMS2 mutations. 
Gastroenterology 135: 419-428.
Sjursen W, Haukanes BI, Grindedal EM, Aarset H, 
Stormorken A, Engebretsen LF, Jonsrud C, 
Bjørnevoll I, Andresen PA, Ariansen S, Lavik 
LA, Gilde B et al. 2010. Current clinical criteria 
for Lynch syndrome are not sensitive enough to 
identify MSH6 mutation carriers. J Med Genet 
47: 579-585.
Stoffel E, Mukherjee B, Raymond VM, Tayob N, 
Kastrinos F, Sparr J, Wang F, Bandipalliam 
P, Syngal S, Gruber SB. 2009. Calculation of 
Risk of Colorectal and Endometrial Cancer 
Among Patients With Lynch Syndrome. 
Gastroenterology 137: 1621-1627
Stojic L, Brun R, Jiricny J. 2004. Mismatch repair and 
DNA damage signalling. DNA Repair 3: 1091-
1101.
Stojic L, Cejka P, Jiricny J. 2005. High doses of SN1 
type methylating agents activate DNA damage 
signaling cascades that are largely independent 
of mismatch repair. Cell Cycle 4: 473-477.
Stojic L, Mojas N, Cejka P, di Pietro M, Ferrari S, 
Jiricny J. 2004. Mismatch repair-dependent G2 
checkpoint induced by low doses of SN1 type 
methylating agents requires the ATR kinase. 
Genes Dev 18: 1331-1344.
Strand M, Prolla TA, Liskay RM, Petes TD. 1993. 
Destabilization of tracts of simple repetitive 
DNA in yeast by mutations affecting DNA 
mismatch repair. Nature 365: 274-276.
Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, 
Edwards M, Mace R. 1996. Role of postreplicative 
DNA mismatch repair in the cytotoxic action of 
thioguanine. Science 273: 1109-1111.
Taketo MM, Edelmann W. 2009. Mouse models of 
colon cancer. Gastroenterology 136: 780-798.
Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, 
te Riele H, Arends MJ, Wyllie AH, Margison 
GP, Clarke AR. 1999. Msh2 status modulates 
both apoptosis and mutation frequency in the 
murine small intestine. Proc Natl Acad Sci USA 
96: 3911-3915.
Umar A, Risinger JI, Hawk ET, Barrett JC. 2004. 
Testing guidelines for hereditary non-polyposis 
colorectal cancer. Nat Rev Cancer 4: 153-158.
28
CHAPTER 1
van Duijnhoven FJ, Botma A, Winkels R, Nagengast 
FM, Vasen HF, Kampman E. 2013. Do lifestyle 
factors influence colorectal cancer risk in Lynch 
syndrome? Fam Cancer 12: 285-293.
Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, 
Alonso A, Aretz S, Bernstein I, Bertario L, Burn 
J, Capella G, Colas C, Engel C et al. 2013. Revised 
guidelines for the clinical management of Lynch 
syndrome (HNPCC): recommendations by a 
group of European experts. Gut 62: 812–823
Warren JJ, Forsberg LJ, Beese LS. 2006. The structural 
basis for the mutagenicity of O(6)-methyl-
guanine lesions. Proc Natl Acad Sci USA 103: 
19701-19706.
Warren JJ, Pohlhaus TJ, Changela A, Iyer RR, 
Modrich PL, Beese LS. 2007. Structure of the 
human MutSalpha DNA lesion recognition 
complex. Mol Cell 26: 579-592.
Wei K, Clark AB, Wong E, Kane MF, Mazur DJ, Parris 
T, Kolas NK, Russell R, Hou H, Kneitz B, Yang G, 
Kunkel TA et al. 2003. Inactivation of Exonuclease 
1 in mice results in DNA mismatch repair defects, 
increased cancer susceptibility, and male and 
female sterility. Genes Dev 17: 603-614.
Wei K, Kucherlapati R, Edelmann W. 2002. Mouse 
models for human DNA mismatch-repair gene 
defects. Trends in molecular medicine 8: 346-353.
Win AK, Macinnis RJ, Dowty JG, Jenkins MA. 2013. 
Criteria and prediction models for mismatch 
repair gene mutations: a review. J Med Genet 
50:785–793
Wu Y, Berends MJ, Post JG, Mensink RG, Verlind E, 
Van Der Sluis T, Kempinga C, Sijmons RH, van 
der Zee AG, Hollema H, Kleibeuker JH, Buys CH 
et al. 2001a. Germline mutations of EXO1 gene in 
patients with hereditary nonpolyposis colorectal 
cancer (HNPCC) and atypical HNPCC forms. 
Gastroenterology 120: 1580-1587.
Wu Y, Berends MJ, Sijmons RH, Mensink RG, 
Verlind E, Kooi KA, Van Der Sluis T, Kempinga 
C, van Der Zee AG, Hollema H, Buys CH, 
Kleibeuker JH et al. 2001b. A role for MLH3 in 
hereditary nonpolyposis colorectal cancer. Nat 
Genet 29: 137-138.
Yamane K, Schupp JE, Kinsella TJ. 2007. BRCA1 
activates a G2-M cell cycle checkpoint 
following 6-thioguanine-induced DNA 
mismatch damage. Cancer Res 67: 6286-6292.
York SJ, Modrich PL. 2006. Mismatch Repair-
dependent Iterative Excision at Irreparable 
O6-Methylguanine Lesions in Human Nuclear 
Extracts. J Biol Chem 281: 22674-22683
Yoshioka K, Yoshioka Y, Hsieh P. 2006. ATR 
kinase activation mediated by MutSalpha 
and MutLalpha in response to cytotoxic O6-
methylguanine adducts. Mol Cell 22: 501-510.
Yuan F, Gu L, Guo S, Wang C, Li GM. 2004. Evidence for 
involvement of HMGB1 protein in human DNA 
mismatch repair. J Biol Chem 279: 20935-20940.
Zhang Y, Yuan F, Wang D, Gu L, Li GM. 2008. 
Identification of RFX as a novel mismatch repair 














Pathological Assessment of Mismatch 
Repair Gene Variants in Lynch Syndrome: 
Past, Present, and Future 
Lene Juel Rasmussen, Christopher D. Heinen, 
Brigitte Royer-Pokora, Mark Drost, Sean Tavtigian, 
Robert M.W. Hofstra, and Niels de Wind 
Adapted from Rasmussen et. al 2012 Hum Mutat 33:1617–1625
ABSTRACT 
Lynch syndrome (LS) is caused by germline mutations in DNA mismatch repair (MMR) 
genes and is the most prevalent hereditary colorectal cancer syndrome. A significant 
proportion of variants identified in MMR and other common cancer susceptibility genes 
are missense or noncoding changes whose consequences for pathogenicity cannot be easily 
interpreted. Such variants are designated as “variants of uncertain significance” (VUS). 
Management of LS can be significantly improved by identifying individuals who carry a 
pathogenic variant and thus benefit from screening, preventive, and therapeutic measures. 
Also, identifying family members that do not carry the variant is important so they can be 
released from the intensive surveillance. Determining which genetic variants are pathogenic 
and which are neutral is a major challenge in clinical genetics. The profound mechanistic 
knowledge on the genetics and biochemistry of MMR enables the development and use of 
targeted assays to evaluate the pathogenicity of variants found in suspected patients with 
LS. We describe different approaches for the functional analysis of MMR gene VUS and 
propose development of a validated diagnostic framework. Furthermore, we call attention to 
common misconceptions about functional assays and endorse development of an integrated 




Mismatch Repair Genes and Cancer 
Lynch syndrome (LS; also often named hereditary nonpolyposis colorectal cancer, HNPCC) 
is an autosomal dominant hereditary cancer syndrome caused by heterozygous germ line 
mutations in one of the major DNA mismatch repair (MMR) genes MSH2 (MIM# 609309) and 
MLH1 (MIM# 120436), but also MHS6 (MIM# 600678) and PMS2 (MIM# 600259) [Li, 2008; 
Peltomäki, 2001, 2003]. Sporadic somatic mutation or loss of heterozygosity of the wild-type allele 
leaves the cell with a defective MMR system. Because MMR repairs misincorporations during 
replication, its loss results in the accumulation of spontaneous mutations (a mutator phenotype) 
that are thought to drive, or contribute to, the neoplastic transformation process. The majority 
of MMR gene mutations that currently are detected in patients with LS cause truncations or 
deletions and can be securely classified as pathogenic. However, missense mutations comprise 
a significant proportion of all mutations (30–40%) [de La Chapelle, 2004] and the functional 
consequences of many of these so-called variants of uncertain significance (VUS) are not clear. 
It is a major and urgent challenge to develop validated tools to securely classify MMR VUS, 
whose prevalence is expected to rise sharply with the advent of next-generation sequencing. 
DNA Mismatch Repair 
MMR is a postreplicative DNA repair system that corrects errors made by the DNA polymerases 
(Pol) δ or ε during replication of the bulk genome, including DNA base-base mispairs, caused 
by accidental misincorporation, and insertion/deletion loops (IDL) that arise during slippage 
of polymerases at simple sequence repeats (also called microsatellites) [Kunkel and Erie, 2005; 
Li, 2008]. MMR thereby protects the cells from spontaneous mutations, including microsatellite 
instability (MSI). The MMR pathway is initiated by the recognition of a mismatch or IDL by 
either the MutSα heterodimer, consisting of the MSH2 and MSH6 proteins (Fig. 1), or the 
MutSβ heterodimer consisting of MSH2 and MSH3. MutSα is responsible for the recognition 
of base-base mispairs and small IDLs whereas MutSβ is responsible for the redundant repair of 
IDLs. Upon DNA mismatch recognition MutSα (or MutSβ) recruits the MutLα heterodimer 
(consisting of MLH1-PMS2). MutLα binds several MMR proteins and modulates their activity 
in a mismatch-dependent manner [Kunkel and Erie, 2005; Li, 2008]. PMS2 introduces a nick 
in the daughter strand, 5’ or 3’ of the mismatch [Kadyrov et al., 2006]. This nick serves as entry 
point for the 5’-exonuclease EXO1 that carry out excision of the misincorporation-containing 
DNA strand. It should be noted that MMR can occur in the absence of EXO1 [Kadyrov et al., 
2009]. Replication Protein A (RPA) protects the MMR excision intermediate from nuclease 
degradation. The excised DNA strand is resynthesized by Pol δ or ε in the presence of PCNA, 
the clamp loader RFC and RPA [Kunkel and Erie, 2005; Li, 2008]. 
A Diagnostic Tree for Assessing the Pathogenicity of VUS in MMR Genes 
To develop a widely applicable and standardized procedure for assessing the pathogenicity 
of VUS in MMR genes, we have previously proposed the development of a well-defined 




































part of the current diagnostic procedure of patients with LS, and involves the analysis of the 
tumor phenotype in suspected individuals by immunohistochemistry and/or MSI analysis, 
followed by testing for a mutation in the MMR genes (Fig. 2, Step 1). We proposed that, in 
case a VUS is found, the diagnostic procedure continues with a number of assays that largely 
are based on the profound knowledge of the biology of MMR. Step 2 (Fig. 2) may comprise 
any or all of a number of assays, such as in silico assessment of missense substitution severity 
with respect to cross-species sequence conservation at the relevant position of the protein, 
in silico prediction of the effect of the underlying nucleotide change on mRNA spicing, and 
analysis of the activity of the VUS protein in a comprehensive in vitro MMR reaction (see 
below). The combined Steps 1 and 2 will enable the classification of many VUS in a clinical 
diagnostics laboratory, as was recently demonstrated in a pilot study [Kansikas, 2011]. If 
results from the analyses in Steps 1 and 2 are inconclusive, the VUS remains unclassified. 
Such variants require an additional layer of diagnostic assays (Step 3; Fig. 2). Detailed cell-
biological, biochemical, and biophysical analysis of MutSα and MutLα and their prokaryotic 
homodimeric homologs MutS and MutL, combined with the elucidation of their crystal 
structures, has revealed important information about the biochemistry of the MMR pathway. 
Figure 1. Steps in MMR. The replicative DNA polymerase misincorporates a nucleotide during DNA replication. 
The MSH2–MSH6 heterodimer recognizes and binds to the mismatch, followed by mismatch validation by ADP 
→ ATP exchange. This complex recruits the MLH1–PMS2 heterodimer that, in turn, exchanges ADP for ATP. 
The latent endonuclease activity of PMS2 introduces a nick in the daughter strand, 5’ of the misincorporation. 
The nick serves as entry point for the EXO1 exonuclease that degrades a patch of the daughter strand that 
includes the misincorporation. The remaining single-stranded DNA gap is covered by the single-strand DNA 
binding protein RPA and filled by the replicative DNA polymerase. 
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Based on this body of work, specific biochemical and cell-biological characteristics of the 
MMR protein VUS can be investigated in Step 3. Furthermore, depending on the predictions 
of the in silico analyses of Step 2, splicing of the variant mRNA can be assessed in Step 2. 
In addition, most, if not all, assays described here investigate aspects of protein function, 
but VUS that do not cause any functional defect in the protein may still cause aberrations 
in mRNA splicing or stability or in lowered translation of the mutant protein or aberrant 
localization in vivo. It is important to combine results from different functional assays 
(looking at different functional aspects or at function as a whole), in silico analyses of the 
variants (e.g., conservation of the amino acid, severity of amino acid change) and indirect 
evidence such as segregation and pathological features [Hofstra et al, 2008]. Individual 
assays have been developed that may contribute to Steps 2 and 3 of this diagnostic decision 
tree. However, most of these assays investigate only restricted aspects of MMR proteins, 
are not widely applicable, have not been validated and are currently not in use in the 
clinic. Nevertheless, the recent development of second-generation assays hold promise for 
the development of a widely applicable diagnostic procedure. The Step 1 assays include 




































diagnostic criteria to start detailed tumor analysis of potential patients with LS. In the 
following section, we will focus on available Step 2 and Step 3 assays. 
Step 2 Functional Assays In Silico Assays 
The classification of VUS can be aided by computational analyses [Tavtigian et al., 2008]. 
Two types of potential problems need to be examined essentially independently: potential 
dysfunction of the protein caused by amino acid substitutions or small in-frame insertion 
or deletion mutations, and splicing defects caused by underlying changes to the nucleotide 
sequence. Algorithms that attempt to predict dysfunction of the protein often use evolutionary 
conservation as a measure for residue importance, severity of the amino acid substitution 
relative to the evolutionarily tolerated range of variation at its position, and, in some algorithms, 
structural features of wild-type and variant proteins [Arnold et al., 2009; Chao et al., 2008; 
Olatubosun et al., 2012; Tavtigian et al., 2008]. For these programs, three key issues are (1) 
to build really high-quality protein multiple sequence alignment of the four MMR genes, 
which helps to reduce the noise in measures of sequence conservation and evolutionarily 
tolerated range of variation, (2) to calibrate the output of the programs so that their output 
can be interpreted as a probability in favor of pathogenicity, and (3) to explicitly determine 
whether the outputs of any pairs or sets of programs can be combined to give more accurate 
predictions than the most accurate individual program. Similarly, splice site prediction 
programs have been developed that investigate the possibility of faulty splicing [Reviewed in 
Spurdle, 2010]. These in silico analyses make use of the relatively well-understood sequence 
requirements of the consensus splice donor and splice acceptor sites, both to predict whether 
sequence variants will damage function of the wild-type splice sites and to predict whether 
they might create de novo splice sites. Sequence variation in exonic splice enhancers also 
plays an important role [Tournier et al., 2008], but systematic identification functional splice 
enhancers and the ability to predict the effect of sequence variation on their functional lags 
behind analysis of donor and acceptor sites. However, it is important to keep in mind that 
neither in silico prediction of protein dysfunction nor prediction of splice defects have by 
themselves the predictive values required for counseling individuals carrying the variants. 
Splicing Assays 
It has been realized only recently that a significant fraction of VUSs in the MMR genes 
disrupt splicing, rather than protein activity per se [Arnold et al., 2009; Sharp et al., 2004; 
Tournier et al., 2008]. For this reason, VUS that, on the basis of their position within the 
gene (close to splice sites) and on in silico predictions, are suspected to affect splicing 
should be tested for splice defects. In such a splicing assay, the VUS is PCR-amplified from 
patient genomic DNA with flanking sequences, and subsequently cloned into a splicing 
reporter minigene. Splicing effects are then evaluated after transfection of the minigene in 
HeLa cells, followed by RNA isolation and RT-PCR analysis. It is also possible to analyze 
the RNA from patient lymphocytes directly for splicing alterations, culturing the cells for a 
short time in the presence of nonsense-mediated RNA decay inhibitors. 
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Functional Assays Using Yeast 
Yeast-based assays for the functional analysis of MMR gene VUS are based on the fact that 
MMR is evolutionarily conserved [Ou et al., 2007]. In one assay, evolutionarily conserved amino 
acids in the yeast protein are replaced with its human mutated counterpart, and it is investigated 
whether this replacement has functional consequences in the yeast cells in vivo. As the human 
and yeast MLH1 proteins share only significant homology in the NH2- and COOH-termini, 
mutations located only in these conserved regions can be analyzed in this way. 
Yeast functional assays were mainly used for analyzing mutations in MLH1. At least 
three different strategies have been used: (1) expression of the mutant yeast MMR gene in 
a haploid yeast strain deficient for the same MMR gene [Shcherbakova and Kunkel, 1999; 
Wanat et al., 2007]; (2) expression of a human MMR gene in a haploid wild-type yeast 
strain: this approach makes use of the dominant-negative effect that wild-type human MMR 
proteins have in these cells [Clark et al., 2000; Shimodaira et al., 1998; Takahashi et al., 
2007]; and (3) expression of a mutant yeast MMR gene in a diploid yeast strain containing 
only one functional allele of the same MMR gene [Drotschmann et al., 1999a]. 
Several methods have been applied to evaluate the spontaneous mutation rates in 
various yeast strains expressing mutant MMR proteins, all of which make use of reporter 
genes that are either located in the yeast chromosome or expressed extra-chromosomally. 
These reporter genes serve as selection markers; when mutated, they lose or regain their 
function and can be used to determine the MMR capacity of the introduced mutant MMR 
protein [Polaczek et al., 1998; Shimodaira et al., 1998; Takahashi et al., 2007; Tran et al., 
1997; Wanat et al., 2007]. The reporter genes vary in the length of repeat sequences located 
in the gene. Such repeat sequences can form loops of different sizes, which are substrates 
for MMR and can, therefore, influence the results. In addition, a difference can be observed 
when the mutation is introduced in the yeast gene at corresponding positions, that is, 
present as a single copy gene at the corresponding locus in the chromosome or when the 
human variants are expressed from a high copy number plasmid. Furthermore, the human 
proteins expressed in yeast might not be modified in the same way, as they would have 
been when expressed in human cells. Such modifications could be phosphorylation of the 
MMR proteins. Lastly, the strain background can affect the outcome, making the assay less 
or more sensitive. In summary, although yeast assays are performed in living cells in vivo 
there are limits to their use. The results should always be correlated with the function of a 
wild-type protein and, when possible, a known pathogenic variant. In this way, quantitative 
differences can be determined [Hardt et al., 2011]. However, yeast assays cannot easily be 
set up in diagnostic laboratories and special expertise in yeast genetics is required. 
Cell-Based In Vitro MMR Functional Assays Using a Human Expression System 
The largest advantage of using human cell lines and mammalian proteins over yeast-based 
assays is the ability to test all VUS, irrespective of their evolutionary conservation, inside 
the cell. Such studies have tested the ability of transfected variant MLH1 or MSH2 cDNAs 




































et al., 2006] or the MSH2-deficient endometrial tumor cell line Hec59 [Mastrocola and 
Heinen, 2010], respectively. In the complemented cells, the MMR status was investigated by 
measuring the cellular response to methylating agents (MMR-deficient cells have acquired 
tolerance to these agents [Li, 2008]), the spontaneous mutation rate at the endogenous 
HPRT gene, repair of an exogenously added mismatch-containing GFP plasmid, and by 
measuring microsatellite instability. A challenge when testing VUS function in mammalian 
cells is the choice of cell line. Most cell-based studies use a human cancer cell line that has 
lost expression of the endogenous MMR protein. These models provide an MMR-deficient 
background for testing the ability of a variant MMR gene to restore repair function compared 
to wild type. However, these transformed lines have likely undergone multiple rounds of 
mutation and selection, creating a variable and uncertain genetic background that may affect 
the performance of the altered MMR protein. Another disadvantage is that the expression 
of the variant MMR gene is ectopic, and therefore unregulated. The expressed gene may be 
toxic to the cells and, therefore, these approaches may be susceptible to artefacts. In a recent 
study, the MMR status of four MSH2 VUS was investigated after their introduction in the 
endogenous Msh2 gene in mouse embryonic stem (ES) cells, using oligonucleotide-directed 
gene targeting. This avoids the possible artefacts of unregulated expression and involves 
a non-transformed cell line, although in these cells both Msh2 alleles contained the VUS 
whereas in LS only one of the alleles carries a VUS [Wielders et al., 2011]. 
Cell-Free MMR Assays 
The activity of variant MMR proteins can be measured in in vitro assays that study the 
canonical MMR process as a whole. In one approach, MLH1 variants are transfected 
together with wild-type PMS2 in the 293T cell line [Trojan et al., 2002] or the HCT116 line 
[Takahashi et al., 2007] (both human cell lines lackMLH1 and, consequently, PMS2). MMR 
efficiency is measured by incubating bacteriophage M13 DNA, containing a mismatched 
basepair in the LacZ α-complementation domain, in cytoplasmic cell extracts from these 
lines. After incubation, these heteroduplexes are introduced into Escherichia coli cells, 
and the repair efficiencies are measured by the number and color of the resulting plaques 
[Thomas et al., 1991]. 
In another approach, extracts from cell lines lacking a defined MMR protein are 
complemented with the missing MMR protein [Holmes et al., 1990; Li and Modrich, 1995]. 
The complemented extracts are added to an artificial substrate that carries a mismatch 
within a restriction site, interfering with its cleavage. Proficiency in repair results in 
recreation of the restriction site, which can be determined by simple digestion and gel 
electrophoresis. Complementation of the repair defect after the addition of a variant MMR 
protein to this reaction allows the assessment of its activity. Lack of complementation 
suggests pathogenicity of the variant. This principle has been used in several publications 
that tested variants in MLH1 [Kosinski et al., 2010; Nyström-Lahti et al., 2002; Raevaara et 
al., 2005], MSH2 [Ollila et al., 2006], and MSH6 [Kariola et al., 2002]. The variant proteins 
were expressed in Sf9 insect cells, after transfection with recombinant baculoviruses 
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encoding the variant MMR protein. In this assay, the amount of Sf9-produced protein 
frequently exceeds physiological amounts of the protein, and the presence of an excess of 
the variant in the MMR reaction may mask a partial loss of activity, yielding a false-negative 
(i.e., non-pathogenic) result [Kansikas et al., 2011]. 
The assays described above have more practical and technical issues, including the need of 
molecular cloning and the production of recombinant proteins in cell culture. Furthermore, 
their labor intensiveness and costs preclude their wide applicability and independent 
validation. Some of the latter problems were recently tackled by the development of a 
rapid next-generation assay for testing the integral activity of variants in MLH1 [Drost et 
al., 2010], MSH2 and MSH6 [Drost et. al, 2012]. In these modified assays, variant MMR 
genes are produced using a site-directed mutagenic PCR procedure, and variant proteins 
are produced by expression of these PCR fragments in a commercially available in vitro 
expression kit. Together with their respective (wild-type) heterodimeric partner, these 
variants can directly be used in an in vitro complementation assay, similar to that described 
above, albeit the substrate is fluorescent here, which facilitates the quantification of the 
repair efficiency. Because this procedure results in non-saturating amounts of variant 
proteins, variants that also result in a moderate reduction of activity may be diagnosed. 
To accurately determine pathogenicity in these in vitro complementation assays, one needs 
to determine the relationship between the MMR efficiency in vitro and cancer penetrance 
in carriers. Importantly, it should be realized that most of these assays are not capable of 
detecting splicing defects, poor expression or degradation in vivo or a lack of nuclear import, 
which may result in false-negative/positive results. The validation of in vitro complementation 
assays, using a large panel of well-studied variants, could especially aid in the classification of 
variants displaying low to intermediate levels of repair. Especially when the functional assays 
are inconsistent or display wild-type activity of a VUS that the in silico assessments predicted 
to be pathogenic, additional analytical tools, including Step 3 assays may be required. 
Step 3 Functional Assays Interaction assays: yeast two-hybrid assay 
The Yeast 2 hybrid (Y2H) assay can be used to measure the physical interaction between 
two proteins in vivo in the yeast cell. In this assay, one of the proteins of interest (e.g., 
MSH2) is fused to a DNA binding domain of a transcription factor (e.g., GAL4), whereas its 
interacting partner (e.g., MSH6) is fused to the transcription activation domain of the same 
transcription factor. If the two proteins of interest interact, the DNA-binding activation 
domains are brought into each other’s proximity upon which they activate the transcription 
of a reporter gene or genes (e.g., His3 or LacZ) [Kondo et al., 2003]. 
For a proper interpretation of the results in Y2H analysis it is important to analyze the 
expression level of the hybrid MLH1-lexA (or MSH2-Gal4) protein in the yeast strain. It is 
known that changing a single amino acid can have effects on protein folding, resulting in 
targeted degradation. Therefore, Western blot analysis of protein extracts from transformed 
yeast cells, using an internal reference control protein to determine the level of the variant 




































low expression levels in yeast and four of these displayed essentially no interaction. These 
should be interpreted with caution, as a low protein level would also result in a low level of 
interaction. Therefore, for a safe interpretation of Y2H results it is advisable to use results 
only for those variants that are expressed at a level between 50% and 100% in comparison 
to the wild-type protein [Gammie et al., 2007]. 
Interaction Assays: GST Pull-Down Assay 
The glutathione S-transferase (GST)-fusion interaction (pulldown) assay is a different 
approach to measure the physical interaction between two proteins. It is an in vitro 
technique that consists of a fusion-tagged “bait” protein for which a binding partner 
(i.e., the “prey”) is being sought. In most cases, a GST-tagged bait protein is bound to an 
immobilized glutathione support, after which a labeled potential interacting partner, the 
prey (in vitro transcribed and translated) is added. If interaction occurs, the labeled protein 
can be visualized. [Guerrette et al. 1998, 1999] used this assay to show that 9 of 11 MLH1 
VUSs displayed reduced binding to PMS2. The disadvantage of this assay is that the IVTT 
proteins are all expressed at the same level and protein stability due to degradation in cells 
cannot be evaluated. In addition, the fusion protein (GST-PMS2) is produced in bacteria 
and, therefore, does not harbour all protein modifications that might be important for a 
normal interaction. Also, the tag (GST) may influence dimerization of the proteins and 
generate false positive/negative results. 
Both the Y2H assays and the GST pull-down assays are based on the physical interaction 
between two MMR proteins, such as MSH2 and MSH6, or MLH1 and PMS2. Both systems 
can only analyze variants that interfere with proper binding and will not, therefore, detect all 
the possible functional defects of the mutant protein being investigated. A major difference is 
that Y2H assays are done in live (albeit yeast) cells and the GST pull down is entirely an in vitro 
assay. In addition, the fusion protein needed for the Y2H assay might affect the interaction. 
Interaction Assays: Transient Expression of MMR Genes in MMR-Deficient 
Cell Lines 
Some of the MMR proteins require binding with their protein partner for stabilization. 
Brieger et al. (2002) showed that the MSH6 protein became detectable in LoVo cells (cells 
carrying homozygous mutations in MSH2 resulting in destabilization of MSH6), after 
transfection with wild-type MSH2. In contrast, the MSH6 protein was not detectable in 
LoVo cells when some mutant MSH2 proteins were expressed (such as MSH2 Cys697Arg). 
These data indicate a defect in MSH2–MSH6 interaction due to the MSH2 VUS. The same 
assay works for MLH1 variants when transfected in MLH1 defective HCT116 cells. Only 
wild-type MLH1, or stable proteins capable of normal protein–protein interaction, increase 
the stability of PMS2. The advantage of this assay is that it is relatively easy to perform. 
However, PMS2 stabilization is observed only after 72 hr, which corresponds to the time 
when the level of the transfected protein starts to decrease. Therefore, a disadvantage is that 
variants that result in a low level of protein cannot be tested. 
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DNA Mismatch-Binding Assays 
The ability of VUS to affect MSH2–MSH6 mismatch binding has been assessed through the 
use of electrophoretic mobility shift assay (EMSA) [Clark et al., 1999; Drotschmann et al., 
1999b; Lützen et al., 2008; Ollila et al., 2008]. More recently, the effect of missense mutations 
on MSH2–MSH6/MSH2–MSH3 heterodimer mismatch interaction has been examined 
using surface plasmon resonance (SPR) [Cyr and Heinen, 2008; Cyr et al., 2012; Heinen et 
al., 2002; Hess et al., 2002, 2006]. SPR measures the interaction between small molecules 
in real time. The majority of VUS-containing MSH2– MSH6 heterodimers examined bind 
G/T mismatches more readily than homoduplex DNA; however, some display a decreased 
affinity for mismatches compared to wild-type proteins that may affect overall MMR 
function [Clark et al., 1999; Cyr and Heinen, 2008; Cyr et al., 2012; Drotschmann et al., 
1999b; Heinen et al., 2002; Hess et al., 2002, 2006; Lützen et al., 2008; Ollila et al., 2008]. 
Although they enable the precise kinetic analysis of MMR protein binding to mismatch-
containing DNA oligonucleotides, SPR and EMSA are unlikely to become widely applicable 
assays for MMR protein variants due to their complexity and technical requirements. 
Assays Based on the MutS ADP-ATP Cycle 
In addition to mismatch recognition, MSH2–MSH6 performs mismatch verification, which 
prevents it from initiating repair at non-mismatched DNA. This kinetic “proofreading” 
activity is mediated by the DNA binding induced exchange of ADP for ATP in a Walker-
type ATPase domain that is distally located from the mismatch-binding domain. In case of 
mismatch binding, the ATP-bound form of MSH2–MSH6 is stabilized, and it undergoes 
a conformational change into a DNA-embracing clamp that allows binding of MLH1–
PMS2. The ability of the MSH2–MSH6 heterodimer to coordinate mismatch binding with 
adenosine nucleotide processing is essential for MMR [Fishel, 1998; Kunkel and Erie, 
2005; Modrich, 2006]. Thus, in addition to affecting mismatch binding, the VUS may affect 
ATP binding and/or hydrolysis. In vitro assays that examine the steps of this molecular 
mechanism have been used to test MSH2 and MSH6 VUS [Cyr et al., 2012; Cyr and Heinen, 
2008; Heinen et al., 2002; Lützen et al., 2008; Ollila et al., 2008]. A VUS that disrupts ATP-
stimulated mismatch release or mismatch-stimulated ATPase activity would likely not be 
fully functional in vivo, strongly suggesting an effect of the VUS on pathogenicity. The 
major strength of these assays is that they provide a more specific description of how a VUS 
disrupts MMR function. Although this may not be immediately relevant to the clinician 
who seeks to simply determine whether the patient should be managed as an LS patient 
or not, it will be very useful to basic and translational researchers who wish to better 
understand the mechanism of MMR and how it prevents mutations. 
Protein Localization Experiments 
Clearly, MMR proteins need to be transported to the nucleus to reach their target, the DNA. 
The regulation of the subcellular localization of MMR proteins, although important for their 




































of MMR protein localization depends on (1) specific sequences in the MMR proteins that interact 
with factors known to be involved in the nuclear import of proteins, (2) sequences involved in 
translocation of the protein to the nucleus, and (3) specific protein–protein interactions in the 
MMR complexes [Brieger et al., 2005; Knudsen et al., 2007]. Subcellular localization of mutant 
MMR proteins can be investigated by immuno-staining or by expressing fluorescent fusion 
proteins in mammalian cells and investigation of their localization by fluorescent microscopy. 
A major strength of these assays is that they provide a more specific description of how a VUS 
disrupts MMR function. However, the assays are technically difficult and the results must be 
analyzed carefully in relation to proper controls since both expression levels and nature of 
fluorescent fusion proteins play a major role for the results [Brieger et al., 2012]. 
MMR proteins may be co-imported by each other. Co-import of excision repair proteins 
refers to the situation where a protein is imported via the nuclear localization signal (NLS) of 
its binding partner. Such complex formation between proteins in the cytoplasm seems to have 
a large effect on their subcellular localization; however, it is not clear whether this protein 
“piggy-backing” works as a backup mechanism or if it is essential for import regulation 
in vivo. Nonetheless, it ensures that the stoichiometry of the nuclear repair complexes 
is sustained [Knudsen et al., 2009]. MMR proteins utilize co-import as a mechanism for 
increasing nuclear accumulation. Some studies have suggested that MSH2– MSH6 complex 
formation affects nuclear translocation of MSH2, as MSH6-deficient cells display an increased 
cytoplasmic level of MSH2 compared to MSH6-proficient cells [Christmann and Kaina, 
2000]. The importance of MSH2–MSH6 localization is illustrated in patients with LS carrying 
specific amino acids substitutions in MSH2. Two MSH2–LS mutants (P622L and C697F) 
display decreased nuclear accumulation compared to wild-type protein [Lützen et al., 2008]. 
MLH1–PMS2 complex formation affects the nuclear translocation of both MLH1 and 
PMS2 in human and mice [Mohd et al., 2006; Wu et al., 2003]. Each subunit contains a 
functional NLS sequence but mutations in the NLS sequence of either MLH1 or PMS2 
lead to impaired nuclear localization of both subunits [Brieger et al., 2005; Wu et al., 2003] 
suggesting that heterodimers form in the cytoplasm prior to import into the nucleus and 
may be required for efficient nuclear localization. Indeed, recent reports show that human 
MLH1 and PMS2 as well as yeast Msh2 are imported into the nucleus in the absence of their 
dimerization partners, but that transport of human MLH1–PMS2 and yeast Mlh1–Pms1 
are synergistically enhanced by heterodimerization [Hayes et al., 2009; Leong et al., 2009]. 
The importance of MMR complex formation is also illustrated in patients with LS, carrying 
specific amino acids substitutions in MLH1. One missense mutation MLH1 (R659P), not 
located within the NLS sequence, was found to abolish the interaction with PMS2 in vitro, 
and also display decreased nuclear localization [Raevaara et al., 2005]. 
General Discussion MMR and the DNA Damage Response 
Published studies addressing the functional effects of MMR VUS have focused almost 
exclusively on the role of the MMR proteins in DNA repair. However, MMR proteins are 
involved in other processes that may also have implications for tumorigenesis [Heinen et al., 
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2002]. Studies of MMR-deficient human cancer cell lines as well as embryonic fibroblasts 
from Msh2, Mlh1, and Msh6 knockout mice suggest that the MMR proteins are necessary for 
the activation of cell cycle checkpoints and apoptosis in response to certain DNA damaging 
agents [Aebi et al., 1996; Branch et al., 1995; Cejka et al., 2003; de Wind et al., 1998; Kat et 
al., 1993; Stojic et al., 2004; Toft et al., 1999; Wu et al., 1999; Zhang et al., 1999]. Whether 
the DNA repair functions of the MMR proteins are required for this damage response is still 
debated [Jiricny, 2006; Peña-Diaz and Jiricny, 2012; Stojic and Jiricny, 2004]. Thus, it cannot 
be excluded that certain VUSs affect either the repair or the damage response function while 
leaving the other function intact. However, expression of four MSH2 VUSs in an MSH2-null 
cancer cell line revealed that loss of repair and of DNA damage responses coincided in the 
tested variants [Mastrocola and Heinen, 2010]. In a separate study, four MSH2 variants 
were introduced into the endogenous locus in mouse embryonic stem cells and tested for 
different MMR functions including damage responses and a mutator phenotype, a measure 
for repair [Wielders et al., 2011]. Similar to the study in human cancer cells, the VUS that 
maintained the damage response function also did not display a mutator phenotype. These 
studies support the hypothesis that repair and the induction of cell cycle responses are linked 
properties of the MMR pathway. In contrast, mouse studies revealed missense mutations 
in Msh2, Msh6, Mlh1, and Pms2 that disrupted DNA repair function, but not the damage-
induced apoptotic response suggesting that these functions may be separable [Avdievich 
et al., 2008; Lin et al., 2004; Marinovic-Terzic et al., 2008; van Oers et al., 2010; Yang et al., 
2004]. Determining the effect of VUSs on the MMR-dependent DNA damage response also 
may be important for predicting the response to therapy. Multiple studies have suggested 
that patients with MMR-deficient tumors are not as responsive to some commonly used 
chemotherapies that function by damaging DNA [Carethers et al., 2004; Ribic et al, 2003; 
Watanabe et al., 2000]. Biochemical studies suggest that the MMR proteins may be involved 
in the mechanism by which these drugs kill cells [Aebi et al., 1996; Meyers et al., 2005]. 
Technical Limitations of Functional Assays 
The type of functional assays used has changed over the years. Before 1999, almost all 
functional assays were yeast-based or used pulldown assays, and most of them were used 
to study only MLH1 and MSH2 variants. After 1999, more and more publications describe 
in vitro MMR assays or (human) expression systems for analyzing repair capacity as well 
as the subcellular localization of the mutant proteins. Unfortunately, many of the assays or 
methods described above require specialized expertise, laboratory facilities, and trained 
scientific personnel, and this currently precludes their widespread adoption and independent 
validation. Possibly, the biggest problem of functional assays is the fact that currently for 
hardly any of the assays the reproducibility, sensitivity, and specificity have been determined. 
This is reflected by the many inconsistencies in the database that lists all MMR gene VUS and 
results of functional assays on these VUS (www.mmruv.info). As long as a test is not validated, 
results should be utilized with great caution, and one might even argue that functional assays 




































and clinical/ genetic) data. When an assay result predicts a pathogenic nature of a variant 
one should realize that it is of the utmost importance that the proper positive and negative 
controls were included in the study. For analysis of transfected proteins, the expression level 
is very important as high levels of these proteins might be toxic or could disturb normal 
functioning of the overexpressed protein and, conversely, overexpression may mask a partial 
loss of activity. On the other hand, under expression may result in false negative results as the 
too little protein may also affect MMR function [Cejka et al., 2003]. 
A further challenge when interpreting the results from the biochemical assays is 
determining how moderate alterations in activity translate into disease phenotype. At the 
moment, there is no obvious way to address this important issue and, therefore, it should be 
given high priority in future to develop methods to correlate intermediate activity of MMR 
proteins to LS. In addition, examining the same VUS in multiple assays will allow researchers 
to correlate in vitro biochemical function with in vivo function. Examplifying these 
problems, four MSH2 VUS were recently expressed in an MSH2-null human cancer cell line 
to study their ability to restore cellular MMR function [Mastrocola and Heinen, 2010]. Two 
of these VUS, D167H and K393M, were previously determined to have intermediate effects 
on MSH2-MSH6 ATP/ADP processing [Heinen et al., 2002]. Both variants restored cellular 
MMR function to near wild-type levels suggesting that the biochemical defects associated 
with these VUS are not sufficient to contribute to disease. However, as noted above, the 
partial restoration of function may have been a consequence of inexact expression levels 
of the transfected variant genes. The MSH2 P622L VUS, alternatively, had more dramatic 
effects on in vitro biochemical function [Guerrette et al., 1999; Heinen et al., 2002; Lutzen 
et al., 2008], which is consistent with the clear MMR defects observed when this variant is 
expressed in yeast [Drotschmann et al., 1999a; Gammie et al., 2007; Polaczek et al., 1998] 
or mammalian cell culture systems [Lutzen et al., 2008; Mastrocola and Heinen, 2010]. 
In addition, most, if not all, assays described here investigate aspects of protein function, 
but VUS that do not cause any functional defect in the protein may still cause aberrations 
in mRNA splicing or stability or in lowered translation of the mutant protein or aberrant 
localization in vivo. It is important to combine results from different functional assays 
(looking at different functional aspects or at function as a whole), in silico analyses of the 
variants (e.g., conservation of the amino acid, relative severity of amino acid change) and 
indirect evidence such as segregation and pathological features [Hofstra et al., 2008]. 
FUTURE PERSPECTIVES 
To achieve a widely applicable, integrated, validated, and cost-effective diagnostic procedure 
for the diagnosis of MMR gene VUS, as proposed in Figure 2, further work is needed to 
select and validate a set comprising the most predictive and feasible assays. An integral 
part of the diagnostic procedure, furthermore, is the development and use of a computer 
algorithm that, based on prior calibration, stratifies and integrates the results from all 
assays, and calculates the probability in favor of pathogenicity. 
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Whether the outcome of such a validated diagnostic procedure should be used for 
clinical decisions is a question that needs to be addressed by clinicians, clinical geneticists, 
and patient advocates and probably will depend on whether individuals are comfortable 
using the results for clinical decisions knowing that they may include errors. If that is the 
case, one needs to make sure that the target audience understands all the limitations in the 
assays, is aware of all possible pitfalls, and understands the significance of each class used 
in the classification. In addition, genetic counselors and clinicians should receive specific 
training and teaching aids to help the patient make informed decisions. 
In conclusion, only the tight integration of genetic, pathology, in silico, in vitro and, 
possibly, in vivo data will provide reliable pathological assessment of any gene implicated in 
cancer predisposition. The thorough knowledge of the pathology and genetics of LS and of 
the biochemistry of MMR may enable to provide a paradigm for the diagnostic assessment 
of cancer-associated gene variants in the age of personalized genomics. 
REFERENCES 
Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng 
H, Fink D, Christen RD, Boland CR, Koi 
M, Fishel R, Howell SB. 1996. Loss of DNA 
mismatch repair in acquired resistance to 
cisplatin. Cancer Res 56:3087–3090. 
Arnold S, Buchanan DD, Barker M, Jaskowski L, 
Walsh MD, Birney G, Woods MO, Hopper JL, 
JenkinsMA, BrownMA, Tavtigian SV, Goldgar 
DE, Young JP, Spurdle AB. 2009. Classifying 
MLH1 and MSH2 variants using bioinformatic 
prediction, splicing assays, segregation, and 
tumor characteristics. Hum Mutat 30:757–770. 
Avdievich E, Reiss C, Scherer SJ, Zhang Y, Maier SM, 
Jin B, Hou Jr H, Rosenwald A, Riedmiller H, 
Kucherlapati R, Cohen PE, Edelmann W, Kneitz 
B. 2008. Distinct effects of the recurrent Mlh1 
G67R mutation on MMR functions, cancer, and 
meiosis. Proc Natl Acad Sci USA 105:4247–4252. 
Branch P, Hampson R, Karran P. 1995. DNA 
mismatch binding defects, DNA damage 
tolerance, and mutator phenotypes in human 
colorectal carcinoma cell lines. Cancer Res 
55:2304–2309. 
Brieger A, Plotz G, Hinrichsen I, Passmann S, Adam 
R, Zeuzem S. 2012. C-terminal fluorescent 
labeling impairs functionality of DNA 
mismatch repair proteins. PLoS One 7:e31863. 
Brieger A, Plotz G, Raedle J, Weber N, Baum 
W, Caspary WF, Zeuzem S, Trojan J. 2005. 
Characterization of the nuclear import of 
human MutLalpha. Mol Carcinog 43:51–58. 
Brieger A, Trojan J, Raedle J, Plotz G, Zeuzem S. 2002. 
Transient mismatch repair gene transfection 
for functional analysis of genetic hMLH1 and 
hMSH2 variants. Gut 51:677–684. 
Carethers JM, Smith EJ, Behling CA, Nguyen L, 
Tajima A, Doctolero RT, Cabrera BL, Goel A, 
Arnold CA, Miyai K, Boland CR. 2004.Use of 
5-fluorouracil and survival in patients with 
microsatellite-unstable colorectal cancer. 
Gastroenterology 126:394– 401. 
Cejka P, Stojic L, Mojas N, Russell AM, Heinimann 
K, Cannavo E, di Pietro M, Marra G, Jiricny 
J. 2003. Methylation-induced G(2)/M arrest 
requires a full complement of the mismatch 
repair protein hMLH1. EMBO J 22:2245–2254. 
Chao EC, Velasquez JL, Witherspoon MS, Rozek 
LS, Peel D, Ng P, Gruber SB, Watson P, Rennert 
G, Anton-Culver H, Lynch H, Lipkin SM. 
2008. Accurate classification of MLH1/MSH2 
missense variants with multivariate analysis 
of protein polymorphisms-mismatch repair 
(MAPP-MMR). Hum Mutat 29:852–860. 
Christmann M, Kaina B. 2000. Nuclear translocation 
of mismatch repair proteins MSH2 and MSH6 
as a response of cells to alkylating agents. J Biol 
Chem 275:36256– 36262. 
Clark AB, Cook ME, Tran HT, Gordenin DA, Resnick 
MA, Kunkel TA. 1999. Functional analysis of 
human MutSalpha and MutSbeta complexes in 
yeast. Nucleic Acids Res 27:736–742. 
Clark AB, Valle F, Drotschmann K, Gary RK, 
Kunkel TA. 2000. Functional interaction of 
proliferating cell nuclear antigen with MSH2-





































Couch FJ, Rasmussen LJ, Hofstra R, Monteiro 
AN, Greenblatt MS, De Wind N, Group 
IARCUGVW. 2008. Assessment of functional 
effects of unclassified genetic variants. Hum 
Mutat 29:1314–1326. 
Cyr JL, Brown GD, Stroop J, Heinen CD. 2012. The 
predicted truncation from a cancer associated 
variant of the MSH2 initiation codon alters 
activity of the MSH2-MSH6 mismatch repair 
complex. Mol Carcinog 51:647–658. 
Cyr JL, Heinen CD. 2008. Hereditary cancer-
associated missense mutations in hMSH6 
uncouple ATP hydrolysis from DNA mismatch 
binding. J Biol Chem 283:31641– 31648. 
de La Chapelle A. 2004. Genetic predisposition to 
colorectal cancer. Nat Rev Cancer 4:769–780. 
De Wind N, Dekker M, van Rossum A, van der 
ValkM, te Riele H. 1998. Mousemodels for 
hereditary non-polyposis colorectal cancer. 
Cancer Res 58:248–255. 
Drost M, Zonneveld JB, Van Dijk L, Morreau H, Tops 
CM, Vasen HFA, Wijnen J, De Wind N. 2010. 
A cell-free assay for the functional analysis of 
variants of the mismatch repair protein MLH1. 
Hum Mutat 31:247–253. 
Drost M, Zonneveld JB, van Hees S, Rasmussen LJ, 
Hofstra RM, de Wind N. 2012. A rapid and cell-
free assay to test the activity of lynch syndrome-
associated MSH2 and MSH6 missense variants. 
Hum Mutat 33:488–494. 
Drotschmann K, Clark AB, Kunkel TA. 
1999b. Mutator phenotypes of common 
polymorphisms and missense mutations in 
MSH2. Curr Biol 9:907–910. 
Drotschmann K, Clark AB, Tran HT, Resnick MA, 
Gordenin DA, Kunkel TA. 1999a. Mutator 
phenotypes of yeast strains heterozygous for 
mutations in the MSH2 gene. Proc Natl Acad 
Sci USA 96:2970–2975. 
Fishel R. 1998. Mismatch repair, molecular switches, 
and signal transduction. Genes Dev 12:2096–
2101. 
Gammie AE, Erdeniz N, Beaver J, Devlin B, Nanji A, 
Rose MD. 2007. Functional characterization of 
pathogenic human MSH2 missense mutations in 
Saccharomyces cerevisiae. Genetics 177:707–721. 
Guerrette S, Acharya S, Fishel R. 1999. The 
interaction of the human MutL homologues in 
hereditary non-polyposis colon cancer. J Biol 
Chem 274:6336–6341. 
Guerrette S, Wilson T, Gradia S, Fishel R. 1998. 
Interactions of human hMSH2 with hMSH3 
and hMSH2 with hMSH6: examination of 
mutations found in hereditary non-polyposis 
colorectal cancer. Mol Cell Biol 18:6616–6623. 
Hardt K, Heick SB, Betz B, Goecke T, Yazdanparast 
H, K¨uppers R, Servan K, Steinke V, Rahner N, 
Morak M, Holinski-Feder E, Engel C, M¨oslein 
G, Schackert HK, von Knebel Doeberitz M, 
Pox C, Peter Propping; German HNPCC 
consortium, Hegemann JH, Royer-Pokora B. 
2011. Missense variants in hMLH1 identified in 
patients from the German HNPCC consortium 
and functional studies. Fam Cancer 10:273–284.
Hayes AP, Sevi LA, Feldt MC, Rose MD, Gammie AE. 
2009. Reciprocal regulation of nuclear import of 
the yeast MutSα DNA mismatch repair protein 
Msh2 and Msh6. DNA repair 8:739–751. 
Heinen CD, Wilson T, Mazurek A, Berardini M, Butz 
C, Fishel R. 2002. HNPCC mutations in hMSH2 
result in reduced hMSH2-hMSH6 molecular 
switch functions. Cancer Cell 1:469–478. 
Hess MT, Gupta RD, Kolodner RD. 2002. Dominant 
Saccharomyces cerevisiae msh6mutations 
cause increased mispair binding and decreased 
dissociation from mispairs by Msh2-Msh6 in the 
presence of ATP. J Biol Chem 277:25545–25553. 
Hess MT, Mendillo ML, Mazur DJ, Kolodner RD. 2006. 
Biochemical basis for dominant mutations in the 
Saccharomyces cerevisiae MSH6 gene 10.1073/
pnas.0510078103. PNAS 103:558–563. 
Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de 
Wind N, Hoogerbrugge N, Hogervorst FB; IARC 
Unclassified Genetic Variants Working Group. 
2008. Tumor characteristics as an analytic tool 
for classifying genetic variants of uncertain 
clinical significance. Hum Mutat 29:1292–1303. 
Holmes Jr J, Clark S, Modrich P. 1990. Strand-specific 
mismatch correction in nuclear extracts of 
human and Drosophila melanogaster cell lines. 
Proc Natl Acad Sci USA 87:5837–5841. 
Jiricny J. 2006. The multifaceted mismatch-repair 
system. Nat Rev Mol Cell Biol 7:335– 346. 
Kadyrov FA, Dzantiev L, Constantin N, Modrich P. 
2006. Endonucleolytic function of MutLalpha 
in human mismatch repair. Cell 126:297–308. 
Kadyrov FA, Genschel J, Fang Y, Penland E, Edelmann 
W, Modrich P. 2009. A possible mechanism for 
exonuclease 1-independent eukaryotic mismatch 
repair. Proc Natl Acad Sci USA 106:8495–8500. 
Kansikas M, Kariola R, Nyström M. 2011. 
Verification of the three-step model in 
assessing the pathogenicity of mismatch repair 
gene variants. Hum Mutat 32:107– 115. 
Kariola R, Raevaara TE, Lonnqvist KE, Nystrom-
Lahti M. 2002. Functional analysis of MSH6 
46
CHAPTER 2
mutations linked to kindreds with putative 
hereditary non-polyposis colorectal cancer 
syndrome. Hum Mol Genet 11:1303–1310. 
Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, 
Modrich P. 1993. An alkylation tolerant, 
mutator human cell line is deficient in strand-
specific mismatch repair. Proc Natl Acad Sci 
USA 90:6424–6428. 
Knudsen NØ, Andersen SD, Lützen A, Nielsen FC, 
Rasmussen LJ. 2009. Nuclear translocation 
contributes to regulation of DNA excision 
repair activities. DNA Repair 8:682–689. 
Knudsen NØ, Nielsen FC, Vinther L, Bertelsen R, 
Holten-Andersen S, Liberti SE, Hofstra R, Kooi 
K, Rasmussen LJ. 2007. Nuclear localization of 
human DNA mismatch repair protein exonuclease 
1 (hEXO1).Nucleic Acids Res 35:2609–2619. 
Kondo E, Suzuki H, Horii A, Fukushige S. 2003. A 
yeast two-hybrid assay provides a simple way to 
evaluate the vast majority of hmlh1 germ-line 
mutations. Cancer Res 63:3302–3308. 
Kosinski J, Hinrichsen I, Bujnicki JM, Friedhoff P, 
Plotz G. 2010. Identification of Lynch syndrome 
mutations in the MLH1-PMS2 interface that 
disturb dimerization and mismatch repair. 
Hum Mutat 31:975–982. 
Kunkel TA, Erie DA. 2005. DNA mismatch repair. 
Annu Rev Biochem 74:681–710. 
Leong V, Lorenowicz J, Kozij N, Guarne N. 2009. 
Nuclear import of human MLH1, PMS2 and 
MutLα: redundancy is the key. Mol Carcinog 
48:742–750. 
Li GM. 2008. Mechanisms and functions of DNA 
mismatch repair. Cell Res 18:85–98. 
Li GM, Modrich P. 1995. Restoration of mismatch 
repair to nuclear extracts of H6 colorectal tumor 
cells by a heterodimer of human MutL homologs. 
Proc Natl Acad Sci USA 92:1950–1954. 
Lin DP,Wang Y, Scherer SJ, Clark AB, Yang K, 
Avdievich E, Jin B,Werling U, Parris T, Kurihara 
N, Umar A, Kucherlapati R, Lipkin M, Kunkel 
TA, Edelmann W. 2004. An Msh2 point 
mutation uncouples DNA mismatch repair and 
apoptosis. Cancer Res 64:517–522. 
Lutzen A, de Wind N, Georgijevic D, Nielsen F, 
Rasmussen L. 2008. Functional analysis of 
HNPCC-related missense mutations in MSH2. 
Mutat Res 645:44–55. 
Marinovic-Terzic I, Yoshioka-Yamashita A, Shimodaira 
H, Avdievich E, Hunton IC, Kolodner RD, 
Edelmann W, Wang JY. 2008. Apoptotic function 
of human PMS2 compromised by the non-
synonymous single-nucleotide polymorphic 
variant R20Q. Proc Natl Acad Sci USA 105:13993–
13998. 
Mastrocola A, Heinen C. 2010. Lynch syndrome-
associated mutations in MSH2 alter DNA 
repair and checkpoint response functions in 
vivo. Hum Mutat 31:E1699– E1708. 
Meyers M, Wagner MW, Mazurek A, Schmutte C, 
Fishel R, Boothman DA. 2005. DNA mismatch 
repair-dependent response to fluoropyrimidine-
generated damage. J Biol Chem 280:5516–5526. 
Modrich P. 2006. Mechanisms in eukaryotic mismatch 
repair. J Biol Chem 281:30305– 30309. 
Mohd AB, Palama B, Nelson SE, Tomer G, Nguyen 
M, Huo X, Buermeyer AB. 2006. Truncation 
of the C-terminus of human MLH1 blocks 
intracellular stabilization of PMS2 and disrupts 
DNA mismatch repair. DNA Repair 5:347–361. 
Nyström-Lahti M, Perrera C, Räschle M, Panyushkina-
Seiler E, Marra G, Curci A, Quaresima B, 
Costanzo F, D’Urso M, Venuta S, Jiricny J. 2002. 
Functional analysis of MLH1 mutations linked 
to hereditary non-polyposis colon cancer. Genes 
Chromosomes Cancer 33:160–167. 
Olatubosun A, Väliaho J, Härkönen J, Thusberg J, 
VihinenM. 2012. PON-P: Integrated predictor 
for pathogenicity of missense variants. Hum 
Mutat 33:1166–1174. 
Ollila S, Dermadi Bebek D, Jiricny J, Nystrom M. 2008. 
Mechanisms of pathogenicity in human MSH2 
missense mutants. Hum Mutat 29:1355–1363. 
Ollila S, Sarantaus L, Kariola R, Chan P, Hampel 
H, Holinski-Feder E, Macrae F, Kohonen-
Corish M, Gerdes AM, Peltomaki P, Mangold 
E, de la Chapelle A, Greenblatt M, Nystrom 
M. 2006. Pathogenicity of MSH2 missense 
mutations is typically associated with impaired 
repair capability of the mutated protein. 
Gastroenterology 131:1408–1417. 
Ou J, Niessen RC, Lützen A, Sijmons RH, Kleibeuker 
JH, de Wind N, Rasmussen LJ, Hofstra RM. 
2007. Functional analysis helps to clarify the 
clinical importance of unclassified variants 
in DNA mismatch repair genes. Hum Mutat 
28:1047–1054. 
Peltomäki P. 2001. Deficient DNA mismatch repair: 
a common etiologic factor for colon cancer. 
Hum Mol Genet 10:735–740. 
Peltomäki P. 2003. Role of DNA mismatch repair 
defects in the pathogenesis of human cancer. J 
Clin Oncol 21:1174–1179. 
Pena-Diaz J, Jiricny J. 2012. Mammalian mismatch 
repair: error-free or error-prone? Trends 




































Polaczek P, Putzke AP, Leong K, Bitter GA. 1998. 
Functional genetic tests of DNA mismatch 
repair protein activity in Saccharomyces 
cerevisiae. Gene 213:159– 167. 
Raevaara TE, Korhonen MK, Lohi H, Hampel 
H, Lynch E, Lonnqvist KE, Holinski- Feder 
E, Sutter C, McKinnon W, Duraisamy S, 
Gerdes AM, Peltomaki P, Kohonen- Corish 
M, Mangold E, Macrae F, Greenblatt M, de 
la Chapelle A, Nystrom M. 2005. Functional 
significance and clinical phenotype of non-
truncating mismatch repair variants of MLH1. 
Gastroenterology 129:537–549. 
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, 
French AJ, Goldberg RM, Hamilton SR, 
Laurent-Puig P, Gryfe R, Shepherd LE, Tu 
D, Redston M, Gallinger S. 2003. Tumor 
microsatellite-instability status as a predictor 
of benefit from fluorouracilbased adjuvant 
chemotherapy for colon cancer. N Engl J Med 
349:247–257. 
Sharp A, Pichert G, Lucassen A, Eccles D. 2004. RNA 
analysis reveals splicing mutations and loss of 
expression defects in MLH1 and BRCA1. Hum 
Mutat 24:272. Shcherbakova PV, Kunkel TA. 
1999. Mutator phenotypes conferred by MLH1 
overexpression and by heterozygosity for mlh1 
mutations. Mol Cell Biol 19:3177–3183. 
Shimodaira H, Filosi N, Shibata H, Suzuki T, Radice 
P, Kanamaru R, Friend SH, Kolodner RD, 
Ishioka C. 1998. Functional analysis of human 
MLH1 mutations in Saccharomyces cerevisiae. 
Nat Genet 19:384–389. 
Spurdle AB. 2010. Clinical relevance of rare germline 
sequence variants in cancer genes: evolution 
and application of classification models. Curr 
Opin Genet Dev 20:315– 323. 
Stojic L, Brun R, Jiricny J. 2004. Mismatch repair and 
DNA damage signalling. DNA Repair 3:1091–
1101. 
TakahashiM, Shimodaira H, Andreutti-Zaugg C, 
Iggo R, Kolodner R, Ishioka C. 2007. Functional 
analysis of human MLH1 variants using yeast 
and in vitro mismatch repair assays. Cancer Res 
67:4595–4604. 
Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes 
GB. 2008. IARC unclassified genetic variants 
working group in silico analysis of missense 
substitutions using sequence-alignment based 
methods. Hum Mutat 29:1327– 1336. 
Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, 
te Riele H, Arends MJ, Wyllie AH, Margison 
GP, Clarke AR. 1999. Msh2 status modulates 
both apoptosis and mutation frequency in the 
murine small intestine. Proc Natl Acad Sci 
USA96:3911– 3915. 
Tournier I, Vezain M, Martins A, Charbonnier F, 
Baert-Desurmont S, Olschwang S, Wang Q, 
Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M. 
2008. A large fraction of VUS of the mismatch 
repair genesMLH1 and MSH2 is associated with 
splicing defects. Hum Mutat 29:1412–1424. 
Trojan J, Zeuzem S, Randolph A, Hemmerle C, 
Brieger A, Raedle J, Plotz G, Jiricny J, Marra G. 
2002. Functional analysis of hMLH1 variants 
and HNPCC-related mutations using a human 
expression system. Gastroenterology 122:211– 
219. 
van Oers JM, Roa S, Werling U, Liu Y, Genschel J, 
Hou Jr H, Sellers RS, Modrich P, Scharff MD, 
Edelmann W. 2010. PMS2 endonuclease 
activity has distinct biological functions and 
is essential for genome maintenance. Proc Natl 
Acad Sci USA 107:13384–13389. 
Wanat JJ, Singh N, Alani E. 2007. The effect of genetic 
background on the function of Saccharomyces 
cerevisiae mlh1 alleles that correspond to HNPCC 
missense mutations. Hum Mol Genet 16:445–452. 
Watanabe Y, Haugen-Strano A, Umar A, Yamada 
K, Hemmi H, Kikuchi Y, Takano S, Shibata 
Y, Barrett JC, Kunkel TA, Koi M. 2000. 
Complementation of an hMSH2 defect in 
human colorectal carcinoma cells by human 
chromosome 2 transfer. Mol Carcinog 29:37–49. 
Wielders EA, Dekker RJ,Holt I,Morris GE, te Riele 
H. 2011. Characterization of MSH2 variants 
by endogenous gene modification in mouse 
embryonic stem cells. Hum Mutat 32:389–396. 
Wu J, Gu L, Wang H, Geacintov NE, Li GM. 1999. 
Mismatch repair processing of carcinogen-
DNA adducts triggers apoptosis. Mol Cell Biol 
19:8292–8301. 
Wu X, Platt JL, Cascalho M. 2003. Dimerization of 
MLH1 and PMS2 limits nuclear localization of 
MutLalpha. Mol Cell Biol 23:3320–3328. 
Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin 
M, Kucherlapati R, Kolodner RD, Edelmann 
W. 2004. Dominant effects of an Msh6 
missense mutation on DNA repair and cancer 
susceptibility. Cancer Cell 6:139–150. 
Zhang H, Richards B, Wilson T, Lloyd M, Cranston 
A, Thorburn A, Fishel R, Meuth M. 1999. 
Apoptosis induced by overexpression of 





A Rapid and Cell-free Assay to Test 
 the Activity of Lynch Syndrome-associated 
MSH2 and MSH6 Missense Variants 
Mark Drost, José B.M. Zonneveld, Sandrine van Hees, 
Lene Juel Rasmussen, Robert M.W. Hofstra 
and Niels de Wind
Adapted from Drost et. al 2012 Hum Mutat 33:488–494
ABSTRACT
Lynch Syndrome (LS) is an autosomal dominant disorder that predisposes to colon, 
endometrial and other cancers. LS is caused by a heterozygous germline mutation in one 
of the DNA mismatch repair (MMR) genes. A significant proportion of all mutations found 
in suspected LS patients comprises single amino acid alterations. The pathogenicity of these 
Variants of Uncertain Significance (VUS) is difficult to assess, precluding diagnosis of carriers 
and their relatives. Here we present a rapid cell-free assay to investigate MMR activity of 
MSH2 or MSH6 VUS. We used this assay to analyze a series of MSH2 and MSH6 VUS, selected 
from the Leiden Open Variation Database. Whereas a significant fraction of the MSH2 VUS 
has lost MMR activity, suggesting pathogenicity, the large majority of the MSH6 VUS appears 
MMR proficient. We anticipate that this assay will be an important tool in the development of 




Lynch Syndrome (LS) is an autosomal dominant cancer syndrome that predisposes to a 
variety of malignancies, including colon, gastric, brain, ovarian and urological cancers 
(MIM# 120435)[Lagerstedt Robinson et al., 2007]. The syndrome is caused by mutations in 
one of the DNA Mismatch Repair (MMR) genes, most frequently MSH2 (MIM# 609309), 
MSH6 (MIM# 600678) or MLH1 (MIM# 120436). In a significant proportion of individuals 
suspected of LS, missense mutations or small in-frame deletions are detected in MMR 
genes (18% in MSH2, 38% in MSH6 and 32% in MLH1 [Peltomäki and Vasen, 2004]). Since 
the causality of such variants is difficult to assess, they are often referred to as Variants 
of Uncertain Significance (VUS) [Ou et al., 2007]. The lack of classification of these VUS 
precludes LS diagnosis for carriers and their relatives. For this reason, there is a need 
for convenient functional assays that may play a key role in the diagnostic assessment of 
suspected LS patients carrying an MMR gene VUS.
The MMR pathway repairs spontaneous misincorporations during replication. In 
eukaryotic cells, the major MMR pathway is initiated by a heterodimer that recognizes 
mismatched basepairs, called MutSα and consisting of MSH2 and MSH6 [Hsieh and 
Yamane, 2008]. This leads to the recruitment of the downstream repair components MutLα 
(composed of MLH1 and PMS2) and EXO1. These enzymes will nick and then degrade the 
newly synthesized DNA, which is followed by resynthesis, usually incorporating the correct 
nucleotide. The entire MMR reaction can also be performed in vitro in wild type (WT) 
human cell extracts [Holmes et al., 1990], but also in cell extracts lacking defined MMR 
proteins, complemented with purified or overexpressed protein [Li and Modrich, 1995]. 
Consequently, the ability of an MMR VUS protein to complement such a MMR-deficient 
cell extract may contribute to the assessment of its pathogenicity [Ou et al., 2007; Kansikas 
et al., 2011]. Unfortunately, the need for laborious and cost-intensive molecular cloning and 
cell culture has precluded the wide applicability and independent validation of these assays.
Recently, we described a cell-free assay for the functional analysis of VUS in the MLH1 
gene that avoids these drawbacks [Drost et al., 2010]. Here, we report on the development of a 
similar assay for the functional analysis of VUS in MSH2 and MSH6. Using this assay we have 
tested a series of VUS in MSH2 and MSH6 that have been found in suspected LS patients. In 
contrast to many VUS in MSH2, most VUS in MSH6 demonstrate no defect in MMR. 
METHODS 
In Vitro MMR Assays
In vitro MMR assay conditions were as described (Fig. 1A) [Wang and Hays, 2006; Drost et al., 
2010]. Reactions were carried out in a total volume of 25μl containing 75μg nuclear extract (NE). 
NE was prepared from LoVo colon cancer cells, that lack both MSH2 and MSH6, as described 
[Holmes et al., 1990; Jiricny, 2003]. The NE was complemented with 12μl dimerized variant 
MutSα (see below) and 100 ng pJHGT3’lnFAM as a mismatch-containing substrate. After 40 




























Germantown, MD). The substrate was then digested with HinDIII and BsrBI (Fermentas). 
One-fifth (2μl) of digested substrate was mixed with 8μl Hi-Di Formamide containing 0.2μl 
GeneScan-500 ROX size standards (Applied Biosystems) and fragment analysis was performed 
on a 3730 DNA analyzer (Applied Biosystems) at the Leiden Genome Technology Center. Data 
was analyzed using PeakScan Software (Applied Biosystems). Repair levels are calculated by 
dividing the height of the MMR-specific peak by the total fluorescent signal.
Recombinant purified wild type MutSα, produced in Sf9 insect cells, was a gift from 
Prof. Titia Sixma, The Netherlands Cancer Institute.
Generation of MSH2 and MSH6 VUS by PCR and In Vitro Expression 
of MMR VUS Proteins
The human MSH2 (Genbank NM_000251.1) and MSH6 (Genbank NM_000179.2) cDNAs 
were cloned into the pCITE4a expression vector (Novagen, Beeston, UK). These constructs 
were used as templates in a PCR procedure to recreate VUS, including the vector-derived 
T7 promoter and CITE-sequences that are required for efficient protein expression in vitro. 
In brief, overlapping 5’ and 3’ mutant fragments of the gene were generated in separate, 
parallel, PCR reactions (Fig. 1B). In a subsequent PCR the two mutant fragments were 
joined and re-amplified. Oligonucleotides (Supp. Table S1 and S2) were ordered at Biolegio 
(Nijmegen, The Netherlands). All PCRs were performed in 10μl reactions, containing 0.4 
U of Pfx Platinum Polymerase (Invitrogen, Carlsbad, CA, USA). Proper introduction of the 
mutation was confirmed by direct sequencing of all full-length PCR fragments.
After amplification, PCR fragments were purified using the PCR Purification Kit 
(Qiagen, Germantown, MD, USA) and eluted in 40μl TE. These purified fragments 
were then used for in vitro protein expression in the TnT T7 Quick Coupled in vitro 
Transcription/Translation (IVTT) System (Promega, Madison, WI, USA), in the presence 
of PCR Enhancer. Expression levels were verified by producing parallel 35S-Methionine-
labeled reactions according to the manufacturer’s instructions, which were analyzed by 
SDS-polyacrylamide gel electrophoresis and Phosphorimaging (Perkin Elmer, Waltham, 
USA). The WT heterodimeric partner of the variant proteins was produced by large-scale in 
vitro expression from the pCITE4A clones. MutSα for in vitro activity testing was generated 
by allowing in vitro-expressed wild type or VUS MSH2 and MSH6 (1:1 v/v), to dimerize for 
20 minutes at room temperature.
Western Blotting
After addition of Laemmli SDS sample buffer, samples were separated by 8% SDS-
polyacrylamide gel electrophoresis and transferred to Hybond-C membranes (GE Healthcare, 
Little Chalfont, UK). Membranes were incubated with a rabbit α-MLH1 antibody (H300, 
Santa Cruz Biotechnology, Santa Cruz, CA) or a mouse antibody against MSH2 (Ab-2, 
Calbiochem). After incubation with peroxidase-conjugated secondary antibodies (Bio-Rad, 
Hercules, US), proteins were visualized by enhanced chemiluminescence detection. Signals 
were quantified using Optiquant software (Packard Instrument Company, Meriden, USA).
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Generation of Cloned VUS
As controls, a subset of the VUS was also introduced into MSH2 or MSH6 expression plasmids 
(derived from pCITE4A), using site-directed mutagenesis (Quick Change Site-Directed 
Mutagenesis, Stratagene, LaJolla, USA). Amplifications were carried out using Pfx Platinum 
Polymerase. The mutant plasmids were propagated in E. coli. The sequences of the resulting 
plasmids were verified by direct sequencing of the variant MSH2 or MSH6 open reading frames.
RESULTS 
A Cell-Free Assay that Measures the Repair Activity of MSH2 and MSH6 
Proteins
We have recently described a rapid and completely cell-free assay for the functional analysis 
of VUS in MLH1, which may become instrumental in the assessment of their pathogenicity 
[Drost et al., 2010]. Here, we describe a similar approach for the functional analysis of VUS 
in MSH2 and MSH6. The assay relies on the use of an engineered plasmid containing a G∙T 
mismatch and a linked fluorescent label. The mismatch is embedded in a HinDIII restriction 
site, making this site refractory to cutting. Cleavage of the HinDIII site is possible only 
after MMR-mediated repair of the G∙T mismatch, resulting in the generation of a 75 base 
pair fluorescently-labeled restriction fragment that can be identified and quantified on an 
automated fragment analyzer (Fig. 1A). 
To enable the efficient construction of a series of MSH2 or MSH6 VUS we developed a 
two-stage PCR procedure, analogous to the generation of VUS in MLH1 (Fig. 1B) [Drost et 
al., 2010]. This PCR procedure was optimized using non-mutant primers, to recreate wild 
type MSH2 and MSH6 genes. The variant proteins encoded by these PCR-amplified genes 
were expressed in a commercially available reticulocyte lysate-based transcription/translation 
kit. Analysis of proteins expressed in the presence of 35S-Methionine demonstrated similar 
expression levels for MSH2 and MSH6 (Fig. 1C). Subsequently, identical volumes of the in 
vitro expressed MSH2 and MSH6 proteins were heterodimerized and added to an MSH2- and 
MSH6-deficient LoVo NE under conditions of the cell-free assay. To relate the quantity of in 
vitro produced MutSα with the physiological quantity of the dimer a second reaction was 
set up, containing NE of MMR-proficient HeLa cells. The concentration of MSH2 in both 
reactions was then determined by Western blotting. The concentration of in vitro expressed 
MSH2 in the reconstituted LoVo NE was slightly lower than the concentration of endogenous 
MSH2 in the reaction containing WT HeLa NE (Fig. 1D). This indicates that the in vitro 
expression procedure yields MSH2 or MSH6 proteins in near-physiological quantities.
To enable the detection of subtle defects in the activities of the VUS proteins, the amount 
of MSH2 and MSH6 in the assay should not be saturating [Drost et al., 2010; Kansikas et al., 
2011]. Complementation of a NE of LoVo cells by the addition of increasing amounts of purified 
MutSα, produced in Sf9 insect cells, resulted in saturation at 58% repair of the substrate (Fig. 1E). 
Complementation of the LoVo NE with in vitro expressed MSH2 and MSH6 resulted in repair 




























Figure 1. Outline of the cell-free assay. (A) Flow scheme of the cell-free assay. Fluorescently (FAM)-labeled 
substrate pJHGT3’lnFAM is incubated in LoVo NE, complemented with an in vitro produced MutSα heterodimer, 
in which either MSH2 or MSH6 is a VUS. After incubation, the substrate is purified and cleaved with BsrBI and 
HinDIII. Repair products are analyzed by automated fragment analysis and subsequently quantified. The light 
bulb represents the fluorescent FAM label. (B) PCR design and primer positions for generating 5’ and 3’ VUS “half ” 
fragments in parallel reactions and the final, full-length fragment, produced in a second ‘joining’ PCR. Vertical bar: 
position of the introduced mutation. Primer sequences can be found in Supplementary Tables 1 and 2. (C) In vitro 
expression of 35S-Methionine-labeled MSH2 and MSH6, visualized after gel electrophoresis and Phosphorimaging. 
(D) Western blot analysis of MMR protein levels within the repair reaction. Repair assay reactions were assembled 
and a fraction was subjected to Western blotting. The relative amount of MSH2 versus endogenous MLH1 is 
determined. Error bar: S.E.M. (E) In vitro repair activity of in vitro produced wild type MutSα (IVTT), and of 
increasing amounts of purified Sf9-expressed MutSα, added to LoVo NE. Data are shown as mean±S.E.M. of 3 
independent experiments. Bottom: Western blot showing MSH2 protein levels in the repair assay reactions.
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MSH6 is limiting for MMR. Importantly, the addition of in vitro expressed MSH2 or MSH6 
alone to LoVo NE did not result in detectable repair (see also below). This confirms that neither 
the in vitro expression mixture, nor the NE contained measurable amounts or either wild type 
protein, which might interfere with testing VUS proteins. Combined, these results indicate that 
a complementation assay that comprises completely in vitro produced protein may be a feasible 
approach to test the functional activity of MSH2 and MSH6 VUS.
MMR Activities of MSH2 and MSH6 VUS Measured Using a Cell-Free Assay
To investigate the use of the cell-free assay in the functional assessment of MSH2 and MSH6 
VUS, identified in suspected LS patients, we determined the repair activity of 25 VUS in 
MSH2 and 20 VUS in MSH6. An overview of these VUS and their associated pathology 
data, in silico analysis and references can be found in Table 1.  For validation purposes, 
we included MSH2-P622L, MSH2-A636P and MSH6-T1219I as repair-deficient controls 
and MSH2-G332D, MSH2-A834T, MSH6-S144I, MSH6-P1087R and MSH6-P1087T as 
repair-proficient controls. The MMR status of these control variants has been assessed in 
first-generation assays (see Table 1 for references). As an additional repair-deficient control 
we produced MSH6-G1139S, which alters an essential residue in the ATPase domain of 
MSH6 [Woods et al., 2005]. The remaining VUS for both genes were selected in an unbiased 
fashion and were predominantly derived from Dutch and Danish suspected LS patients.
All MSH2 and MSH6 VUS proteins were generated by the two-stage PCR procedure, 
followed by their expression in vitro. The in vitro expressed VUS proteins were similar in yield 
despite occasional variation in the quantities of PCR products (Fig. 2A-D). Sequence analysis, 
performed on all PCR-generated VUS, demonstrated the absence of contamination with wild 
type gene (Fig. 2E and 2F). All VUS proteins were dimerized with their wild type partner to 
recreate variant MutSα proteins, and these were tested in the in vitro MMR assay. The repair 
activity of WT MSH2 or WT MSH6 alone, or of all established repair-deficient heterodimerized 
controls was 16% or less, relative to wild type (Fig 3A and B). In contrast, all repair-proficient 
controls displayed a repair activity that was significantly higher than the MMR-deficient controls. 
This result indicates that the assay has sufficient resolution to distinguish repair-proficient from 
repair-deficient MMR VUS proteins. As a tentative cutoff for MMR proficiency we assumed a 
repair level that was significantly higher (Student’s one-tailed T-test, p<0.05) than the average 
repair efficiency of the repair-deficient controls. The remaining VUS displayed variable repair 
levels but, notably, MSH2-Y165D, MSH2-N596del, MSH2-G674R, MSH2-K675A, MSH2-
C697F, MSH2-S723F and MSH2-G759E were considered repair-deficient by these criteria (Fig. 
3A). Surprisingly, all tested MSH6 VUS were repair-proficient (Fig. 3B). 
To exclude that a low level of contamination of mutant PCR fragments with wild type 
MSH2 or MSH6 had confounded the results of the assay, we also investigated the repair 
efficiency of a representative selection of the VUS after cloning and propagation in E. coli. 
Repair levels of these cloned MSH2 or MSH6 VUS were not significantly different from 
those of their counterparts produced from the mutant PCR fragments (Supp. Fig S1). 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VUS (Table 1 and data not shown). This result excludes that the detected MMR proficiency 
results from carry-over of the PCR-based VUS proteins with wild-type contaminant. 
DISCUSSION 
The assessment of pathogenicity to an MMR gene VUS provides certainty to carriers. 
Conversely, relatives who do not carry the pathogenic mutation are liberated from the 
burden of surveillance, a procedure that effectively reduces morbidity and mortality in 
individuals diagnosed with LS [Jarvinen et al., 2009]. With the advent of personalized 
genomics the number of identified MMR gene VUS will likely increase, further emphasizing 
the need for a validated and standardized diagnostic procedure [Heinen, 2009]. In this 
work, we present a reproducible, rapid and cell-free assay for the functional analysis of 
VUS in MSH2 and MSH6. The substrate, NE and reagents can be prepared and stored in 
large quantities. Patient-derived material is not required, PCR enzymes and the in vitro 
transcription/translation kit are commercially available, and the assay only uses common 
laboratory equipment. The amount of in vitro recreated variant MutSα protein is limiting 
and therefore the assay may be suited to detect subtle losses-of-function of the VUS. 
Figure 2. Overview of the production of MSH2 and MSH6 VUS by PCR and their subsequent in vitro expression. (A) 
Representative agarose gel showing 5’ and 3’ ‘half ’, and joint, PCR products of all tested MSH2 VUS. (B) As A, but 
for MSH6 VUS. (C) Representative expression of 35S-Methionine-labeled MSH2 VUS, visualized after SDS-PAGE 
gel electrophoresis and autoradiography. (D) As C, but for MSH6 VUS. (E) Example of sequence chromatograms of 
two randomly chosen PCR-generated full-length MSH2 VUS fragments and a WT control. G674R carries a GàC 
transversion at position 2020 of the open reading frame; L805V carries a CàG transversion at position 2413, 
as indicated by the dotted box. No contamination with wild type gene is detected. (F) As E, but for MSH6 VUS.
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Based on these characteristics we infer that the assay may become a key ingredient in a 
comprehensive diagnostic procedure for LS-associated VUS.
All MSH2 VUS tested here were also analyzed in silico with PolyPhen, as well as with 
MAPP-MMR, a tailored alignment-based algorithm [Ramensky et al., 2002; Chao et al., 
2008]. As MAPP-MMR is not available for MSH6, the MSH6 VUS were tested only with 
PolyPhen. Results from these algorithms correspond with our functional data in 83% and 
73% of all cases, respectively (Table 1). Our functional results are consistent with previously 
published activity assays on the mammalian VUS. VUS MSH2-H639R demonstrates low 
repair levels in our assay, albeit reproducibly and significantly higher than controls. This 
is in agreement with minor mismatch-binding defects [Lützen et al., 2008], supporting the 
notion that the cell-free complementation assay can be used to detect subtle defects of VUS. 
However, the assay described here requires more validation to classify VUS displaying low 
to intermediate levels of repair. Also, the validation of this assay using a much larger panel of 
well-studied variants should prove its specificity and sensitivity. Ultimately, this may allow 
the determination of the relation between repair efficiency in vitro and cancer penetrance in 
suspected LS patients. These steps may be important for the future integration of the assay 
in a Bayesian integrated evaluation of MMR gene VUS [Goldgar et al., 2008]. 
Remarkably, besides the repair-deficient controls we have included, none of the MSH6 
VUS were repair-deficient, in line with other functional studies [Martinez and Kolodner, 
2010; Kansikas et al., 2011]. Consequent to its redundancy with a minor MSH3-dependent 
MMR pathway, inactivating mutations in MSH6 may be less penetrant, and therefore 
Figure 3. MMR activity of MSH2 and MSH6 VUS as measured in the cell-free assay. (A) Relative repair efficiencies 
for MSH2 VUS. (-): Repair-deficient controls, (+): Repair-proficient controls. Results are shown as mean±S.E.M. of 
3-4 fully independent experiments for all VUS and >6 experiments for controls. Mock: Mock expression. Asterisks: 
Significantly higher than repair-deficient controls. *=p<0.05, **=p<0.01, ***=p<0.001 (Student’s one-tailed t-test). 




























less prevalent, in suspected LS patients than MSH2 mutations. Suspected LS families are 
usually identified using the Amsterdam or Bethesda criteria that are biased towards high 
disease penetrance. Indeed, these criteria were recently shown to lack sensitivity to identify 
MSH6 mutation carriers [Sjursen et al., 2010]. Alternatively, a lack of pathogenicity may be 
caused by a bias in MSH6 VUS databases. Pathogenic VUS may be underrepresented in the 
relatively small absolute number of MSH6 VUS currently registered, and the relative amount 
of pathogenic MSH6 VUS may increase along with the total number of VUS. Also, we 
cannot exclude that some VUS that show normal activity in vitro are non-functional in vivo, 
e.g. resulting from defects in splicing, stability or intracellular localization. Thus, although 
loss of activity in an in vitro MMR assay may be a strong indication of pathogenicity, wild 
type activity does not exclude pathogenicity of the VUS. For this reason, the latter class of 
MMR gene VUS might require additional analyses, including splice analysis [Tournier et 
al., 2008] and in vivo stability and localization assays [Lützen et al., 2008]. 
Together with our previous work describing a similar cell-free assay for the functional 
assessment of VUS in MLH1 [Drost et al., 2010] rapid, reproducible and cell-free assays are 
now available for the analysis of VUS in all major genes, implicated in LS. We anticipate 
that these assays will be important tools for the development of a comprehensive diagnostic 
procedure for LS-associated VUS [Couch et al., 2008; Kansikas et al., 2011].
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Supplementary Figure S1. Comparison of MMR activity of VUS expressed in vitro from PCR products or from 
their cloned counterparts. (A) Relative repair efficiencies for MSH2 VUS, expressed from either PCR products 
(black bars, results are as in Fig. 3) or from plasmids (grey bars). Results are shown as mean±S.E.M. of 3-4 




























Supplementary Table S1. Oligonucleotide primer sequences used for the generation of all MSH2 VUS using 
two-stage PCR amplification.







































Supplementary Table S1. Continued


















External oligo 1 For AATTAACCCTCACTAAAGGTGGTGCACTCTCAGTACAATC
External oligo 2 Rev AGGCTTGTACATATTGTCGT
Tag Specific oligo For AATTAACCCTCACTAAAGG
Nested oligo Rev TTAGGTGACACTATAGAATAC
a Amino acid numbering is based on the cDNA with +1 corresponding to the translation initiation codon.
b “Forward” refers to mutagenic oligo 2 in Figure 1B, “Reverse” refers to mutagenic oligo 1 in Figure 1B.
c Bold, underlined font: VUS introducing  nucleotide.
d Wild type primers do not introduce a mutation and have been chosen randomly. 




























Supplementary Table S2. Oligonucleotide primer sequences used for the generation of all MSH6 VUS using 
two-stage PCR amplification.
Mutant a Forward/ Reverse b Sequence 5’-3’ c






































Supplementary Table S2. Contiuned







For explanation of a, b, c, and d, see Supplementary Table S1.
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ABSTRACT
The hereditary colon and endometrium cancer predisposition Lynch Syndrome (also called 
HNPCC) is caused by a germ-line mutation in one of the DNA mismatch repair (MMR) 
genes. A significant fraction of the gene alterations detected in suspected Lynch Syndrome 
patients is comprised of amino acid substitutions. The relevance for cancer risk of these 
variants is difficult to assess as currently no time- and cost-effective, validated and widely 
applicable functional assays for the measurement of MMR activity are available. Here we 
describe a rapid, cell-free and easily quantifiable MMR activity assay for the diagnostic 
assessment of variants of the MLH1 MMR protein. This assay allows the parallel generation 
and functional analysis of a series of variants of the MLH1 in vitro using readily available, or 
pre-prepared, reagents. Using this assay we have tested 26 MLH1 variants and of these, 15 
had lost activity. These results are in concordance with those obtained from first-generation 
assays and with in silico and pathology data. After its multifocal technical and clinical 
validation this assay could have great impact for the diagnosis and counseling of carriers of 




Lynch Syndrome (or Hereditary Non-Polyposis Colorectal Cancer, HNPCC; OMIM# 
120435 and 609310) is an autosomal dominant disorder that predominantly predisposes 
to colon and endometrial cancer [Vasen et al., 2007; Stoffel et al., 2009]. Lynch Syndrome 
is caused by a germ-line mutation in one of the DNA mismatch repair (MMR) genes. In a 
Lynch syndrome patient loss of the wild-type allele leads to MMR deficiency which results 
in a spontaneous mutator phenotype that drives rapid carcinogenesis [Li, 2008]. 
A definitive diagnosis of Lynch syndrome can only be made by finding a causative 
germ-line mutation in an MMR gene [Vasen et al., 2007; Stoffel et al., 2009]. Additionally, 
the identification of a causative mutation allows the presymptomatic screening of affected 
relatives [Vasen et al., 2007]. Of all mutations found in suspected Lynch Syndrome patients, 
~15% in MSH2 (OMIM# 609309), ~30% in MLH1 (OMIM# 120436) and ~40% in MSH6 
(OMIM# 600678) give rise to single amino acid alterations [Peltomäki and Vasen, 2004; 
Lagerstedt Robinson et al., 2007] of which the pathological significance is often unclear (so-
called Variants of Uncertain Significance, or VUS). Lack of classification of these variants 
precludes diagnosis for carriers and their relatives. Therefore, when a suspected Lynch 
syndrome patient carries a VUS, all first-degree relatives currently enroll lifelong periodic 
screening, irrespective of their mutation status [Castells et al., 2009]. Screening poses a 
physical and psychological burden on these families, but also a burden on the preventive 
health care apparatus. To enable correct diagnosis and to avoid unnecessary screening it is 
of great relevance to develop a widely applicable, validated and standardized approach for 
the diagnostic assessment of VUS in MMR genes.
The MMR pathway corrects misincorporations arising during DNA replication and 
thereby prevents the accumulation of spontaneous mutations [Hsieh and Yamane, 2008; 
Li, 2008]. MMR is initiated by the recognition of a misincorporation by the heterodimeric 
MutSα protein, consisting of the MSH2/MSH6 subunits. This triggers the recruitment 
of the MLH1/PMS2 heterodimeric protein (called MutLα) and of Exonuclease 1 that 
removes the misincorporation-containing DNA strand. Removal is directed towards the 
misincorporation-containing daughter strand by the presence of a strand discontinuity 
(‘nick’), 5’ or 3’ of the mismatch. The excised DNA strand is subsequently resynthesized. 
Functional MMR activity of a VUS is considered an important diagnostic criterion [Couch 
et al., 2008; Goldgar et al., 2008; Plon et al., 2008]. In vitro MMR activity assays have been 
developed [Li and Modrich, 1995] and in such a complementation assay the inability of a variant 
to restore MMR activity to a MMR-deficient cell extract almost certainly assigns pathogenicity 
to the VUS [Ou et al., 2007; Couch et al., 2008]. However, the requirement for molecular cloning, 
cell culture and the use of bacteria precludes their independent validation and wide applicability, 
complicating diagnosis and screening of suspected patients and their relatives. 
Here, we present the analysis of in vitro MMR activity of 26 MLH1 VUS using a completely 
cell-free MMR complementation assay. The results from this assay are consistent with those 




























assay is amenable to independent validation and applicable in molecular diagnostic laboratories 
and therefore could greatly contribute to the diagnostic classification of MLH1 VUS.
METHODS
Substrate preparation
The plasmid pUC19CPD has been used for the generation of MMR substrates [Wang and 
Hays, 2006] and was modified by introducing additional recognition sites for nicking 
endonucleases. The resulting plasmid was named pJH and, after the introduction of a 
mismatch (see below), allows to measure MMR activity at each DNA strand, directed by 
the presence of a nick either at the 5’ or the 3’ side of the mismatch (Figure 1A and Supp. 
Figure S1). The substrate for MMR was prepared from pJH, essentially as described [Wang 
and Hays, 2006], with modifications. Briefly, a 26 basepair (bp) single-stranded DNA 
stretch between two Nt.BstNBI sites was removed by heating and annealing to an excess of 
complementary oligonucleotide. The resulting gapped pJH was purified on Sephacryl S-400 
HR colums (GE Healthcare, Piscataway, NJ). Phosphorylated oligonucleotide G/T-Fam, 
containing a mismatching nucleotide and an internal 6-FAM fluorescent label, was annealed 
into the gapped plasmid and ligated. After purification the resulting mismatched substrate 
was nicked at the bottom strand, 138 bp 3’ to the mismatch with Nb.BsmI. Finally, the 
substrate, named pJHGT3’lnFAM (Figure 1B, top panel), was purified, aliquoted and frozen 
until use. All enzymes were purchased from New England Biolabs.
Preparation of Nuclear Extracts
HCT116 MutLα-deficient colon cancer cells [Jiricny, 2003] were grown at 37oC in 
RPMI-1640 (Gibco, Paisley, UK) supplemented with 10% FCS (PAA, Pasching, Austria), 
penicillin, streptomycin and Pyruvate (Gibco). Cells were harvested in log-phase and 
nuclear extracts were prepared as described [Holmes et al., 1990]. These extracts can be 
prepared in large quantities, distributed, and stored for prolonged periods.
Generation of MLH1 mutants by PCR and in vitro Expression of MMR VUS 
Proteins
The human MLH1 (GenBank NM_000249.3) and PMS2 (GenBank U14658.1) cDNAs were 
cloned into the pCITE4a vector (Novagen, Beeston, UK). The MLH1 plasmid was used to 
generate MLH1 mutants, containing vector-derived T7 promoter- and CITE sequences 
required for efficient expression in vitro in a two-step PCR procedure (Figure 2A-C). In the 
first round of PCR, overlapping mutant 5’ and 3’ MLH1 fragments were generated separately. 
In a second round of amplification, the 5’ and 3’ overlapping mutant MLH1 fragments were 
pooled and amplified to generate the full-length mutant MLH1 gene. For all PCR reactions we 
used Pfx Platinum polymerase (Invitrogen). All oligonucleotide primer sequences can be found 
in Supp. Table S1. Nucleotide numbering reflects cDNA numbering with +1 corresponding 
to the A of the translation initiation codon in the GenBank reference sequence. Amino acid 
numbering is based on the cDNA with +1 corresponding to the translation initiation codon.
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MLH1-mutant PCR fragments were directly used for in vitro protein expression in the TnT 
Quick Coupled Transcription/Translation Kit (Promega, Madison, WI) in the presence of PCR 
Enhancer®, according to the manufacturer’s instructions. To quantify expression levels, proteins 
were labeled with 35S-Methionine in parallel reactions. Alternatively, protein expression was 
investigated by Western blotting using rabbit α-MLH1 (Santa Cruz Biotechnology, Santa Cruz, 
CA, 1:1000) or mouse α-PMS2 (BD Pharmagen, 1:1.000). Proteins were visualized by enhanced 
chemiluminescence detection. Signals were quantified using OptiQuant software.
Detailed protocols for all procedures are available upon request.
In vitro MMR Complementation Assays
After estimation of quantities of expressed VUS MLH1 proteins by Western blotting, the 
proteins were diluted to similar concentrations in expression mix. This was followed by 
dimerization with in vitro produced wild type PMS2 protein in expression mix (1:1 vol/vol), 
for 30 minutes at room temperature.
Assay reactions were performed in a total volume of 25 µl containing 75 µg of HCT116 
nuclear extract. The extract was complemented with 12 µl of in vitro produced MutLα and 
100 ng of substrate pJHGT3’lnFAM. Reaction conditions for MMR were as described [Wang 
and Hays, 2006]. After the MMR reaction and purification using the MinElute kit (Qiagen, 
Germantown, MD), the substrate was digested with HinDIII and BsrBI (both Fermentas). 
One-fifth (2μl) of digested substrate was mixed with 8μl Hi-Di Formamide containing 
0.2μl GeneScan-500 ROX size standards (Applied Biosystems) and fragment analysis was 
performed on a 3730 DNA analyzer (Applied Biosystems) at the Leiden Genome Technology 
Center. Data was analyzed using PeakScan Software (Applied Biosystems). Repair levels are 
calculated by dividing the height of the MMR-specific peak by the total fluorescent signal.
Generation of cloned mutants
Most mutations were additionally introduced into MLH1, cloned in pCITE4a, by site directed 
mutagenesis (Quick Change Site-directed Mutagenesis, Stratagene, LaJolla, CA). Primer sets 
(Biolegio, Nijmegen, The Netherlands) were designed (Supp. Table S2) and PCR was performed 
using Pfx Platinum polymerase (Invitrogen). PCR products were ligated and used to transform 
E. coli. Resulting plasmids were verified by direct sequencing of the entire mutant MLH1 insert.
In silico analysis
All MLH1 VUS tested in this work were subjected to in silico analyses [Tavtigian et al., 
2008] using the the Sorting Intolerant From Tolerant (SIFT) [Ng and Henikoff, 2003] and 
the MAPP-MMR [Chao et al., 2008] algorithms.
RESULTS
Construction of fluorescent heteroduplex substrate for MMR assays
For the current study we constructed a T/G mismatch-containing substrate, called 




























strand by a nick at that strand, 3’ from the mismatch. Repair of the T/G mismatch to T/A 
by MMR creates a recognition site for HinDIII, within a 174 bp BsrBI restriction fragment. 
This generates a 75 bp fluorescent diagnostic fragment (Figures 1B and 1C, bottom panels). 
A 174 bp BsrBI fragment represents the unrepaired substrate. 
A functional assay using in vitro-produced MutLα
Wild type MLH1 and PMS2 were cloned into pCITE4A. The MLH1 clone was used as a 
template to amplify by PCR the open reading frame of the gene, together with sequences 
required for in vitro transcription/translation. MLH1 and PMS2 were expressed from the PCR 
fragment and from the expression vector, respectively, as judged by W blotting (Figure 1D, left 
panel). Importantly, the reticulocyte lysate was devoid of detectable rabbit MLH1 or PMS2 that 
might give false-positive results. Both proteins were synthesized in approximately equimolar 
amounts as judged by 35S-Methionine levels in both proteins, using a parallel expression 
reaction (Figure 1D, right panel). Next, MLH1 and PMS2 were used to complement an MLH1-
deficient HCT116 nuclear extract for the repair of substrate pJHGT3’lnFAM (Figure 1B). 
Using this assay, nearly half of the substrate was repaired (Figure 1C, left panel). This result 
is similar to the repair efficiency in other assays that use non-fluorescent substrates and in 
vivo produced MutLα [Raevaara et al., 2005; Plotz et al., 2006]. Importantly, mock-expression 
reactions and reactions containing only MLH1 or PMS2 did not result in significant repair 
(Figure 1C, right panel, see also Figure 3). Moreover, the MMR protein stochiometry in our 
MMR assay mimics the in vivo stochiometry, as evidenced by comparing MLH1:MSH6 ratios 
between an MMR complementation assay and wild type cells (Figure 1E). Taken together, 
these results indicate that our cell-free assay is suited for testing MLH1 activity.
Production of MLH1 mutants in a two-step PCR procedure
To create MLH1-mutant genes suited for transcription/translation in vitro without the need 
of prior cloning we developed a two-step PCR-based method to produce 26 MLH1 mutants 
together with regulatory sequences (Table 1, Figure 2A-D, Supp. Table S1 and Methods). 
This procedure was successful for all mutants, although final DNA yields varied somewhat 
(Figure 2E). Sequencing of the MLH1-mutant fragments showed no visible contamination 
with wild type input MLH1 (Figure 2F and Supp. Figure S2). To investigate the PCR fidelity 
more extensively, a PCR product of one of the mutants was cloned and ten independent 
clones were fully sequenced. This revealed no mutations, additional to the desired one (not 
shown). We conclude that the PCR-based approach to generate mutant MLH1 genes for 
expression in vitro is efficient and free of detectable artifacts. 
MMR activities of in vitro produced MLH1 VUS 
The panel of 26 MLH1 mutants included the three putative polymorphisms and four 
presumed pathogenic mutants (for references see Table 1). All mutants are described in the 
database of the International Society for Gastrointestinal Hereditary Tumours [Peltomäki and 
Vasen, 2004] (http://chromium.liacs.nl/LOVD2/colon_cancer) and most of them also in the 
MMR Gene Unclassified Variants Database [Ou et al., 2008] (http://www.mmrmissense.net). 
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An overview of pathology data is shown in Table 1. Mutant MLH1 PCR fragments (Figure 
2E) were used to produce proteins in vitro (Figure 2G). No relation between quantities of 
the input PCR fragments and the amount of expressed protein was observed, and incidental 
Figure 1. Outline of the cell free MMR complementation assay. (A). Plasmid pJH. Bold line: single-stranded 
DNA fragment that can be removed by cleavage with Nt.BstNBI and heating. To generate the substrate 
pJHGT3’lnFAM, the latter fragment is replaced with a mismatch- and fluorescent label (star)-containing 
fragment. Then, the bottom strand is nicked at Nb.BsmI to provide strand specificity to the MMR reaction. 
See Supp. Figure S1 for more details. (B). Flow-scheme of the MMR assay. Top panel: MMR substrate, derived 
from pJH. To the substrate in vitro expressed MutLα-variant protein and MutLα-deficient HCT116 cell extract 
are added in the presence of cofactors. After incubation, substrate is purified and cleaved with BsrBI and 
HinDIII (bottom panel). The latter enzyme only cleaves when the mismatch is repaired, resulting in a diagnostic 
fluorescent fragment of 75 bp. Numbers: sizes of restriction sites. (C). Examples of automated fragment analysis 
after a MMR assay. Left panel: Fragment analysis after testing an MMR-proficient variant. Right panel: Example 
of a fragment analysis chromatogram after testing of a mock MutLα expression. (D). Left panel: Western blot 
showing PMS2 and MLH1 proteins produced in vitro from PCR-amplified genes, as well as a mock expression. 
Right panel: 35S-Methionine-labeled PMS2 and MLH1, expressed in vitro from cloned PMS2, and from PCR-
amplified MLH1 genes. (E). Quantification of relative MLH1:MSH6 ratios in VH10 nuclear extracts and in a 




























differences in expression levels were not reproducible between experiments (not shown). 
Next, approximately equal amounts of each protein were tested for MMR activity. The putative 
polymorphisms all repaired more than 84% of wild type, whereas the presumed pathogenic 
mutants all repaired less than 20% (Figure 3, black bars and Supp. Figure S3). This difference 
allows us to selectively identify pathogenic MLH1 mutants. In the other 19 MLH1 mutants we 
found a large variation in MMR activity (Figure 3). As a tentative cutoff for MMR deficiency 
we assumed a repair level that was not significantly higher (Student’s two-tailed T-test, 
p<0.05) than the average repair efficiency of the presumed pathogenic mutants. In support, 
all repair deficient VUS were predicted to be deleterious using SIFT analysis and most also by 
MAPP-MMR, an algorithm focused at MMR gene variants (Table 1).
Figure 2. In vitro generation of MLH1-variant genes and proteins. (A,B). PCR design and primer positions for 
generating 5’ and 3’ MLH1-mutant ‘half ’ fragments, respectively. (C). The 5’ and 3’ mutant MLH1 fragments 
are joined in a second PCR step, resulting in mutant MLH1, preceded by regulatory sequences. (D). Functional 
domains of MLH1 [Raevaara et al., 2005; Wanat et al., 2006], with all 26 constructed and tested VUS. Amino acid 
numbering is based on the cDNA with +1 corresponding to the translation initiation codon. (E). Representative 
agarose gel picture of the PCR-based generation of 26 MLH1-mutant PCR fragments. Top panel: 5’ mutant ‘half ’ 
fragments, middle panel: 3’ mutant ‘half ’ fragments, bottom panel: full-length mutant MLH1 fragments. Left: 
size markers (kbp). (F). Example of sequencing results from three randomly chosen PCR-generated full-length 
MLH1-mutant fragments. Top sequence: wild type sequence Bottom sequence: mutant sequence. The desired 
nucleotide alterations are encircled. See Supp. Figure 2 for a color version. (G). Representative Western blot of 
all 26 in vitro produced MLH1-variant proteins, expressed directly from mutagenic PCR-generated templates. 
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Repair efficiencies of cloned mutants mirror repair efficiencies  
of PCR-based mutants
To further investigate the robustness of the PCR product-based expression system, we 
investigated the activity of MLH1 VUS, expressed after their cloning. Although the 
activities of cloned VUS reflected those of PCR-generated VUS (Figure 3), repair levels for 
the MMR-proficient cloned VUS were somewhat higher than those of the PCR-based VUS, 
due to the presence of MMR-inhibitory contaminants in the PCR-based expressions (not 
shown). Nevertheless, the generation of MLH1 VUS in a two-step PCR followed by their 
direct expression provides a rapid and reliable alternative for cloning.
MMR VUS classification does not critically depend on protein levels
As the expression levels between individual variant proteins was subject to some random 
variation (see above) we wanted to investigate whether the MMR assay is tolerant to 
variations in MLH1 levels. To this end, wild type MLH1, MMR-proficient VUS E578G 
and MMR-deficient VUS G67R were expressed from PCR products (Figure 2G). Then, 
the reactions were diluted up to twofold such that each contained a similar concentration 
of MLH1. During further serial dilution, both the wild type protein and E578G retained 
activity that discriminates them from G67R (Figure 4). Remarkably, at increasing dilutions 
the activity of E578G was more affected than of wild type MLH1, indicating that the 
mutation may confer partial loss of function. This result shows that the assay is tolerant to 
stochastic variations in in vitro expression levels of the MLH1 variants.
Figure 3. MMR activity as measured in the in vitro MMR complementation assay. MMR activity assays of PCR 
fragment-based MLH1-variant proteins (black bars) and of plasmid clone-based MLH1 variant proteins (grey 
bars). Pathogenic: Putative pathogenic Lynch Syndrome VUS, Polymorphisms: Putative MLH1 polymorphisms. 
Results are mean±S.E.M. of at least three completely independent (from PCR to MMR assay) experiments. *: 
Significantly higher repair activity as compared to the four putatively pathogenic variants (two-tailed T test, 
p<0.05). The repair activity of wild type MLH1 was set at 100%. Representative examples of fragment analysis 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Proper genetic counseling of suspected Lynch Syndrome patients requires an accurate 
diagnosis based on the nature of the germ line mutation found. Cancer risk resulting from 
non-truncating, and especially missense, variants is difficult to predict. This results in anxiety 
and, frequently, unnecessary periodic screening in carriers of such a variant, but also in both 
VUS-carrying and non-carrying relatives. In this work we present a cell-free assay for the 
functional analysis of MLH1 VUS that enables the rapid identification of pathogenic variants. 
Repair deficiency for a VUS in our assay was, with few exceptions, consistent with the in 
silico prediction of pathogenicity and with pathology data (Table 1). Some of the same VUS were 
analyzed before by others and most MLH1 VUS that were inactive in our assay were also inactive 
in other assays. Notable exceptions are VUS R265C that, although classified repair-deficient 
in three studies [Plotz et al., 2006; Takahashi et al., 2007; Wanat et al., 2007], was classified 
proficient in another [Trojan et al., 2002]. Additionally, L550P, A589D and P654L were active in 
another assay [Raevaara et al., 2005] but inactive in yeast-based assays [Takahashi et al., 2007; 
Wanat et al., 2007]. The latter VUS are located at the protein-protein interaction domain (Figure 
2G). In vitro binding studies (Andersen et al., personal communication) support a defect for 
these variants and another study has shown binding defects for other VUS in this region of the 
protein [Guerrette et al., 1999]. Furthermore, the observed lack of nuclear import of PMS2 by 
these VUS [Raevaara et al., 2005] supports a dimerization defect, since heterodimerization of 
MLH1 and PMS2 stimulates nuclear import of MutLα [Knudsen et al., 2009]. Additionally, all 
four VUS that show discrepant results (R265C, L550P, A589D and P654L) are predicted to be 
defective by in silico analyses and were associated with microsatellite instability, a hallmark of 
MMR deficiency (Table 1). For these reasons, we conclude that a lack of activity in our assay is 
in agreement with most other functional data, with pathology data and with in silico analysis. 
Figure 4. Limited dependence of MMR activity on MLH1 concentration. To achieve similar protein 
concentrations, wild type MLH1 and variant G67R (Figure 2G) were initially diluted twofold. After further 
dilution, MMR activity was tested for all three proteins. Error bars: S.E.M.
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Since a loss of MMR is strongly predictive for Lynch Syndrome, the positive predictive 
value of our assay is bound to be high. Further validation of our assay seems warranted, 
using a much larger group of accepted polymorphisms and pathogenic mutations from 
well-studied patients. This could aid in determining the relation between MMR activity and 
disease penetrance, enabling to assess pathogenicity of VUS that display a low- to intermediate 
level of repair. However, as our assay does not address specific in vivo MMR defects, such 
as a splicing, stability or intracellular localization, nor subtle in vitro defects, the negative 
predictive value will probably be lower. As an example, E578G displayed reduction in MMR 
activity only after its dilution (Figure 4) that may reflect a subtle dimerization defect. We 
infer that, in addition to a cell-free complementation assay as described here, additional 
functional data might be used for final diagnosis of VUS that display residual activity. This 
may include nuclear localization assays [Raevaara et al., 2005], splicing assays [Tournier 
et al., 2008], protein-protein interaction studies [Guerrette et al., 1999] or stability studies 
[Perera and Bapat, 2008]. A combination of different analytical approaches, pathological 
and family data should result in a comprehensive, validated, diagnostic procedure of VUS 
in MLH1 and other MMR genes [Plon et al., 2008]. 
In conclusion, with this assay, we have developed a simple, rapid, cost-effective and 
reliable method that may fill a niche in diagnostic labs [Heinen, 2009]. Cell extracts, 
substrate and other ingredients can be prepared, stored and distributed in large quantities. 
The full assay (recreation of the mutants by PCR, in vitro expression and in vitro MMR 
assay) can be performed in three to four days, and many mutants can be tested in parallel. 
The procedure can be used to screen the large amount of mutants already detected, a number 
that, due to the advent of personalized genomics, is likely to rise sharply. Alternatively, the 
assay may be used for high-resolution a priori VUS analyses as was done for p53 [Kato 
et al., 2003]. Currently we are developing and testing very similar cell-free assays to test 
functional activity of VUS in the MSH2 and MSH6 MMR genes.
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Supplementary Figure S1. Schematic overview of substrate production at the nucleotide level. (A) Relevant sequences 
of plasmid pJH. (B) A single-stranded DNA stretch of 26 nucleotides between two NtBstNBI nicking endonuclease 
sites is removed. (C) In the single-stranded DNA gap, an oligonucleotide that introduces a T/G mismatch and in 
addition contains a fluorescent label (star) is annealed and ligated. Then, the bottom strand is nicked 138 nucleotides 
3’ of the T/G mismatch with Nb.BsmI. This directs the MMR reaction towards the lower, G-containing strand. (D) 
MMR-mediated correction of the T/G mismatch results in the generation of a diagnostic HinDIII restriction site. 
Double cleavage with HinDIII and BsrBI (not shown) results in a diagnostic fluorescent fragment of 75 bp.
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Supplementary Figure S2. Functional assessment of MLH1 variants in vitro. The Figure represents MMR 
assays for a mock reaction and 26 MLH1 variants, performed in a single run. See Figure 1 for an explanation. 




























Supplementary Table S1. Primer sequences used for the generation of all MLH1 mutants using the two-step 
PCR amplification.








































Supplementary Table S1. Continued






















External oligo 1 For TTAGGTGACACTATAGAATACTCAGGCTGCGCAACTGTTGG
Nested oligo 2 Rev TCGCCACCTCTGACTTGAGC
pCite 1 Rev CAGTGGCGATAAGTCGTGTCTTACCG
pCite 2 Rev CGAACTGAGATACCTACAGCGTGAGCTATG
1 Wild type primers do not introduce a mutation and have been chosen randomly.
All primers are shown from 5’ to 3’ polarity




























Supplementary Table S2. Primer sequences for site-directed mutagenesis of cloned MLH1.



























Amino acid numbering is based on the cDNA with +1 corresponding to the translation initiation codon.
Bold, underlined font: mutant nucleotide. 
Small, italic font: silent mutations introducing a restriction site for identification of the linked nucleotide 
substitution
All mutant plasmids used in this study, but not listed in this table have been gently provided from Professor 





Inactivation of DNA Mismatch Repair 
by Variants of Uncertain Significance 
in the PMS2 Gene
Mark Drost, Hester Koppejan and Niels de Wind
Adapted from Drost et. al 2013 Hum Mutat 34:1477-1480
ABSTRACT
Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation 
in one of four DNA mismatch repair (MMR) genes. Frequently a variant of uncertain 
significance (VUS), rather than an obviously pathogenic mutation, is identified in one 
of these genes. The inability to define pathogenicity of such variants precludes targeted 
healthcare. Here, we have modified a cell-free assay to test VUS in the MMR gene PMS2 for 
functional activity We have analyzed nearly all VUS in PMS2 found thus far and describe 
loss of MMR activity for five, suggesting the applicability of the assay for diagnosis of LS.
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LS predisposes to various cancers, most notably to colon and ovarian cancer [de la Chapelle, 
2004]. LS is caused by heterozygous inactivating mutations in one of the MMR genes 
MSH2 (MIM# 609309), MSH6 (MIM# 600678), MLH1 (MIM# 120436) or PMS2 (MIM# 
600259) [de la Chapelle, 2004]. Inadvertent loss of the second, wild type, allele in somatic 
cells results in MMR deficiency, which underlies the accumulation of spontaneous genomic 
mutations and the rapid development of cancer [de la Chapelle, 2004]. Confirmed LS patients 
enroll in lifelong preventive surveillance programs and may benefit from personalized 
chemoprevention and chemotherapy [Hewish et al., 2010; Burn et al., 2011]. Unfortunately, 
genetic diagnosis of LS patients is complicated by the fact that a significant fraction of all 
MMR gene alterations found are so-called Variants of Uncertain Significance (VUS) [de la 
Chapelle, 2004]. In the absence of data on the impact of the VUS on gene function, it is 
often difficult to interpret their pathogenicity. Moreover, the incidence of VUS is believed 
to increase steeply with the advent of personalized genomics [Rasmussen et al., 2012]. To 
enable personalized healthcare for carriers of pathogenic variants and to liberate unaffected 
relatives from the burden associated with the uncertain pathogenicity of the VUS, it is of great 
importance to develop procedures to evaluate their pathogenicity [Rasmussen et al., 2012]. 
Of all MMR genes, VUS in PMS2 have the highest incidence, comprising ~49% of all 
alterations described in this gene (http://www.med.mun.ca/MMRvariants/statistics.aspx). We 
have recently described a cell-free assay to measure the functional activity of VUS in the 
MMR genes MSH2, MLH1 and MSH6 [Drost et al., 2010, 2012]. To facilitate the assessment of 
pathogenicity of VUS in PMS2 we have modified the cell-free assay to analyze their functional 
activity. In this assay the mutated cDNA is recreated by PCR, followed by in vitro transcription/
translation of the variant PMS2 protein and of its wild type heterodimeric partner MLH1 
(Figure 1A). To serve as template for the generation of the variant PMS2 alleles we used a 
wild type PMS2 fused to short S and thrombin tags, as this fusion protein displayed higher 
in vitro expression than the native PMS2 (Supp. Figure S1A, compare the first two lanes), 
while it did not affect its activity (Supp. Figure S1B). The variant MLH1/PMS2 heterodimer is 
added to an MLH1/PMS2-deficient cell extract and tested for its ability to restore a HinDIII 
restriction enzyme recognition site that is disrupted by an embedded G·T mismatch (Figure 
1B). The inability to restore repair of the mismatch is indicative of the pathogenicity of a 
PMS2 VUS. All experimental procedures are described in the Supp. Materials & Methods. 
The assay appeared relatively insensitive to the amount of PMS2 included in the reaction, 
contributing to its robustness (Supp. Figure S1). The absolute repair efficiency of tagged wild 
type PMS2 under the conditions used in this assay is 43.5%±4.2 (mean±S.E.M.) and this is 
highly reproducible (Supp. Figure 1B). As the substrate concentration is in excess, absolute 
repair efficiencies are not a relevant measure for defects of a VUS. For this reason the in vitro 
MMR assay data is expressed as percentage of repair relative to wild type.
To test the applicability of the assay we have determined repair efficiencies of 27 
VUS in PMS2, representing the large majority of all VUS registered in the Leiden Open 
Variation Database (LOVD; Table 1). Of these, variant E705K served as an MMR-deficient, 





























E541K and G857A were included as innocuous polymorphisms, as judged from their high 
allele frequencies (dbSNP rs2228006 and rs1802683, respectively). PMS2 variants registered 
in the LOVD as PMS2 pseudogene-derived were excluded from analysis. All alleles were 
recreated by PCR and protein was produced in vitro (Figure 1C). 
As the polymorphic PMS2 alleles enabled repair activities significantly higher than 
the known pathogenic control E705K, the assay has sufficient resolution to distinguish 
repair-proficient from repair-deficient VUS (Figure 1D). Variants with repair efficiencies 
not significantly higher than the pathogenic control (E41A, S46I, S46N and C843Y) were 
Figure 1. Mismatch repair activity of PMS2 VUS. (A) Production of variant PMS2 alleles and proteins. All alleles, 
including template vector-derived T7 promoter and CITE sequences that are required for efficient transcription/
translation in vitro, are generated by two sequential site-specific mutagenic PCR reactions. Variant PMS2 alleles 
are then used as a template in an in vitro transcription/translation reaction to produce variant PMS2 proteins. (B)
Flow scheme of the cell-free assay. Left: Fluorescently labelled (light bulb) substrate pJHGT3’lnFAM is incubated 
in HCT-116 nuclear extract and in vitro produced heterodimeric variant PMS2/wild type MLH1 protein. Middle: 
After incubation, the substrate is purified and digested. Right: Repair products are visualized by automated fragment 
analysis and quantified. (C) Representative expression of 35S-Methionine-labeled variant PMS2 proteins, visualized 
after SDS-PAGE gel electrophoresis and autoradiography. Arrow: full-length PMS2 variants. (D)Relative repair 
efficiencies for PMS2 VUS. (−): Repair-deficient control, (+): Repair-proficient controls. Results are shown as 
mean±S.E.M. of 3–4 independent experiments for all VUS and >6 experiments for controls. Mock: Mock expression. 
Asterisks: Significantly higher than repair-deficient control E705K. * p<0.05; ** p<0.01; *** p<0.001 (Student’s one-
tailed t-test). For the “Mock” and “PMS2 only” reactions, no repair was detected in any of the experiments.
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I18V c.52A>G + 1, 2 
R20Q c.59G>A + H3 1, 2, 3, 4, 5
E41A c.122A>C - 5
S46I c.137G>T - H3, 6 Neg3, 6 Pos6 2, 3, 4, 6, 7, 8
S46N c.137G>A - 7, 8
D60E c.180C>G + LOVD
Q205P c.614A>C + LOVD
G207E c.620G>A + H9 Neg9 9
L263V c.787C>G + LOVD
A423T c.1267G>A + 10
H479Q c.1437C>G + 11, 12
T485K c.1454C>A + H6 Neg6 Pos6 1, 2, 4, 6, 11
T511A c.1531A>G + H3 2, 3, 6, 11, 12
T511M c.1532C>T + LOVD
Y519C c.1556A>G + LOVD
E541K c.1621A>G + 1, 2, 5, 6
R563L c.1688G>T + 1, 2, 8
L571I c.1711C>A + 2
L585I c.1753C>A + 1
T597S c.1789A>T + L3 1, 3, 4, 5, 11
M622I c.1866G>A + 1, 2, 4, 6, 8, 11
E663A c.1988A>C + 8
E705K c.2113G>A - 2, 6, 8, 13, 14
G750D c.2249G>A + 8
M797R c.2390T>G + 2
C843Y c.2528G>A - 8
G857A c.2570G>C + 1, 2, 6, 12
a Amino acid numbering is based on the PMS2 reference sequence NP_000526.1 with +1 corresponding to 
the translation initiation amino acid.
b Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the translation 
initiation codon of the PMS2 GenBank reference sequence (NM_000535.5). 
c MSI=Microsatellite Instability. H=High, L=Low, IHC=Immunohistochemistry. Neg = Negative for 
staining, Pos = Positive for staining. In case cells are empty, the variant was not tested.
d Variants have been selected from the LOVD (http://chromium.liacs.nl/LOVD2/colon_cancer/variants.php?
select_db=PMS2&action=view_all&view=Prot_sub). Appropriate references are shown. References: 1 [Hendriks 
et al., 2006], 2 [Clendenning et al., 2006], 3 [Pastrello et al., 2011], 4 [Thompson et al., 2012], 5 [Borràs et al., 2013], 
6 [Nakagawa, 2004], 7 [Jackson et al., 2008], 8 [Senter et al., 2008], 9 [Montazer Haghighi et al., 2009], 10 [Ganster 





























considered repair deficient and therefore presumably are pathogenic (Figure 1D). We 
conclude that this assay effectively identifies repair-deficient PMS2 variants. Variants such 
as Q205P, T511M and G750D that display repair efficiencies significantly higher than 
E705K but are compromised compared to wild type were not classified as repair deficient 
and we surmise that these variants might be pathogenic with reduced penetrance. Extensive 
calibration of the assay with clinical data is required to assess pathogenicity of alleles 
displaying such intermediate repair efficiencies.
For some of these VUS microsatellite instability (MSI), a hallmark of MMR deficient cancer, 
was previously investigated. Indeed, the MSI of a tumor carrying the S46I allele corresponds with 
its deficiency in MMR (Table 1). However, the MSI in tumors of carriers of the R20Q, G207E, 
T485K or T511A alleles is in apparent contrast with their normal MMR activity in vitro (Table 
1). Possibly these patients carry another, yet unidentified MMR gene defect. Contrariwise, we 
cannot exclude that these alleles cause a defect that is only apparent in vivo. For this reason, all 
variants that are repair proficient in this assay cannot be classified as neutral, but may require 
additional analyses such as splicing assays, protein stability assays or nuclear localization assays 
[Rasmussen et al., 2012]. Ultimately, after the calibration of the assay, it may become a part of an 
integrated Bayesian analysis that determines pathogenicity of MMR gene VUS, as proposed by 
us and others [Goldgar et al., 2008; Rasmussen et al., 2012].
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Cloning of PMS2. The human PMS2 (GenBank NM_000535.5) cDNA was cloned into the 
pCITE4a expression vector (Novagen, Beeston, UK). PMS2 cDNA was PCR-amplified using 
forward primer 5’-CGCGGATCCGCCACCATGGAGCGAGCTGAGAGCTCGAGTAC-3’ 
and reverse primer 5’-GCGCGGCCGCGGTCAGTTCTGAGAAATGACAC-3’. The PCR 
fragment was cloned into pCITE4a after BamHI and NotI (New England Bioland, Ipswich, 
MA, USA) digestion. The encoded PMS2 protein carries a 40 amino acid N-terminal tail, 
containing both an s tag and a thrombin tag. This tail increases protein expression without 
affecting protein activity (Supplementary Figure 1). 
Generation of variant PMS2 proteins by PCR and In Vitro Expression. The plasmid 
construct described above was used as a template in a PCR procedure to recreate variant 
PMS2 alleles, including the vector-derived T7 promoter and CITE sequences that are 
required for efficient transcription/translation in vitro. PCR reactions were performed as 
described (Figure 1A) [Drost et al., 2012]. In brief, overlapping 5’ and 3’ PCR fragments were 
generated in separate, PCR reactions. 5’ PCR fragments were generated using a common 
pCITE forward primer and a reverse primer specific for the VUS. 3’ PCR fragments were 
produced using a forward primer complementary to the reverse primer in the 5’ PCR, 
specific to the VUS, and a common pCITE reverse primer. In a subsequent PCR reaction, the 
two mutant fragments were joined and reamplified using nested primers. Oligonucleotide 
sequences are available upon request and were ordered from Biolegio (Nijmegen, The 
Netherlands). All PCR reactions were performed in a total volume of 10 μl, containing 
0.4 U of Pfx Platinum Polymerase (Invitrogen, Carlsbad, CA). Proper introduction of the 
variant codon was confirmed by direct sequencing of PCR fragments.
Following amplification, all final PCR products were purified using the PCR Purification 
Kit (Qiagen). These purified fragments were then used for in vitro protein expression in 
the TnT Quick Coupled in vitro Transcription/Translation System (Promega, Madison, 
WI), in the presence of PCR Enhancer with minor modifications to the manufacturer’s 
protocol. Expression levels were verified by producing parallel 35S-Methionine-labeled 
reactions according to the manufacturer’s instructions. Labeled proteins were analyzed by 
SDS-polyacrylamide gel electrophoresis and Phosphorimaging (Perkin Elmer, Waltham). 
Wild type MLH1, the heterodimeric partner of PMS2, was produced by large-scale in vitro 
expression from its pCITE4a clone [Drost et al., 2010]. The PMS2/MLH1 heterodimers 
were generated by allowing in vitro-expressed wild type or variant PMS2 and WT MLH1 
(1:1 v/v) to dimerize for 30 minutes at room temperature.
In Vitro MMR Assays. In vitro MMR assays were performed as described (Figure 1B)
[Drost et al., 2010, 2012]. Reactions are carried out in 25μl containing 75μg of nuclear 
extract. Nuclear extract was prepared from HCT-116 colon cancer cells that lack both 
PMS2 and MLH1, as described [Holmes et al., 1990]. Extracts were complemented with 
12μl of dimerized PMS2/MLH1 and 100ng of fluorescent substrate pJHGT3’lnFAM. After 
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40 min of incubation at 37oC, substrate DNA was purified using the MinElute kit (Qiagen, 
Germantown, MD). Then, the substrate was digested with HinDIII and BsrBI (Fermentas, 
Burlington, ON, Canada). One-fifth (2 μl) of digested substrate was mixed with 7.8 μl Hi-Di 
Formamide and 0.2 μl GeneScan-500 ROX size standard (Applied Biosystems, Bedford, 
MA) and fluorescent fragment analysis was performed under standard conditions. Signal 
was quantified using GeneMarker software (Softgenetics, State College, PA). Repair levels 
were calculated by dividing the height of the MMR-specific peak by the total fluorescent 
signal, and then normalized to wild type levels.
SUPPLEMENTARY REFERENCES
Supplementary Figure 1. The 40 amino acid N-terminal tag on PMS2 does not influence MMR activity. 
(A) Representative expression of 35S-Methionine-labeled proteins, visualized after SDS-PAGE gel electrophoresis 
and autoradiography. (B) Repair efficiencies of in vitro produced PMS2 with or without fused N-terminal tags. 
PMS2 proteins were sequentially diluted twofold and dimerized to MLH1. Repair assays were carried out as 
described. MMR-proficient HeLa nuclear extract serves as a positive control. No significant differences were 
found between any of the PMS2 measurements, supporting the robustness of the assay. Results are shown as 
mean±S.E.M. of 4 independent experiments. 
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ABSTRACT
In many individuals suspected of the common cancer predisposition Lynch syndrome a 
variant of unclear significance (VUS), rather than an obviously pathogenic mutation, is 
identified in one of the DNA mismatch repair (MMR) genes. The uncertainty whether 
such VUS inactivate MMR, and therefore are pathogenic, precludes targeted healthcare for 
both carriers and their relatives. To facilitate the identification of pathogenic VUS we have 
developed an in cellulo genetic screen-based procedure for the large-scale mutagenization, 
identification and cataloging of residues of MMR genes, critical for DNA mismatch repair 
gene function in vivo. When a residue, identified as mutated in an individual suspected 
of Lynch syndrome, is listed as critical in such a ‘reverse diagnosis catalog’ there is a high 
probability that the human VUS is pathogenic. To investigate the applicability of this 
approach we have generated and validated a prototypic reverse diagnosis catalog for the 
MMR gene Msh2 by mutagenizing, identifying and cataloging 26 deleterious mutations in 23 
amino acids. Extensive in vivo and in vitro analysis of mutants listed in the catalog revealed 
both recessive and dominant-negative phenotypes. Nearly half of these critical residues 
match with VUS, previously identified in individuals suspected of Lynch syndrome. This 
aids in the assignment of pathogenicity to these human VUS and validates the approach 
described here as a diagnostic tool. In a wider perspective, this work provides a model for 




Lynch syndrome is a prevalent, dominantly inherited, predisposition to colon and other visceral 
cancers, caused by heterozygosity for a deleterious defect in one of the DNA mismatch repair 
(MMR) genes MSH2, MSH6, MLH1 or PMS2. Inadvertent loss of the second, wild type, allele 
in somatic cells results in MMR deficiency. The consequent inability to remove accidental 
nucleotide misincorporations during DNA replication leads to the accumulation of spontaneous 
genomic mutations and the rapid development of cancer [Lynch and de la Chapelle, 2003]. 
Lifelong preventive surveillance is an effective means to reduce cancer incidence and 
mortality in carriers of a pathogenic MMR gene mutation [Lagerstedt Robinson et al., 
2007] . Additionally, carriers may benefit from both targeted chemoprevention [Burn et al., 
2011] and chemotherapy [Hewish et al., 2010]. Unfortunately, in a significant fraction of 
all individuals suspected of Lynch Syndrome a subtle alteration of one of the MMR genes 
is identified, such as a single amino acid alteration or a mutation of a putative splice site 
[Peltomäki and Vasen, 2004]. The pathogenicity of these so-called Variants of Unclear 
Significance (VUS) often cannot be assessed, due to the absence of conclusive clinical and 
segregation data, and of data on the impact of the mutation on gene function. It is furthermore 
believed that primary screening for MMR gene mutations in selected populations, a cost-
effective approach to improve general health, will cause a further increase in the incidence 
of MMR gene VUS [Barnetson et al., 2008; Dinh et al., 2011; Heinen et al., 2010]. The 
development and use of robust and accessible approaches to identify pathogenic VUS 
will enable the implementation of targeted preventive and curative healthcare for carriers 
of pathogenic MMR gene VUS. Meanwhile, unaffected relatives of such carriers can be 
liberated from the burden associated with the uncertain pathogenicity of the VUS while 
unwarranted inflow into preventive healthcare systems is reduced [Castells et al., 2009].
The genetics and biochemistry of the MMR pathway have been established in detail 
[Hsieh et al., 2008], which has enabled the development of functional assays to predict 
pathogenicity of MMR gene VUS [Rasmussen et al., 2012]. Although these assays can be 
useful tools in the prediction of pathogenicity of VUS they are often laborious and time 
consuming, whereas defects that specifically affect functions of the variant genes in vivo, 
such as splicing, intracellular localization or stability, may escape detection. To circumvent 
these issues we have taken an in vivo, genetic screen-based, approach. This approach 
comprises the large-scale mutagenesis and identification of critical amino acids of MMR 
genes, the analysis of the mutant cell lines and proteins, and the compilation of these data 
in an annotated ‘reverse diagnosis catalog’. Such a catalog enables to rapidly see whether 
the VUS is at a residue that is critical for gene function in vivo, and therefore aids in the 
assessment of pathogenicity. Here, we describe the construction and extensive validation of 































A genetic screen to mutagenize and map critical MMR gene residues
We argued that residues, critical for MMR gene function in vivo, could be identified by a three-
step procedure: (i) Treatment of cultured cells using a wide-spectrum mutagen to randomly 
induce genetic variants, (ii) Isolation of clones that have lost MMR consequent to mutation of a 
critical amino acid, (iii) Identification of the causal mutations and their compilation in a reverse 
diagnosis catalog. Mouse embryonic stem (ES) cells is a suited cell type for such a screen as ES 
cells are primary diploid cells, though immortal. Furthermore, ES cell lines monoallelic for each 
of the MMR genes are available [de Wind et al., 1995; de Wind et al., 1999], which requires the 
inactivation of only the single, wildtype, allele by a mutagenic event. Importantly, mouse and 
human MMR genes are >95% identical or homologous at the amino acid level.
To generate a pilot reverse diagnosis catalog we used an ES cell line, monoallelic for Msh2 
[Msh2+/-; de Wind et al., 1995]. This line was treated with the powerful, wide-spectrum, and 
relatively non-toxic point mutagen N-ethyl-N-nitrosourea [ENU; Fig. 1A; Borgdorff et al., 
2005; Russel et al., 1979]. To isolate cell clones that have become MMR-deficient resulting 
from a mutagenic event at the monoallelic MMR gene we subsequently exposed cells to a 
low concentration of the nucleotide analog 6-thioguanine (6TG; Fig. 1B), to which MMR-
deficient cells are tolerant [Jansen et al., 1995; Glaab et al., 1998]. Then, unwanted clones that 
had acquired 6TG tolerance due to mutational inactivation of the X-linked Hprt gene, rather 
than by loss of MMR, were killed by culture in Hypoxanthine-Aminopterine-Thymidine-
supplement-containing medium (Fig. 1C). In the remaining clones, the single Msh2 allele 
might be lost by either an ENU-induced substitution at a critical residue (Msh2M/- in Fig. 
1D), or by loss of heterozygosity [Msh2-/- in Fig. 1D; Borgdorff et al., 2005]. The latter clones 
were discarded after screening with an Msh2 allele-specific PCR. The remaining cell clones 
are expected to harbor an ENU-induced substitution that inactivates a critical residue of the 
monoallelic Msh2 gene. Importantly, when wild type (Msh2+/+) ES cells were subjected to these 
treatments no surviving clones were obtained, indicating that this procedure does not result in 
clones with a simultaneous mutational inactivation of both alleles of any of the MMR genes.
To identify ENU-induced amino acid substitutions in Msh2 in the selected clones we 
sequenced the complete Msh2 open reading frame of clones that had retained expression 
of full-length Msh2 cDNA, as judged by reverse-transcriptase PCR (Table 1). This resulted 
in the identification of an amino acid substitution in monoallelic Msh2 in 41 clones. These 
substitutions alter 23 different amino acids, of which 3 amino acids were represented by 
two different substitutions in individual clones. These residues were then compiled in a 
prototypic reverse diagnosis catalog (Tables 2 and S1). Mapping of these amino acids to 
the MSH2 crystal structure revealed a clustering around the lever, connector and ATPase 
domains of the protein indicating the relative importance of these domains [Fig. 2A, 2B 
and S3; Warren et al., 2007]. Conversely, few deleterious mutations were found in the 
N-terminal region of the Msh2 protein (Fig. 2A). MAPP-MMR [Chao et al., 2008], an 
alignment-based algorithm, predicted 25 of 26 Msh2 mutants in the reverse diagnosis 
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catalog to be deleterious and one to be borderline deleterious, a result that cross-validates 
both MAPP-MMR and our reverse diagnosis screen (Table 2). 
To investigate the applicability of our approach to aid in the identification of pathogenic 
human MMR gene variants we then aligned the database that lists MSH2 variants, 
identified in the human population (The Leiden Open Variation Database) with the reverse 
Figure 1. A genetic screen to identify critical MMR gene residues. (A) An ES cell line, hemizygous for Msh2 
(Msh2+/-) is subjected to mutagenic treatment with ENU. Preexisting, inadvertent, Msh2-/- cells [Borgdorff 
et al., 2005] are not displayed here. (B) Cells that have acquired low-level 6TG tolerance, either by loss of 
heterozygosity at Msh2 (LOH, Msh2-/-), by an ENU-induced loss-of-function mutation at a critical residue in 
the monollelic Msh2 gene (Msh2M/-), or by a deleterious mutation at the monoallelic Hprt gene are selected using 
two brief 6TG selections. (C) Unwanted Hprt-deficient clones are eliminated using HAT-supplemented medium. 
(D) Unwanted clones that have lost the wild type Msh2 allele by loss of heterozygosity are excluded using an 
allele-specific PCR. (E) The inactivating mutation in the remaining clones is identified by sequence analysis. A 






























diagnosis catalog. This revealed that, of the 23 residues listed as critical in the catalog, 10 
were previously identified as mutated in humans. Moreover, in 6 out of these 10 cases, the 
ENU-induced deleterious amino acid substitution was identical to a human VUS (Table 2). 
This result provides strong support for the applicability of reverse diagnosis catalogs to 
identify pathogenic human MMR gene variants.
Msh2-mutant cell lines display phenotypic hallmarks of MMR deficiency 
To validate the genetic screen experimentally we assembled a validation panel consisting of 
13 of the 26 mutant cell lines. These substitutions were chosen because all of these residues 
are represented in the LOVD, either as identical or different substitution, or as silent 
mutation (Table 2). 
Microsatellite instability is a diagnostic hallmark of cancer in Lynch syndrome [Lynch 
and de la Chapelle, 2003]. We measured the size of six different microsatellites in 40-50 
subclones of each line from the validation panel. Microsatellites were shortened in the 
large majority of the subclones of each cell line, in support of MMR deficiency (Fig. 3A). 
The microsatellite size reductions were less pronounced in the cell lines than in Lynch 
Syndrome-associated cancers [Lynch and de la Chapelle, 2003]. This likely is a consequence 
of the absence of iterative cycles of expansion and clonal selection, that characterizes 
carcinogenesis. In addition to microsatellite instability, MMR defects are characterized 
by the accumulation of spontaneous nucleotide substitutions at protein-encoding genes. 
Indeed, all cell lines from the validation panel displayed high frequencies of spontaneous 
Hprt mutants, mimicking the Msh2-disrupted control cell line (Fig. 3B). 
MMR-deficient cells have acquired tolerance of DNA-methylating drugs, a class of agents 
that includes several chemotherapeutic drugs [Hsieh et al., 2008]. We tested our validation 
panel of cell lines for tolerance of the prototypic methylating drug N-Methyl-N’-Nitro-N-
Nitrosoguanidine (MNNG). Indeed, all cell lines proved as tolerant as the Msh2-disrupted 
control line (Fig. 3C). Cumulatively, these results demonstrate that all Msh2-mutant cell 
lines from the validation panel have acquired all phenotypic hallmarks of MMR deficiency.
Table 1. Generation of the pilot Msh2 Reverse Diagnosis Catalog described here.
Total no. of 6TG and HAT-tolerant clones 1483
Clones that did not display LOH at Msh21 426
Clones analyzed for Msh2 mutations2 81
Clones with a single, unique, amino acid substitution3 41 (26)
Mutated amino acids 23
Other mutations identified in Msh24 10
1 LOH was assessed by allele-specific PCR.
2 Only full-length cDNAs were sequenced. 
3 Six substitutions were found in more than one individual clone. Between parentheses: unique substitutions.
4 Comprises nonsense, frameshift or silent mutations, tandem mutations, or small in-frame deletions. 
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MMR deficiency is caused by the ENU-induced mutations in Msh2 
To provide conclusive evidence of the causality of the Msh2 mutations for MMR deficiency 
we followed a biochemical approach, employing a cell-free MMR assay that measures 
Figure 2. Critical Msh2 residues mapped in this study. (A) Schematic representation of all identified deleterious 
amino acid substitutions in Msh2. The colored protein domains are as described [Warren et al., 2007]. It should 
be noted that the term ‘mismatch-binding domain’ is a misnomer as the homologous domain in Msh6, rather than 
Msh2, binds the mismatch. The middle panel of the figure zooms in on an alignment of the Walker A and Walker 
B ATPase domains of human and mouse Msh2, highlighting residues that were mutated in the screen described 
here (orange boxes). Numbers reflect amino acid numbering. (B) Mapping of critical Msh2 residues mutated in our 
screen to the crystal structure of the human MSH2/MSH6 heterodimer. In color: MSH2 (see Fig. 2A for legends), 
in grey: MSH6. Mutated residues are shown as black spheres. The MutS/MutL and EXO1 interaction domains are 






























Table 2. Msh2 mutants generated in this study. 
Mutation1 cDNA MAPP- MMR2 LOVD3
M148K c.443 T>A 3.75 -
I346N c.1037 T>A 18.3 -
I356K c.1067 T>A 14.66 -
I356R c.1067 T>G 16.34 -
L407P c.1220 T>C 18.56 L407L
L503P c.1508 T>C 14.91 L503P
K546E c.1636 A>G 23.7 -
N553K c.1659 C>A 24.75 -
S557P c.1669 T>C 9.71 T557P
M592K c.1775 T>A 8.21 M592V
L595P c.1784 T>C 7.68 -
L599P c.1796 T>C 17.42 -
G669D c.2006 G>A 35.86 G669D/R
N671I c.2012 A>T 22.05 N671K/Y
N671K c.2013 T>A 25.31
S676L c.2027 C>T 28.64 S676P
G683R c.2047 G>A 44 G683R/W
M688K c.2063 T>A 32.5 M688R/I
V695E c.2084 T>A 30.37 -
S699P c.2095 T>C 5.97 -
A700E c.2099 C>A 37.91 -
V702E c.2105 T>A 33.26 V702G
E749K c.2245 G>A 19.98 E749K
E749G c.2246 A>G 28.23
G761R c.2281 G>A 40.89 -
C822Y c.2465 G>A 6.48 -
1 In bold: mutants included in the validation panel.
2 In silico MAPP-MMR prediction of pathogenicity. Scores above 4.55 are predicted to be pathogenic, variant 
M148K is borderline pathogenic (calculated from http://mappmmr.blueankh.com/Impact.php; [Chao et al., 19]).
3 LOVD: A mutation at the same residue identified in a suspected Lynch syndrome patient, as reported 
in the Leiden Open Variant Database (LOVD). In bold: identical substitution found in reverse diagnosis 
catalog and LOVD, allowing to assess pathogenicity to the patient VUS.
the ability of cell extracts to repair a defined G∙T mismatch [Drost et al., 2010]. MMR 
activity was lost in extracts from all lines from the validation panel (Fig. 4A, black bars). To 
determine causality of the Msh2 mutations for MMR loss we investigated whether addition 
of recombinant purified wild type human MSH2/MSH6 rescued the MMR defect in extracts 
from each cell line of the validation panel. Indeed, the defect was significantly complemented 
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in 11 cell extracts, confirming that the MMR deficiency is caused by inactivation of Msh2/
Msh6, rather than by inadvertent loss of one of the other (biallelic) MMR genes (Fig. 4B, 
grey bars). Only in two out of the extracts, each derived from a cell line with a different 
substitution at Msh2 residue N671, the MMR activity was not significantly restored by wild 
type MSH2/MSH6 (Fig. 4A and see below). 
We wanted to directly prove causality for loss of MMR of the mutated Msh2 amino 
acids. To this aim we used a wild type human MSH2 cDNA as template to mimic the 13 
mouse Msh2 mutants from the validation panel by site-directed mutagenic PCR in the 
Figure 3. Analysis of the validation panel. (A) Upper panel: Microsatellite instability analysis on mononucleotide 
microsatellite mBAT-30. The size of each sphere is proportional to the relative number of subclones with 
the indicated mBAT-30 PCR fragment length. All mutants from the validation panel display microsatellite 
instability (p<0.05 compared with the Msh2+/- line). Microsatellite size shifts in the Msh2-/- control line are not 
displayed as in this line the number of cell divisions before subcloning was much higher than in the lines of the 
validation panel, which makes a quantitative comparison impossible. Lower panel: Microsatellite instability 
analysis on mononucleotide repeats mBAT-24, mBAT-26 and mBAT-64, and on dinucleotide repeats D1Mit79 
and D15Mit93 in the ‘patient’ ES cell lines. (+): MSI (p<0.05 compared with the Msh2+/- line); (-): no MSI. 
(B) Assessment of spontaneous mutator phenotypes at the genomic Hprt gene in Msh2-mutant ES cell lines 
from the validation panel. Bars represent Hprt mutant frequencies±S.E.M. *=p<0.05, **=p<0.01, ***=p<0.001 
compared with the parental Msh2+/- line. (C) Tolerance to the methylating drug MNNG in Msh2-mutant ES cell 






























human gene. This was followed by in vitro transcription and translation to recreate MSH2 
mutant proteins [Drost et al., 2010, 2012]. The resulting proteins were heterodimerized with 
wild type MSH6 and tested for their ability to restore MMR in extracts from the MSH2/
MSH6-deficient human cancer cell line LoVo. None of the 13 mutant MSH2/MSH6 human 
proteins complemented the LoVo cell extract (Fig. 4B). This result provides direct and 
conclusive evidence for the causality of each of the ENU-induced amino acid substitutions 
in Msh2 for MMR-deficiency, also in the human setting. Therefore, this result provides 
strong support for pathogenicity of the human mutants. 
Figure 4. Biochemical characterization of Msh2-mutant ES cell lines from the validation panel. (A) In vitro 
repair of a G∙T mismatch in mutant cell extracts in the absence (black bars) and presence of purified wild 
type human MSH2/MSH6 (grey bars). Bars represent mean±SEM. *=p<0.05, **=p<0.01, ***=p<0.001, when 
comparing repair efficiencies in the presence and absence of recombinant MSH2/MSH6 for each extract. 
NS=Not significant. (B) MMR activity in in vitro recreated mutant humanized MSH2 proteins. These proteins 
were tested for the repair of a G∙T mismatch after addition to an MSH2/MSH6-deficient human cell extract. 
Mock: mock Msh2/Msh6 expression. Bars represent mean±S.E.M. *=p<0.05, **=p<0.01, ***=p<0.001 
compared to the mock reaction. (C) Western blot analysis of total lysates from mutant ES cell extracts. Actin: 
β-actin loading control. (D) Binding of control and mutant Msh2/Msh6 cell extracts to a G·T mismatch within 
a double-stranded oligonucleotide probe in an electrophoretic mobility shift assay. Msh2/Msh6 indicates the 
Msh2/Msh6∙DNA complex. (E) ATP-induced mismatch release of Msh2-mutant cell extracts was tested in an 
electrophoretic mobility shift assay. ATP (1.25mM) was added after allowing the proteins to bind to the probe. 
(F) Quantification of ATP-induced mismatch release of Msh2/Msh6, Msh2-N671I/Msh6 or Msh2-N671K/
Msh6. The values represent the average from three independent experiments; error bars: S.E.M.
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MMR deficiency is caused by loss of protein expression or by specific 
biochemical defects 
To provide biochemical insights into the MMR defects in the cell lines we investigated 
levels of mutant Msh2 proteins in the validation panel by Western blotting. This revealed 
that 6 of the cell lines had lost expression of Msh2 (Fig. 4C), suggesting defective protein 
folding and/or stability. The heterodimeric partner of Msh2, Msh6, was also destabilized in 
these ‘low protein-level’ Msh2 mutants (Fig. 4C), consistent with previous results [de Wind 
et al., 1999]. By analyzing levels of mutant Msh2 proteins in fractionated cell extracts, we 
excluded intracellular mislocalization as cause for the MMR defect of the 7 Msh2 mutants 
that had retained significant protein levels (Fig. S1). 
To obtain insights in the biochemical defects of the mutants that had retained protein 
expression we tested binding to G·T mismatched probes in extracts from these cell lines, 
using an electrophoretic mobility shift assay. With the exception of mutants N671I and 
N671K, binding to both the matched and mismatched probes was significantly reduced, 
suggesting a general defect in DNA binding in those mutants (Fig. 4D).
Substitutions at residue N671 of Msh2 confer a dominant-negative 
phenotype
After mismatch binding by Msh2/Msh6, binding of ATP to the distal ATPase domains of the 
protein (Fig. 2) results in the conversion of the mismatch-bound form of Msh2/Msh6 into a 
repair-competent DNA-embracing clamp that releases the mismatch [Hsieh et al., 2008]. We 
tested ATP-induced mismatch release in cell extracts from all 6 mutants that had retained low- 
to normal levels of mismatch binding. ATP released the protein from the mismatch in most of 
these extracts, which indicates that ATP binding nor intramolecular signaling are affected (Fig. 
4E). In contrast, extracts from both mutants at residue N671 displayed a specific defect in the 
ATP-induced release from the mismatch (Fig. 4E, F). Indeed, N671 is a highly conserved residue 
at the Walker A (ATP-binding) motif of the ATPase domain [Fig. 2A; Hsieh et al., 2008]. It is 
not unlikely that the normal mismatch binding of the N671I and N671K mutants, combined 
with the defect in ATP-induced mismatch release, results in persistent binding of inactive 
mutant heterodimer at the mismatch, precluding binding of wild type Msh2/Msh6. This result 
is consistent with the inability of wild type MSH2/MSH6 to restore MMR activity to extracts 
from both mutant cell lines (Fig. 4A and see above). Complementary to this, we show that the 
addition of both N671 mutant proteins, but not the recessive G683R mutant protein, to a HeLa 
cell extract in vitro inhibits MMR activity (Fig. S2). Based on these results we infer that the 
N671I and N671K substitutions confer dominant-negative phenotypes to Msh2.
DISCUSSION 
Genetic screens for the identification of pathogenic MMR gene variants
The absence of well-established procedures to classify VUS in genes associated with cancer 






























or curative healthcare. To aid in resolving this problem in Lynch syndrome we have developed a 
genetic screening procedure to mutagenize and identify critical MMR gene residues. This results 
in reverse diagnosis catalogs that list critical gene residues, together with the associated mutant 
cell lines. Given the causal relation of MMR deficiency for Lynch syndrome, a VUS that is listed 
as deleterious in the reverse diagnosis catalog has a high probability of pathogenicity.
The screens are based on the mutagenic treatment of an ES cell line, monoallelic for 
one of the MMR genes, followed by selection of clones that have acquired a deleterious 
substitution of a critical residue of the monoallelic gene. This procedure mimics the somatic 
inactivation of the wild type allele and the subsequent clonal outgrowth of MMR-deficient 
tumor cells that precedes cancer development in Lynch syndrome [Liu et al., 1995]. 
Therefore, the mutant cell lines can be used as models for cancer cell lines from patients 
carrying the corresponding variant. The generation of reverse diagnosis catalogs to aid 
in the identification of pathogenic variants in Lynch syndrome is not restricted to Msh2, 
since also cells deficient for the other core MMR genes are tolerant to 6TG [Glaab et al., 
1998], and monoallelic ES cell lines for these genes are available. Indeed, we have recently 
generated a prototypic reverse diagnosis catalog for Msh6 using an identical procedure as 
described here (in preparation). A comprehensive reverse diagnosis catalog (Tables 2 and 
S1), linear gene map (Fig. 2A) or structural representation (Fig. 2B and S3), annotated with 
functional data, has to be generated only once for each MMR gene and will aid to assess 
pathogenicity to human MMR gene VUS, now and in the future.
In the prototypic screen presented here we have identified 26 cell lines, each carrying 
a deleterious Msh2 amino acid substitution, in total unveiling 23 amino acids critical for 
Msh2 function in vivo. Ten of these 23 amino acids have previously been identified as 
mutated in humans (Table 2). In 6 out of these, the amino acid substitution in the individual 
and in the reverse diagnosis catalog were identical (Table 2). Since these substitutions were 
proven to be causal for loss of MMR in this work, and since loss of MMR is causal for Lynch 
syndrome, these data strongly suggest the pathogenicity of these human VUS. 
To validate the screen we have extensively tested a panel consisting of 13 of the mutants, 
including those that were also identified as VUS in humans. All mutant cell lines from the 
validation panel display all hallmarks of MMR deficiency (Table S1). With the exception 
of the dominant-negative substitutions at residue N671 (see below) the biochemical MMR 
defect was rescued by wild type human MSH2/MSH6 in extracts from all mutant mouse ES 
cell lines. This demonstrates that the mutagenic treatment has not inadvertently inactivated 
any of the other MMR genes (Fig. 4A). Finally, we have directly proven causality of the 
ENU-induced Msh2 substitutions in these 13 cell lines for the loss of MMR in a human 
setting (Fig. 4B). All taken together, these experiments validate the use of the mouse cell-
based genetic screen presented here to identify critical MMR gene residues, to use these 
data for the assignment of pathogenicity to human MMR gene VUS, and to investigate in 
vivo phenotypes of the mutant cell lines as models for tumor cell lines.
Our pilot screen yielded only a single inactivating mutation at the N-terminus of Msh2. 
This may have different causes, including (i) a bias in the mutagenicity of ENU; (ii) a bias in 
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the recovery of N-terminal deleterious mutations, e.g. resulting from degradation of mRNA 
(our mutants were identified by cDNA sequencing) (iii) an intrinsically low density of 
critical residues in the N-terminal part of Msh2. In our support, deletion of N-terminal 133 
amino acids of Msh2 hardly affects MMR in Saccharomyces cerevisiae, indicating that this 
domain is less important for MMR [Lee et al., 2007]. Conversely, the C-terminal ATPase 
domain of Msh2 is highly conserved and indispensable for gene function, explaining the 
density of substitutions in our pilot screen [Hsieh et al., 2008]. In the Human Gene Mutation 
Database (HGMD; https://portal.biobase-international.com), (presumed deleterious) 
missense variants are ubiquitous in the N-terminal part of MSH2. Possibly, many of these 
N-terminal substitutions represent hypomorphic mutations whereas our screen selects for 
complete loss-of-function. Alternatively, as the criteria for most of these classifications are 
unclear or not stringent, it cannot be excluded that many of these N-terminal (and other) 
substitutions in MSH2 are classified incorrectly. 
Dominant-negative phenotypes of Msh2 variants and cancer predisposition
The extensive analysis of the mutants generated here has allowed the identification of 
dominant-negative phenotypes of Msh2 mutants N671K and N671I. In families suspected of 
Lynch syndrome, both identical (N671K) and non-identical (N671Y) substitutions at MSH2 
N671 have been described [Chao et al., 2008; Lu et al., 1996]. The identification of dominant-
negative mutations is of particular relevance, since these may confer a disease phenotype 
already in a heterozygous state. This may include the accelerated onset and expanded tropism 
of cancer. In fact, a family with an MSH2 N671Y mutation displays both an extended spectrum 
(colon, ovary, breast, esophagus) and a young age of onset of cancer [37 years; Lu et al., 1996]. 
In addition to substitutions N671I and N671K, several other mutants obtained in our screen 
have retained Msh2 protein expression (Fig. 4C). From a diagnostic point-of-view this is a 
significant observation since loss of protein expression frequently is used to direct MMR gene 
sequencing in individuals suspected of Lynch syndrome [Lynch and de la Chapelle, 2003]. 
Therefore, even when immunostaining of a tumor is positive for the presence of all MMR 
proteins, the patient should be analyzed for VUS in the MMR genes.
Approaches to generate comprehensive reverse diagnosis catalogs
In this study we have focused on the identification of ENU-induced mutants that had 
retained full-length Msh2 cDNA. For this reason, Msh2 mutants that cause defects at the 
RNA level will have escaped identification. Indeed, in many of the clones, full-length cDNA 
or protein was not detected and these were discarded (Table 1). In the future, deleterious 
mutations that disrupt transcription, splicing or mRNA stability [Sharp et al., 2004; Tournier 
et al., 2008; Betz et al., 2010] may be identified by genomic, rather than cDNA, sequencing.
Analysis of the mutation spectrum at Msh2 in the clones generated here reveals ENU-
induced substitutions at both A∙T and G∙C base pairs (Fig. S4), supporting the notion that ENU 
is a wide-spectrum mutagen [Russel et al., 1979]. The identification of different ENU-induced 






























the relative saturation of the prototypic screen described here. However, since mutagenesis by 
ENU may be not fully random, the mutagenesis and ensuing identification of all critical gene 
residues may be hindered. Higher saturation of the reverse diagnosis catalog may be achieved 
by the use of drugs with a complementary mutagenic activity, such as 4-nitroquinoline N-oxide 
[Ryu et al., 1999] or 7,12-dimethylbenz[a]anthracene [Manjanatha et al., 1996]. 
Integration of reverse diagnosis catalogs in Lynch syndrome diagnostics
It is conceivable that the genetic screens proposed here may not be fully saturating, even 
when performed at a large scale and using multiple mutagens, which results in the absence 
of critical residues from the reverse diagnosis catalog. In other instances, albeit at the same 
amino acid, the substitution identified in an individual may be different from that listed in 
the catalog. Such variants may correctly be assessed using cell-free MMR assays [Drost et 
al., 2010, 2012]. Conversely, cell-free assays may not correctly identify pathogenic variants 
when the mutation specifically affects in vivo characteristics of the variant protein, such as 
its stability or intracellular localization, and these may rely on reverse diagnosis catalogs for 
functional assessment. We envision that, after their stratification with human variants of known 
pathogenicity, reverse diagnosis catalogs and cell free activity assays will become important 
components of an integrated diagnostic procedure that also includes independent data sources 
such as segregation, pathological and in silico data [Rasmussen et al., 2012]. Such an integrated 
diagnostic procedure is a prerequisite to relieve the bottleneck between personalized genomics 
and targeted healthcare in Lynch syndrome. In the upcoming era of personalized genomics, 
this approach may provide a paradigm for the analysis of pathogenicity of gene variants in any 
genetic disease that has a defined underlying cellular and biochemical phenotype.
MATERIALS AND METHODS
Determination of genomic mutator phenotypes, microsatellite instability analysis, methylation 
tolerance assays and other procedures are described in the Supplementary Methods.
Construction of an Msh2 reverse diagnosis catalog. The outline of the generation of a 
reverse diagnosis catalog for Msh2 is described in Fig. 1. 5x106 Msh2+/- mouse embryonic 
stem (ES) cells [de Wind et al., 1995] were seeded in a P90 dish on irradiated feeder cells in 
ES culture medium (Gibco, Carlsbad, CA, USA). To induce mutations, cells were incubated 
in medium containing 0.2 mg/ml ethylnitrosourea (ENU, Sigma-Aldrich, St. Louis, MI, 
USA) for 2 hours [Borgdorff et al., 2005], or mock-treated. Cells were propagated for a 
week to allow loss of wild type Msh2 transcripts and protein. Then, cells were seeded at a 
density of 2x106 cells per T90, followed by double treatment, with a seven-day interval, with 
40μM 6TG (Sigma-Aldrich) for 4 hours. Inadvertent Hprt-deficient cells were eliminated 
by culturing the clones one week in Hypoxantine-Aminopterine-Thymidine (HAT, Gibco)-
supplemented medium. Surviving clones were picked and expanded in 96-well plates. 
Next, clones that had lost the wild type Msh2 allele by loss of heterozygosity, rather than 
by mutational inactivation, were discarded after their identification by allele-specific PCR 
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on genomic DNA [Borgdorff et al., 2005]. In the remaining clones the status of the Msh2 
mRNA was analyzed by reverse transcriptase-PCR analysis. The Msh2 open reading frame 
of full-length cDNA clones was sequenced as described [Borgdorff et al., 2006].
Statistical analyses. For experiments measuring microsatellite instability (Fig. 2A), mutator 
phenotypes (Fig. 2B) and methylation tolerance (Fig. 2C), p-values were calculated by comparing 
with the Msh2+/- ES cell line, using a one-tailed t-test assuming unequal variance. For the cell-free 
MMR complementation assay (Fig. 4A), p-values were calculated for every extract individually, 
comparing repair efficiencies in the absence or presence of exogenous MSH2/MSH6 using a 
one-tailed t-test assuming unequal variance. For the cell-free MMR assay (Fig. 4B), p-values 
were calculated compared to the Mock using a one-tailed t-test assuming unequal variance.
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Crystal structure modeling. Crystal structures were visualized using PyMOL software 
(Delano Scientific, San Francisco), using the Protein Database (PDB) file from the published 
human MSH2/MSH6 crystal structure (MMDB ID: 53938; (1)).
Determination of genomic mutator phenotypes at Hprt. Spontaneous mutagenesis at the 
monoallelic genomic Hprt gene was determined essentially as described (2). Briefly, cell lines 
were cultured in HAT-supplemented medium for two subsequent passages to eliminate any 
pre-existing Hprt-deficient cells, after which cell lines were propagated for three passages 
in the absence of HAT, to allow the accumulation of spontaneous mutations at Hprt. Cells 
were then continuously cultured in medium containing 60μM 6TG (Sigma-Aldrich) to 
select for Hprt-deficient clones. Of note, MMR-deficient (but Hprt proficient) cells do not 
survive these stringent selection conditions. After 10 days, Hprt-deficient colonies were 
fixed, stained and counted. Counts were corrected for cloning efficiencies. 
Microsatellite instability was analyzed by isolating approximately 50 subclones of each 
Msh2-mutant cell line. From these subclones, genomic DNA was isolated by Proteinase K 
lysis, and microsatellite sizes were determined after amplification by PCR and subsequent 
fragment analysis, as described previously (3). Data was analyzed using GeneMarker 
software (Softgenetics, State College, PA). 
Methylation tolerance assays. Msh2-mutant cells were treated with N-Methyl-N’-Nitro-N-
Nitrosoguanidine and simultaneously with O6-benzylguanine, an inhibitor of the repair enzyme 
Methyl Guanine Methyl Transferase, as described (4). After three days, adhering cells were 
counted, survival relative to the untreated cells was calculated, and the IC50 was determined.
In vitro MMR assays. MMR assays to test humanized variant MMR proteins were performed 
as described (5). To test MMR activity in cell extracts from the validation panel, 130 μg of 
cytoplasmic extract was assayed in the absence or presence of 100ng of recombinant wild 
type human MSH2/MSH6. (kindly provided by Prof. T. Sixma, The Netherlands Cancer 
Institute, Amsterdam). The results for these experiments were verified in a second set of 
experiments using independent batches of cell extracts. 
Western blotting. Analysis of Msh2 and Msh6 protein expression by Western blotting was 
performed as described (4).
Electrophoretic mobility shift assays. Oligonucleotide sequences were as described (6). 170 
fmol of double-stranded matched or mismatched (G·T) oligonucleotide, labeled at the 5’ 
end using γ-32P ATP and polynucleotide kinase, was incubated with 20 µg of cytoplasmic 
extract in 1x DNA binding buffer (12% glycerol, 20 mM HEPES pH 7.9, 100 mM NaCl, 
1 mM DTT, and 0.1 mM EDTA, 0.05 µg/µl poly-dIdC and 425 fmol unlabeled matched 
oligonucleotide) for 20 min. at 37oC in a total volume of 20µl. For adenine nucleotide 
challenge experiments, ATP was added 10 min after addition of the DNA probe. The 
reaction mixture was subjected to electrophoresis in a 4% polyacrylamide:bisacrylamide 
(29:1)  gel in 0.5x TBE buffer containing 5% glycerol. The gels were dried, signals were 
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visualized using a Cyclone Plus Phosphor Imager (PerkinElmer, Waltham, MA, USA) and 
images were analyzed using OptiQuant software.
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Supplementary Figure 1. Western blot analysis of cytoplasmic and soluble nuclear extracts (CE and NE, respectively) 
of mutant cell lines. 53Bp1 is used as a nuclear marker. Ponceau S staining reveals equal loading of extracts.
Supplementary Figure 2. Inhibition of in vitro mismatch repair in HeLa cell extracts by in vitro expressed variants. 
MMR substrate was incubated with 12 μl of reticulocyte lysate containing expressed wild type or variant MSH2/
MSH6 in the presence of buffers and cofactors. After 10 min. of incubation at 37oC, 75 μg of HeLa extract was 
added and the reaction was incubated for an additional 25 min. Reactions were continued as described (5). Bars 
represent mean±SEM. *=p<0.05 compared to WT. NS=Not significant. Partial, rather than complete, inhibition 
by the N671 variants was observed since the substrate concentration exceeds the MSH2/MSH6 concentration.
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Supplementary Figure 3. Mapping of the residues mutated in our screen to the crystal structure of the human 
MSH2/MSH6 heterodimer. All residues are colored according to their in vitro phenotype. In grey: MSH2, in 
black: MSH6. Mutated residues are shown as spheres.
Supplementary Figure 4. Mutations induced by ENU at the wild type Msh2 allele. This spectrum illustrates the 
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M148K c.443 ATG>AAG 3.75 ND5 ND ND ND ND ND ND ND ND
I346N c.1037 ATC>AAC 18.3 ND ND ND ND ND ND ND ND ND
I356K c.1067 ATA>AAA 14.66 ND ND ND ND ND ND ND ND ND
I356R c.1067 ATA>AGA 16.34 ND ND ND ND ND ND ND ND ND
L407P c.1220 CTG>CCG 18.56 + − + + − + − ND ND L407L
L503P c.1508 CTC>CCC 14.91 + ± + + − + − ± + L503P
K546E c.1636 AAG>GAG 23.7 ND ND ND ND ND ND ND ND ND
N553K c.1659 AAC>AAA 24.75 ND ND ND ND ND ND ND ND ND
S557P c.1669 TCC>CCC 9.71 + ± + + − + − ± ND T557P
M592K c.1775 ATG>AAG 8.21 + − + + − + − ND ND M592V
L595P c.1784 CTC>CCC 7.68 ND ND ND ND ND ND ND ND ND
L599P c.1796 CTG>CCG 17.42 ND ND ND ND ND ND ND ND ND
G669D c.2006 GGT>GAT 35.86 + − + + − + − ND ND G669D/R
N671I6 c.2012 AAT>ATT 22.05 + + + + − − − + − N671K/Y
N671K6 c.2013 AAT>AAA 25.31 + + + + − − − + −
S676L c.2027 TCA>TTA 28.64 + + + + − + − + + S676P
G683R c.2047 GGG>AGG 44 + − + + − + − ND ND G683R/W
M688K c.2063 ATG>AAG 32.5 + − + + − + − ND ND M688R/I
V695E c.2084 GTG>GAG 30.37 ND ND ND ND ND ND ND ND ND
S699P c.2095 TCG>CCG 5.97 ND ND ND ND ND ND ND ND ND
A700E c.2099 GCA>GAA 37.91 ND ND ND ND ND ND ND ND ND
V702E c.2105 GTG>GAG 33.26 + − + + − + − ND ND V702G
E749G c.2246 GAG>GGG 28.23 + + + + − + − − ND
E749K c.2245 GAG>AAG 19.98 + + + + − + − ± + E749K
G761R c.2281 GGG>AGG 40.89 ND ND ND ND ND ND ND ND ND
C822Y c.2465 TGT>TAT 6.48 ND ND ND ND ND ND ND ND ND
1 Amino acid position. 2 In silico MAPP-MMR prediction of pathogenicity. Scores above 4.55 are predicted 
to be pathogenic, variant M148K is borderline pathogenic. 3 +: (near) wild type protein level, ±: reduced 
protein level. −: no protein. 4 CIMRA: Complete In vitro MMR Assay (Fig 4B). 5 ND: not determined (not 
in the validation panel). 6 Dominant-negative variant.
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Variants in the Msh6 Gene Suggests 
Defective Mismatch Binding as a Major 
Mechanism of Pathogenicity
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ABSTRACT 
Lynch syndrome (LS) is a hereditary cancer predisposition caused by heterozygous 
inactivating mutations in one of the DNA mismatch repair (MMR) genes. A significant 
proportion of all variants found in these genes are so-called Variants of Uncertain Significance 
(VUS), generally missense mutations. The inability to diagnose such variants hinders 
presymptomatic diagnosis and precludes both targeted chemotherapy and chemoprevention 
for carriers of the VUS and their effected relatives.
To enable the diagnosis of such variants, we have developed a procedure to mutagenize, 
identify and catalog residues of MMR proteins that are essential for its function. Mapping 
of the essential residues on the protein results in “Reverse Diagnosis Catalogs”. In case a 
VUS from a suspected patient and a residue identified in the catalog overlap, there is a high 
probability that the VUS is pathogenic.
In this work, we describe the construction and validation of a pilot catalog for 
the mismatch repair protein Msh6. We show the applicability of this approach for the 
diagnostic assessment of MSH6 VUS. In addition, we make use of the generated cell lines 
to study (intra)molecular signaling in MutSα. We describe a large panel of characterized 
Msh6 mutants and show that many residues are required for mismatch binding in vitro, 




The hereditary cancer predisposition syndrome Lynch syndrome (LS; or Hereditary 
Nonpolyposis Colorectal Cancer, HNPCC; MIM #s 120435, 609310) is an autosomal 
dominant disorder that predisposes to various cancer types, including colon and endometrial 
cancer [Boland and Lynch, 2013]. The syndrome is caused by the germline inactivation of a 
single allele of one of the DNA mismatch repair (MMR) genes MSH2, MSH6, MLH1 or PMS2 
[de la Chapelle, 2004]. The MMR pathway corrects misincorporations or insertion/deletions 
loops (IDLs) generated spontaneously during DNA replication, and thereby prevents the 
accumulation of spontaneous mutations  (reviewed in [Hsieh and Yamane, 2008; Jiricny, 
2013]). Loss of the remaining wild type allele of an MMR gene in LS patients induces cellular 
MMR deficiency, which leads to a mutator phenotype that accelerates carcinogenesis.
The MSH2 and MSH6 proteins compose the MutSα heterodimer, which is the initial 
factor in MMR. MutSα forms a θ-like structure where the (mis)matched DNA is in the upper 
channel, whereas the lower channel is empty, and MSH2 and MSH6 line the sides along the long 
axis [Warren et al., 2007]. DNA mismatch repair is initiated when MutSα binds a mismatch 
through a conserved Phe-X-Glu motif in the mismatch binding domain of the MSH6 subunit, 
proximal to the mismatch [Warren et al., 2007]. Upon DNA binding, an ADP in the more 
distal ATPase domain is exchanged for an ATP molecule. In case MutSα accidentally binds 
homoduplex DNA, this ATP is rapidly hydrolyzed, inducing a conformational change that 
allows the clamp domains (which are at the opposite end of the heterodimer) to open and allow 
MutSα to fall of the DNA. In case MutSα binds a mismatch ATP hydrolysis is inhibited, the 
mismatch binding domain is retracted and MutSα is converted into a sliding clamp [Gradia et 
al., 1999; Antony and Hingorani, 2003], which can freely move along the DNA helix contour 
[Gorman et al., 2007]. These successive events all rely on long-range intramolecular signaling 
between distant domains. ATP binding, its hydrolysis as well as the conformational changes 
are essential for mismatch repair and are thought to play key roles in mismatch discrimination 
[Hays et al., 2005]. All of these steps contribute to the recruitment of the MutLα heterodimer, 
which consists of MLH1 and PMS2. PMS2 has endonuclease activity and nicks the nascent 
strand, 5’ to the mismatch [Kadyrov et al., 2006]. Such nicks serve as entry points for the 
exonuclease EXO1, which degrades the nascent strand, after which the strand is resynthesized 
and repair is completed [Dzantiev et al., 2004; Constantin et al., 2005].
The genetics and biochemistry of the MMR pathway have been established in detail, and 
this has been instrumental in the diagnosis of LS. LS diagnosis is only definitive once an 
inactivating mutation in an MMR gene has been identified. This allows the presymptomatic 
screening of relatives [Vasen et al., 2013]. Confirmed LS patients enroll in lifelong preventive 
surveillance programs and benefit from personalized chemoprevention and chemotherapy 
[Hewish et al., 2010; Burn et al., 2011]. Of all mutations found in the MSH6 gene, ~37% 
gives rise to single amino acid substitutions [Plazzer et al., 2013]. Since the causality of such 
variants is difficult to assess, they are often referred to as Variants of Uncertain Significance 





























her direct relatives [Sijmons et al., 2013]. For this reason it is of great importance to develop 
approaches for the diagnostic assessment of VUS in MMR genes [Rasmussen et al., 2012].
We have previously described an in vivo, genetic screen-based approach which combines 
the large-scale mutagenesis and identification of critical amino acids of Msh2 to generate 
“reverse diagnosis catalogs” [Drost et al., 2013]. Such a catalog enables us to judge the 
importance of residues in MMR proteins for its function, and aids in the rapid assessment 
of pathogenicity of VUS. Furthermore, the missense mutant cell lines that are generated in 
such a screen may serve as tools to study the mechanisms of MMR. Here, we describe the 
construction and validation of a reverse diagnosis catalog for the mismatch repair protein 
Msh6, and show the applicability of such an approach for the diagnostic assessment of 
MSH6 VUS. Additionally, we make use of the generated cell lines to study (intra)molecular 
signaling in MutSα, describe a large panel of characterized mutants and show that most 
mutated residues are required for mismatch binding in vitro.
RESULTS
To generate a prototype Msh6 reverse diagnosis catalog, we applied a stepwise procedure 
[Drost et al., 2013]. To randomly introduce mutations in Msh6, mouse embryonic stem 
cells (mESC) heterozygous for Msh6 (Msh6+/-; [de Wind et al., 1999]) were treated with 
the point mutagen N -ethyl-N -nitrosourea (ENU). ENU is a suited mutagen for this screen, 
as it induces a wide spectrum of point mutations [Jansen et al., 1994] and a relatively low 
amount of loss-of-heterozygosity (LOH; [Borgdorff et al., 2005]). After ENU treatment, 
cells that have lost functional MMR are selected using 6-thioguanine (6-TG), which is a 
nucleotide analog to which MMR-deficient cells are tolerant [Swann et al., 1996]. As 6-TG 
also selects for Hprt mutants, such mutants were selected against by culturing the cells 
in hypoxanthine-aminopterin-thymidine-supplement-containing medium. We screened 
against clones that lost functional MMR due to LOH of the Msh6 locus by means of an 
allele-specific PCR. The remaining clones presumably have lost functional MMR due to an 
ENU-induced inactivating nucleotide substitution in the Msh6 gene. 
In this work, we have focused specifically on amino acid substitutions, as such proteins 
do not only allow us to assess pathogenicity of VUS in MSH6, but also to perform functional 
studies. To identify such substitutions, we selected clones that retained expression of full-
length Msh6 cDNA, as judged by reverse transcription-PCR, and sequenced the complete 
Msh6 open reading frame of these clones. This led to the identification of 76 clones that 
carried a missense substitution, reflecting 51 unique substitutions, affecting 45 residues. All 
of these were compiled into a reverse diagnosis catalog (Figure 1 and Table 1). 
The mapping of the substitutions on the Msh6 protein showed that, in contrast to Msh2 
[Drost et al., 2013], substitutions cover all domains (Figure 1). Substitutions in the mismatch 
binding domain (MBD) of Msh6 are abundant, as >30% of all substitutions found are located 
here. These substitutions include residue F431, which was shown to contact mismatches directly 
[Bowers et al., 1999; Dufner et al., 2000; Warren et al., 2007], but also residues involved in non-
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Table 1. A Pilot Reverse Diagnosis Catalog of Msh6.
Mutation¥ cDNA* LOVD† Mutation¥ cDNA* LOVD†
E264V c.791 A>T C691R c.2071 T>C C694R
L310F c.927_928 delinsTT R769W c.2305 C>T
W371R c.1111 T>A L770P c.2324 T>C
W412R c.1233 T>C c.2308 T>C
V423G c.1268 T>G L818P c.2453 T>C
F431L c.1291 T>C L872P c.2615 T>C
c.1293 T>G S881T c.2641 T>A
F431S c.1292 T>C I964K c.2891 T>A 
H436R c.1307 A>G Y991S c.2972 A>C 
D438E c.1314 T>A Y1003N c.3007 T>A
L448P c.1343 T>C L449P T1005I c.3014 C>T
H457Y c.1369 C>T N1134K c.3402 T>A
Q484K c.1450 C>A M1135K c.3404 T>A
Q484R c.1451 A>G G1137D c.3410 G>A G1139S
V507E c.1520 T>A V509A G1137S c.3409 G>A
V508E c.1523 T>A S1139P c.3415 T>C
R510G c.1528 A>G L1141P c.3422 T>C
I515N c.1544 T>A I516N L1154R c.3461 T>G
G519V c.1556 G>T G1155D c.3464 G>A G1157S
G519D c.1556 G>A C1163R c.3487 T>C
T520K c.1559 C>A L1165P c.3494 T>C
G556D c.1667 G>A G1176D c.3464 G>A
V557D c.1670 T>A D1211G c.3632 A>G D1213V
L636P c.1907 T>C D1211E c.3633 T>A
L678P c.2033 T>C T1217I c.3650 C>T T1219I
G683D c.2048 G>A H1246R c.3737 A>G H1248D
V685D c.2054 T>A
¥ Boldface represents the mutants included in the validation panel. Amino acid numbering is based on the 
Msh6 GenBank reference sequence NP_034960.1 with +1 corresponding to the translation initiation codon.
* Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the translation 
initiation codon in the Msh6 GenBank reference sequence NM_010830.2.
† Substitutions reported in patients suspected of LS, as described in the Leiden Open Variant Database 
(LOVD). In bold: identical substitution found in reverse diagnosis catalog and LOVD, allowing to assess 
pathogenicity to the patient VUS. Amino acid numbering is based on the MSH6 GenBank reference 
sequence NP_000170.1 with +1 corresponding to the translation initiation codon.
specific contacts with the DNA backbone such as L448, V507, V508 and R510 [Warren et al., 
2007]. Besides from residues in the MBD, residues in other critical domains are overrepresented 





























(Figure 1A). Furthermore, residues R769 and L770 were proposed to be important for signal 
transduction between ATPase and DNA binding domains [Warren et al., 2007]. In addition, 
we and others have shown the importance of residue T1217 for mammalian [Yang et al., 2004; 
Drost et al., 2012; Geng et al., 2012] and S. cerevisiae MMR [Das Gupta and Kolodner, 2000; 
Hess et al., 2006]. Finally, functional defects of substitutions at the S. cerevisiae equivalents of 
Q484 [Das Gupta and Kolodner, 2000] and H1246 [Hess et al., 2006; Cyr and Heinen, 2008] 
were shown before. These observations combined suggest that the Msh6 residues identified in 
the screen performed here are enriched for critical/important residues.
Figure 1. A Pilot Msh6 Reverse Diagnosis Catalog. (A) A schematic representation of all inactivating missense 
substitutions in Msh6 identified in this screen. All domains were adapted from [Warren et al., 2007]. The top 
and bottom of the figure shows an alignment of the MBD and ATPase domains of human and mouse Msh6, 
highlighting residues that were mutated in the screen described here (orange boxes). Numbers reflect amino acid 
numbering. (B) Mapping of residues mutated in this screen to the MutSα crystal structure.  In wheat color, MSH6; 
in cyan, MSH2. Mutated residues are shown as spheres. Spheres are colored based on the domain the residue is part 
of (see legend in figure). The MSH6 crystal structure starts from residue 362, therefore not all residues are depicted.
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Reverse Diagnosis Catalogs Aid To Assign Pathogenicity to MSH6 VUS
To investigate the applicability of our screen for the diagnosis of VUS in MSH6, we aligned 
the substitutions in our catalog with those in the Leiden Open Variation Database (LOVD; 
[Fokkema et al., 2011]). This database contains a large collection of variants in MMR genes 
found in humans, irrespective of their pathogenicity. Of the 45 residues affected in our 
screen, eight are represented in the LOVD. More precisely, the four substitutions Msh6-
L449P, I515N, C691R and T1217I from our screen are the functional equivalents of the 
human MSH6-L449P, I516N, C694R and T1219I alleles in the LOVD.  This result strongly 
suggests that these human alleles are pathogenic and provides support for the applicability 
of the Msh6 reverse diagnosis catalog to identify pathogenic human MSH6 variants. 
Reverse Diagnosis Catalog-Derived Cell Lines Show Hallmarks  
of MMR Deficiency
To validate this screen experimentally, we have tested a validation panel of cell lines for 
phenotypic hallmarks of MMR deficiency. The panel was established from cell lines that carry 
substitutions at residues that are represented in the LOVD, either as an identical or different 
substitution (Table 1). MMR deficient cells often show instability of simple repeat sequences, 
a phenotype referred to as microsatellite instability (MSI). Even though MSI is considered a 
diagnostic hallmark of LS cancers [Boland and Goel, 2010], MSH6 deficient tumors show only 
low levels of MSI due to functional redundancy of MutSα with another heterodimer, MutSβ. 
This heterodimer is composed of MSH2 and MSH3 and can partly substitute for MutSα in 
the repair of IDLs. Higher levels of MSI can only be detected in cells or tumors expressing 
dominant negative Msh6 alleles, which interfere with both MutSα and MutSβ function. We 
tested for MSI in the validation panel by measuring the size of different microsatellites in 40-50 
subclones of each line. We detected low levels of MSI in all missense mutant cell lines similar 
to the Msh6-/- control line, suggesting that these lines have an Msh6-like MSI phenotype.
Due to the inability to repair replication errors, MMR deficient cells have a spontaneous 
mutator phenotype [Jiricny, 2013]. We therefore measured mutant frequencies at the Hprt 
reporter gene. All tested clones displayed a spontaneous mutator phenotype that is significantly 
higher than the Msh6+/- control line. We were unable to measure mutant frequencies in the 
Msh6-V508E line due to low cloning efficiency of this line. The T1217I allele displayed highly 
elevated mutation frequencies, which may suggest a dominant-negative phenotype.
These lines are also methylation tolerant, as they were selected for using 6-TG. Therefore, we 
conclude that the cell lines in this validation panel have all hallmarks of cellular MMR deficiency. 
Incidental Lack of Correlation Between In Vivo and In Vitro Phenotypes
To directly prove causality of the mutated residues in Msh6 for loss of MMR, we used a 
wild-type human MSH6 cDNA as a template to recreate the mouse Msh6 mutants by site-
directed mutagenic PCR in the human gene. This was followed by in vitro transcription and 
translation to create “humanized” MSH6 mutant proteins. These proteins were dimerized 





























MSH2/MSH6-deficient human cancer cell line LoVo [Drost et al., 2012]. Out of the 11 
alleles tested, 8 mutant proteins were unable to complement the LoVo cell extract (Fig. 3C). 
This result provides direct and conclusive evidence for the causality of those ENU-induced 
amino acid substitutions in Msh6 for MMR deficiency. Remarkably, the D1211E, D1211G 
and H1246R alleles restored MMR to levels not significantly different from wild type. This 
may imply that these alleles confer MMR defects that are not detectable in the in vitro MMR 
assay, such as in protein stability or in nuclear localization.
Missense Substitutions In Msh6 Typically Impair Mismatch Binding
To gain insights into the mechanism of MMR loss in the missense mutant cell lines we have 
generated we investigated protein expression levels by Western blotting. This revealed that 
~40% of all missense substitutions destabilize Msh6, leading to either a strong reduction or 
absence of Msh6 protein (not shown). This suggests that in these clones defective protein 
folding and/or stability is causal for MMR loss. 
From the remaining clones that had retained (near) normal Msh6 expression levels, we 
tested the ability of these mutant proteins to perform the earliest step in MMR: mismatch 
binding. To do so, we tested the binding of cytoplasmic extracts to a G·T mismatched probe 
in an electrophoretic mobility shift assay. Of the 29 mutants tested, 21 lost the ability to bind 
to mismatched DNA (Figure 2A), suggesting that MMR deficiency in these clones is a result 
of either defective mismatch binding or of defective overall DNA binding. This included the 
earlier mentioned substitutions at residues F431, V507, V508 and R510 that contact either 
the mismatch or DNA backbone, but also residues not directly implicated in mismatch/
DNA binding such as L770, M1135, G1155D and others (Figure 2A). This result suggests 
that for these missense mutant proteins, defective mismatch binding is the mechanistic 
basis for MMR deficiency.
Since cell extracts from mutant lines L310F, S1139P, D1211E, D1211G, T1217I and H1246R 
are proficient for mismatch binding we tested the ability of these cell extracts to perform a 
subsequent event in MMR: to form a sliding clamp after ATP binding. Sliding clamp formation 
leads to a loss of binding to heteroduplex DNA. Of the tested extracts, only T1217I showed a 
defect in ATP-induced mismatch release, suggesting that this allele has decreased capability 
of forming sliding clamps. Since L310F, S1139P, D1211E, D1211G and H1246R show normal 
sliding clamp formation, this suggests that these alleles do not have a (detectable) MMR defect, 
or a defect downstream of sliding clamp formation, such as  in MutLα recruitment.
To investigate whether the mentioned alleles indeed have an MMR defect downstream 
of ATP binding, and to confirm the MMR defect in the other alleles, we tested a selection 
of these alleles as “humanized” MSH6 alleles in the in vitro MMR assay described earlier. 
This experiment showed that the majority of alleles were unable to rescue the in vitro MMR 
defect of LoVo cell extracts, supporting their repair deficiency. In addition, like the previously 
described alleles D1211E, D1211G and H1246R, allele L310F rescued repair efficiency to wild 
type levels. As mentioned, this may imply that this allele confers MMR defects that are not 




Reverse Diagnosis Catalogues As Tools For MSH6 VUS Diagnosis
Assessing pathogenicity of VUS provides certainty to carriers. In contrast, relatives who do not 
carry the VUS are liberated from the burden of extensive screening procedures. Now that Next 
Generation Sequencing technologies are becoming more prevalent, also in clinical genetics, 
the prevalence of identified VUS is likely to increase [Heinen, 2010; Sikkema-Raddatz et al., 
2013]. In this work, we describe a genetic screening procedure that identifies critical residues 
in Msh6, which aids in assessing pathogenicity to MSH6 VUS. The data from such a screen 
may integrate in current diagnostics by becoming a part of diagnostic trees for MMR gene 
VUS [Kansikas et al., 2011; Rasmussen et al., 2012] and/or Bayesian analyses, which integrate 
various data sources for classifying VUS into a single model [Goldgar et al., 2008].
In our previous study, 10 out of the 23 (~44%) mutated residues we identified in the Msh2 
protein were represented in the LOVD [Drost et al., 2013]. In this study, only 8 out of the 45 
residues (~18%) in Msh6 are represented in the LOVD. This difference in LOVD representation 
may reflect an ascertainment bias in the LOVD. Due to redundancy with MSH3, inactivating 
Figure 2. Cell Lines From The Reverse Diagnosis Catalogs Shows Cellular Hallmarks Of MMR Deficiency. 
(A) Microsatellite instability analysis of Msh6 missense mutant cell lines. The PCR amplicon size of subclones 
is depicted for three different microsatellites. (B) Assessment of spontaneous mutator phenotypes at the Hprt 
gene of Msh6 missense mutant cell lines and controls. Bars represent mean Hprt mutant frequencies ± SEM. *p 
< 0.05, **p< 0.01, ***p<0.001 compared with the Msh6+/- line. (C) MMR activity of in vitro recreated mutant 
humanized MSH6 proteins. These proteins were tested for the repair of a G·T mismatch after addition to an 
MSH2/MSH6-deficient human cell extract. Mock: mock Msh2/Msh6 expression. Bars represent mean ± SEM. 





























mutations in MSH6 may be less penetrant in suspected LS patients and remain under detected. 
This is also a consequence of the lack of sensitivity of the Besthesda criteria, a set of criteria used 
to clinically diagnose LS patients, to identify MSH6 mutation carriers [Sjursen et al., 2010].
Discrepancies Between Methylation Tolerance And MMR Status
Even though all cell lines generated in this study are 6-TG tolerant, we have been unable to 
show in vitro MMR deficiency for several alleles (Figure 3C). Remaining alleles will be tested 
for in vitro repair capacity in the near future. The discrepant results between in vivo and in 
vitro repair may have different explanations. Firstly, these alleles may infer in vivo MMR 
defects that are not detected in the in vitro assay, such as defects in nuclear localization. 
Therefore, the repair proficient variants in the in vitro assay may reflect false-negatives, 
strengthening the need for an in vivo assay such as the Reverse Diagnosis Catalogs. Indeed, 
residue L310 was previously implicated in nuclear localization [Gassman et al., 2011]. 
Figure 3. Defective Mismatch Binding Is A Frequent Cause Of MMR Deficiency Binding of control and mutant 
Msh6 cell extracts to a G·T mismatch within a double-stranded oligonucleotide probe in an electrophoretic 
mobility shift assay. Bars represent  mean±SEM. ATP-induced mismatch release of Msh6-mutant cell extracts 
was tested in an electrophoretic mobility shift assay. ATP (1.25 mM) was added after allowing  the proteins to 
bind to the probe. Bars represent mean±SEM. MMR activity of in vitro recreated mutant humanized MSH6 
proteins. These proteins were tested for the repair of a G·T mismatch after addition to an MSH2/MSH6-deficient 
human cell extract. Mock: mock Msh2/Msh6 expression. Bars represent mean ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001 compared with the mock reaction.
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Secondly, these alleles may confer so-called separation-of-function phenotypes, uncoupling 
apoptosis from repair [Lin et al., 2004; Yang et al., 2004]. A third explanation is that there 
is only a minor, difficult to measure, drop in MMR efficiency that is sufficient to induce 
methylation tolerance but insufficient to abolish repair [Claij and te Riele, 2002]. In the latter 
two cases, the induction of methylation tolerance is still highly relevant for LS diagnosis, 
since this phenotype alone may predispose to cancer [Lin et al., 2004; Yang et al., 2004].
The Msh6-T1217I Allele Is Not A Separation-Of-Function Allele
The T1217D allele was previously described to be repair deficient, but methylation sensitive and 
was termed a separation-of-function allele, as it uncouples cell death from repair [Yang et al., 2004]. 
Since our screen selects for methylation tolerance the finding of a very similar allele, T1217I, is 
surprising. The T1217D allele is capable of mismatch binding, but incapable of recruiting MutLα 
[Geng et al., 2012]. This may be related to its weak ability to bind ATP and the subsequent inability 
to release mismatches and form a sliding clamp [Hess et al., 2006; Geng et al., 2012]. MSH2 or 
MSH6 alleles harboring ATP-binding defects often confer dominant-negative phenotypes [Das 
Gupta and Kolodner, 2000; Hess et al., 2002; Yang et al., 2004; Martín-López et al., 2012; Drost et 
al., 2013]. This is corroborated by cancer predisposition in Msh6+/T1217D mice, high microsatellite 
instability in tumors of Msh6T1217D/T1217D mice and inhibition of IDL repair in in vitro assays where 
cell extracts from wild type and Msh6T1217D/T1217D cells are mixed [Yang et al., 2004]. The T1217I 
allele from our screen may also have a dominant negative effect, as judged from high spontaneous 
mutation frequencies (Figure 2B), (possibly) increased MSI compared to Msh6-/- cells (Figure 2A) 
and a defect in ATP-induced mismatch release (Figure 2B). It is plausible that the persistence of 
Msh6-T1217D on DNA impedes cellular processes other than MMR, such as transcription and 
replication. If this is true, one would predict increased spontaneous apoptosis in cells carrying 
this allele compared to cells either wild type or deficient for Msh6, which indeed can be deduced 
from experimental data [Yang et al., 2004]. Therefore, the published apoptosis after treatment 
with methylating agents in the Msh6T1217D/T1217D cells may not reflect a true separation-of-function, 
but merely a consequence of decreased overall cellular fitness.
Inactivating Substitutions in Msh6 Cluster in the MDB and ATPase 
Domain But Are Absent in The N-Terminus
The inactivating substitutions identified in Msh6 are distributed across the protein with 
hotspots in the mismatch binding and ATPase domains, while mutants in the N-terminus 
seem underrepresented. These observations may reflect a bias in our screen, but may also 
represent genuine traits of Msh6. In support of the latter, in S. cerevisiae, the N-terminus of 
MSH6 is not required for nuclear localization, DNA binding, or mismatch discrimination 
[Shell et al., 2007b]. Thus, it is likely dispensable for methylation sensitivity, and substitutions 
in this area will not infer methylation tolerance. In addition, its structure is disordered, 
which likely makes it relatively tolerant to substitutions [Shell et al., 2007b]. Furthermore, 
its low importance is reflected by its poor evolutionary conservation, as prokaryotic MutS 





























The abundancy of inactivating substitutions in the Msh6 MBD is in contrast with the pilot 
reverse diagnosis catalog we generated for Msh2, in which inactivating substitutions in the 
Msh2 MBD were virtually absent. These findings are supported by the notion that residues 
in MSH6, but not in MSH2, contact the mismatch [Bowers et al., 1999; Dufner et al., 2000; 
Warren et al., 2007] and that MSH6 is the monomer that determines substrate specificity 
[Shell et al., 2007a]. 
Mismatch Binding and Intramolecular Signaling
The binding of a mismatch by MutSα is one of the earliest events in the recognition of 
replication errors by DNA Mismatch Repair. As mentioned, previous studies have shown 
that Msh6 is the monomer that contacts the mismatch. Several well-characterized residues 
are involved either in directly binding the mismatch or in non-specific DNA contacts. 
Structural studies have shown that only a subset of residues are in direct contact with the 
mismatched DNA, especially between residues 400-470 [Warren et al., 2007]. We now show 
that an unexpectedly high proportion of residues throughout Msh6 are either directly or 
indirectly involved in mismatch binding (Figure 3c).
When keeping the crystal structure data in mind, the most plausible explanation for the 
involvement of residues distal from the MBD in mismatch binding is a role either structural, 
in conformational changes and/or in intramolecular signaling. Since the proteins we have 
tested are stable in Western blots, there are only minor structural changes expected. Such 
structural changes may influence mismatch binding in an indirect way. As an example, 
residues Y1003 and T1005 are directly in front of an long α helix in Msh6 that spans between 
the clamp and ATPase domains. Mutating these residues may hinder the movement of these 
domains. In this light, conformational changes in MutSα may not only be important after 
mismatch binding, but also during or before mismatch binding. Further research is required 
to elucidate the exact effects of these substitutions on the biochemistry of MMR.
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MATERIALS & METHODS
Generation of Reverse Diagnosis Catalogs for Msh6
Reverse diagnosis catalogs were generated as described [Drost et al., 2013]. In brief, 5x106 
Msh6+/- cells were  cultured on irradiated feeder cells in Knockout-DMEM (Gibco). These cells 
were treated with 0,2 mg/ml ENU (Sigma-Aldrich) for 2h, or mock treated, and subsequently 
cultured for a week. Then, 2x106 cells were seeded per T90 followed by dual brief 40 μM 6-TG 
treatments (Sigma-Aldrich) for 4h, in a 7-day interval. Cells were culture in hypoxanthine-
aminopterin-thymidine (HAT)-supplement containing medium (Gibco) to select against 
Hprt mutants, and surviving clones were isolated and expanded. These clones were screened 
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against LOH by an allele specific PCR for MSH6. The full MSH6 ORF of remaining clones 
expressing full length cDNA was sequenced after RT-PCR and PCR amplification.
Crystal Structure Modeling
Crystal structures were visualized and edited using PyMOL software (Delano Scientific), 
using the Protein Database file from the MutSa crystal structure (Molecular Modeling 
Database ID #53938) [Warren et al., 2007].
Determination of Genomic Mutator Phenotypes 
Mutant frequencies at the Hprt reporter gene were measured as described [Drost et al., 
2013]. Briefly, cells were cultured in HAT-containing medium for two passages to eliminate 
pre-existing Hprt-mutants. Cells were then grown in the absence of HAT for three passages 
to allow spontaneous mutagenesis. Hprt mutants were subsequently selected for by a 
continuous 60 μM 6-TG treatment. 6-TG resistant clones were stained and scored after 14 
days, and counts were corrected for cloning efficiencies.
Microsatellite instability was determined by isolating ~50 subclones of each line. 
Genomic DNA of these subclones was isolated by Proteinase K lysis, and microsatellite 
sizes were measured after PCR amplification and fragment analysis as described [Bacher et 
al., 2005]. Data were analyzed using GeneMarker software (Softgenetics).
In Vitro MMR Assays, Western blotting and Electrophoretic Mobility Shift 
Assays.
All biochemical procedures were carried out as described [Drost et al., 2013].
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Variants of Uncertain Significance (VUS) pose a major problem not only in Lynch 
syndrome diagnostics, but in clinical genetics in general [Spurdle, 2010; Rasmussen et al., 
2012; Sijmons et al., 2013]. A lack of diagnostic assessment of VUS leaves carriers and 
both affected and unaffected relatives in uncertainty regarding their disease status. This, 
combined with the surveillance procedures that such patients and all relatives (both carriers 
and non-carriers) are enrolled in pose a physical and psychological burden on families, but 
also a burden on the preventive health care apparatus. 
The current record of variants in DNA mismatch repair genes is a reflection of 
sequencing efforts from the last few decades [Fokkema et al., 2011; Plazzer et al., 2013]. From 
a diagnostic point-of-view, LS families with many disease cases were probably genetically 
tested first. This likely has resulted in an ascertainment bias where mainly mutations that 
completely inactivate MMR and are highly penetrant have been identified, such as nonsense 
of frameshift mutations. The advent of Next Generation Sequencing technologies has made 
genetic testing easier, cheaper and faster. This will likely lower the criteria for sequencing, 
which will further increase the incidence of VUS [Heinen, 2010; Rasmussen et al., 2012; 
Sikkema-Raddatz et al., 2013]. For these reasons, the development and use of robust and 
accessible approaches to diagnose pathogenic VUS is becoming increasingly important. 
This will enable the implementation of preventive and curative healthcare that is targeted 
only to carriers of pathogenic MMR gene VUS. Meanwhile, unaffected relatives of such 
carriers can be liberated from the burden associated with the uncertain pathogenicity of the 
VUS while unwarranted inflow into preventive healthcare systems is reduced.
Integration Of Novel Assays For Functional Analysis In Current Lynch 
Syndrome Diagnostics
Current LS diagnosis protocols are aimed at determining the inactivating mutation in a 
DNA MMR gene through genetic testing (Chapters 1 and 2). Once such an inactivating 
mutation has been found, LS diagnosis is completed. In case a VUS is found, LS diagnosis 
is halted. To assist geneticists in subsequent diagnostics, we and others have proposed 
additional steps to the current diagnostic tree (discussed in Chapter 2; [Couch et al., 
2008]). We have proposed that, once a VUS has been found, the allele is first tested in 
an in vitro MMR assay (Chapters 3-5) and is simultaneously evaluated using in silico 
analyses [Tavtigian et al., 2008; Thompson et al., 2012b]. As the in vitro MMR assay 
covers (nearly) all aspects of canonical MMR and is relatively quick, this assays seems 
the most feasible approach. Furthermore, owing to the relative simplicity of this assay it 
may be implemented in multiple labs globally. Based on preliminary data the approach 
proposed above appears to be a powerful one for the diagnostic assessment of MMR gene 
VUS [Kansikas et al., 2011].
To integrate the in vitro assay in current LS diagnostics, its output may be integrated in 
a five-class classification system [Plon et al., 2008]. These classes can replace poorly defined 
terms such as ”VUS”, “neutral” and “pathogenic” and may aid clinical management by 



















•	 Class 5 variant - Pathogenic, > 99% probability of pathogenicity 
•	 Class 4 variant - Likely Pathogenic, 95-99% probability of pathogenicity 
•	 Class 3 variant - Uncertain, 5-95% probability of pathogenicity 
•	 Class 2 variant - Likely Neutral, 0.1-5% probability of pathogenicity 
•	 Class 1 variant – Neutral < 0.1% probability of pathogenicity
A five-class classification system can be established by combining multiple criteria for 
assessing pathogenicity to VUS, including well-established ones such as family history, 
immunohistrochemistry and microsatellite instability (MSI), but also in silico assays [Tavtigian 
et al., 2008] and the in vitro MMR assay [Drost et al., 2010, 2012]. These data sets are then 
integrated into a single statistical model [Plon et al., 2008]. For the assays integration and 
validation, the assay should be evaluated prosprectively by large-scale validation efforts that 
include performing the assay on a large number of substitutions, classified in either class 1 or 
class 5, without the use of functional assays. Such a validation effort should aid in determining 
positive and negative predictive values and Likelyhood Ratios, which will eventually help to 
determine a posterior probability of pathogenicity [Thompson et al., 2012a, 2012b]. 
The in vitro MMR assay in its current status has a binary outcome. MMR variants can be 
either repair deficient (not significantly different from a repair deficient control) or repair 
proficient (significantly higher than a repair deficient control). When integrating the in 
vitro MMR assays’ output into a five-class classification system, its readout (percentage of 
repair compared to wild type) could be calibrated to be translated into a probability in favor 
of pathogenicity and may serve as a constant variable. 
The in vitro MMR assay could be a powerful tool to diagnose VUS in MMR genes, 
however, the in vitro nature of the assays has its pitfalls. The assay is not able to pick 
up certain in vivo defects and therefore, in case a VUS is repair proficient in vitro the 
diagnostic value of the in vitro MMR assay is inconclusive and more specialized assays, 
such as protein stability [Perera and Bapat, 2008], nuclear localization assays [Raevaara 
et al., 2005; Andersen et al., 2012; Borràs et al., 2013] and splicing assays [Tournier et al., 
2008] are required to assess pathogenicity [Rasmussen et al., 2012]. In this regard, the 
Reverse Diagnosis Catalogs (RDC) may contribute to diagnostic assessment. The a priori 
knowledge of essential residues in MMR proteins may be valuable information in identifying 
pathogenic missense mutations. In case a human VUS is identified in the RDC, this would 
imply a high probability of pathogenicity of that VUS. Once Likelyhood Ratios for the 
RDC are determined and the RDC is incorporated in a five-class classification system, 
the identification of a certain substitution in the RDC should serve as strong evidence to 
classify a VUS as class 4 or 5.
To integrate both the in vitro assay and the Reverse Diagnosis Catalogs (RDC), these 
assays could be cross-validated. The RDC may then serve as a “golden standard” of 
pathogenic alleles, to which the in vitro assay may be calibrated against. In this manner, the 
RDC are a substitute for patient-derived inactivating alleles. Taking this one step further, the 
cell lines made in the RDC screens could be used to generate mice to determine penetrance 
of the alleles, which then can be linked to in vitro repair efficiencies.
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To continue along this line, the RDCs may serve as a standard not only to validate the in 
vitro assay, but also to validate in silico algorithms such as MAPP-MMR [Chao et al., 2008], 
PolyPhen [Adzhubei et al., 2010] or the combination of both [Thompson et al., 2012b]. 
Once the RDC protocol is adapted to also identify disrupting intronic variants or splice site 
mutations (see below), the data from the RDC may also aid in validating in silico splice site 
prediction software [Vreeswijk et al., 2009; Vreeswijk and van der Klift, 2012].
Towards Comprehensive Reverse Diagnosis Catalogs
This thesis describes the generation of pilot RDCs for Msh2 (Chapter 6) and Msh6 (Chapter 
7). In order to generate saturated, comprehensive catalogs the methodology described in 
this thesis may be adapted in several ways.
First, mutations are introduced into the MMR genes using the mutagen N-ethyl-N-
nitrosourea (ENU). Even though ENU is a relatively wide-spectrum mutagen, using a single 
chemical for mutagenesis may not suffice to saturate a RDC. Higher saturation of the catalog 
could be reached by using additional drugs with a complementary mutagenic activity, 
such as 4-nitroquinoline N-oxide [Ryu et al., 1999] or 7,12-dimethylbenz[a]anthracene 
[Manjanatha et al., 1996]. ENU is not only a suited mutagen due to its diverse mutagenic 
activity, but also due to its property to induce only low amounts of loss of heterozygosity 
(LOH). Using other drugs may induce a higher proportion of LOH events, which will 
decrease the efficiency of the screen. Such an issue may be circumvented by putting selective 
pressure against LOH, by targeting a selectable marker directly next to the non-disrupted 
Msh2 and Msh6 alleles and using the generated cell lines for RDC development.
Second, the current protocol selects for MMR deficiency using 6-thioguanine (6-TG). 
Our experimental data suggests that the selection conditions applied may have been quite 
harsh, as only fully (Msh2-/--like) tolerance of MNNG was measured in all generated cell lines 
(Chapter 6). In future work, selection conditions could be further optimized. By applying a 
less stringent selection the protocol could be adjusted as such, so that alleles with intermediate 
levels of methylation tolerance can be selected for. In this way, the RDC could be extended from 
completely methylation tolerant, probably highly penetrant alleles, towards less penetrant 
alleles. In this respect, 6-TG could also be replaced by MNNG as a selection agent. Other have 
shown that cells tolerant to MNNG can still be proficient in repair [Claij and te Riele, 2002]. 
This could make MNNG a more appropriate drug to select for less penetrant alleles.
Finally, the RDC presented in this thesis are aimed completely at disruptive missense 
mutations as only those 6-TG-tolerant clones that retain expression of full-length cDNAs were 
sequenced. From a clinical geneticists’ point-of-view, additional types of VUS are of interest, 
such as intronic variants or splice site variants. To identify these, one would have to apply 
methods other than cDNA sequencing, such as sequencing of genomic DNA using a classical 



















Functional Assays in Fundamental Research
The assays we have developed will not only allow us to assess pathogenicity of VUS in MMR 
genes, but can also aid in functional studies of MMR. Especially the combination of both 
the in vitro assay and the RDC may help to identify novel functional residues/motifs in 
MMR proteins that are important for in vivo MMR. 
A very interesting allele that shows (relevant) discrepancies between in vivo and 
in vitro phenotypes was recently described by Li and co-workers [Li et al., 2013]. The 
PWWP domain in MSH6 helps to recruit MutSα onto chromatin by interacting with the 
histone mark H3K56me3. Knockdown of SETD2, the transferase that methylates H3K56, 
gives an MSI phenotype suggesting that SETD2 and H3K56me3 are upstream of MMR 
in vivo. MSH6 alleles with mutations in the PWWP motif are MMR deficient in vivo, but 
MMR proficient in the in vitro MMR assay, which might be explained by the difference in 
chromatin states of the DNA substrates. The identification and subsequent characterization 
of this type of alleles may provide new insights into the biochemistry of MMR. Such alleles 
may be identified in the RDC, by using a readout for in vivo MMR and, in parallel, testing 
those alleles in the in vitro MMR assay. The Msh6 RDC may have already identified such 
alleles. Msh6 alleles D1211E, D1211G and H1246R are repair proficient in the in vitro 
assay but show hallmarks of in vivo MMR deficiency (Chapter 7). These are interesting 
alleles for future research.
In Chapters 6 and 7 several methods are described for measuring MMR in vivo, such 
as MSI assessment and determining spontaneous mutation frequencies at a reporter gene. 
An alternative approach would be to introduce a fluorescent reporter such as a GFP, 
rendered out-of-frame due to a microsatellite preceding its ORF. In MMR deficient cells, 
this microsatellite will be unstable, rendering GFP into frame. Therefore, the amount of 
GFP proficient cells in a cell population will be a measure of the MMR capacity of the MMR 
allele(s) expressed in those cells [Koole et al., 2013].
Methylation Tolerance: Futile Cycling Or Direct Signaling?
The mechanism of the MMR-mediated toxicity of methylating agents has been under debate 
for many years now. The MMR field has been divided into two “camps”: One supporting the 
futile cycling model [Stojic et al., 2004; Mojas et al., 2007] and one supporting the direct 
signaling model [Yang et al., 2004; Yoshioka et al., 2006]. Even though both models are 
not mutually exclusive, several arguments are in favor of the futile cycling model. First, 
apoptosis after methylating agents is induced in the second S-phase after treatment, which 
suggests that a (DNA) intermediate from the first cell cycle is carried over to the second 
and only then induces apoptosis [Mojas et al., 2007]. Second, proteins such as ATM [Debiak 
et al., 2004], RAD51 and BRCA1 protect against apoptosis induced by methylating agents, 
which suggests that a DNA double-strand break is involved, which would be unexpected 
with the direct signaling model in mind. Third, methylation-induced apoptosis requires a 
full complement of MLH1 [Cejka et al., 2003] and the catalytic activity of EXO1 [Schaetzlein 
et al., 2013]. This suggests that a canonical MMR complex is required to induce apoptosis. 
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The major pieces of evidence in favor of the direct signaling model are 1) Binding of 
ATR, TopBP1 and CHK1, but not RPA, to chromatin after MNNG treatment in a MutSα 
and MutLα dependent manner [Liu et al., 2009], 2) Protein interactions between MutSα 
and ATR [Liu et al., 2009; Pabla et al., 2011], TopBP1 and CHK1, and between MutLα and 
TopBP1 [Liu et al., 2009], 3) The phosphorylation of CHK1 in the presence of O6-meG·T 
mismatches and MMR proteins in vitro in the absence of excision [Yoshioka et al., 2006] 
and 4) Separation-of-function alleles [Lin et al., 2004; Yang et al., 2004]. The relevance of the 
described protein interactions and chromatin loading briefly after MNNG is questionable, 
as ATR is only activated at later timepoints [Stojic et al., 2004] and, even if ATR would be 
activated at earlier timepoints, there is insufficient signaling to trigger apoptosis [Mojas et 
al., 2007]. The in vitro phosphorylation of CHK1 in the presence of O6-meG·T mismatches 
and MMR proteins, but in the absence of excision, is prone to artefacts. The absence of 
excision is measured in an in vitro MMR assay which is quantified on an agarose gel 
[Yoshioka et al., 2006]. In our experience, quantification on gel is not very sensitive and 
repair percentages of up to 10% can easily stay underdetected, which may suffice to trigger 
signaling in vitro. Therefore, the phosphorylation of CHK1 may still result from single-
stranded DNA and a more sensitive method would be required to rule out excision.
Perhaps the strongest evidence for the direct signaling model is the generation and 
characterization of two separation-of-function alleles in Msh2 [Lin et al., 2004] and Msh6 
[Yang et al., 2004]. Both of these alleles confer a phenotype that is characterized by repair 
deficiency, but methylation sensitivity. It should be noted, though, that both described cell 
lines show high levels of spontaneous apoptosis. This could be a consequence of the ability of 
these MMR alleles to bind DNA, but their inability to subsequently release the heteroduplex 
or the inadvertently bound homoduplex. This may lead to a dominant-negative phenotype, 
in which the persistently DNA-bound MMR alleles impede other cellular processes such 
as transcription and replication. Therefore, the proficiency to induce apoptosis may not 
reflect a true separation-of-function phenotype, but a consequence of decreased cellular 
fitness. An interesting piece of evidence in favor of the direct signaling model would be an 
allele that has the opposite phenotype: repair proficiency, but methylation tolerance. The 
RDC protocol would be a perfect approach to find such an allele, as the screen selects for 
methylation tolerance and, once a GFP reporter is introduced, allows for a high-throughput 
screening for repair proficiency. The pilot Msh2 and Msh6 RDCs that we generated 
(Chapters 6 and 7) argues against the existence of such alleles, as we have only found alleles 
that are repair deficient in vivo as well as methylation tolerant. Conversely, this could be a 
consequence of the limited numbers of alleles identified so far, and increasing the scale of 
the RDC may suffice to identify such alleles. 
Molecular And Clinical Testing And The Future Of Clinical Genomics
Next-generation sequencing technologies are becoming the primary tool in human genetics 
[Goldstein et. al, 2013; Katsanis et. al, 2013].  These technologies are reaching the point of 



















(personalized) medicine. The magnitude of data could lead to weakly justified claims of causality 
between genetic variants and disease [Goldstein et. al, 2013]. In this thesis, multiple methods are 
described that allow to determine causality of DNA variants for the cancer predisposition Lynch 
syndrome. Such methods may be instrumental in facilitating diagnosis in the upcoming age of 
personalized medicine, aiding in the future of clinical molecular diagnostics.
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Lynch syndrome (LS) is a hereditary syndrome that predisposes to various cancer types, 
including colon, endometrial, gastric, brain and urological cancers. The syndrome is caused 
by heterozygosity for a mutation that inactivates one of the DNA mismatch repair (MMR) 
genes MSH2, MSH6, MLH1 or PMS2. In a significant fraction of individuals suspected of LS 
a missense mutation or small in-frame deletion is identified in one of the MMR genes. Since 
the causality of such genetic variants is difficult to assess these are often referred to as variants 
of uncertain significance (VUS). The lack of classification of VUS precludes LS diagnosis. As 
a consequence, targeted chemoprevention and chemotherapy cannot be applied. In addition, 
when a suspected Lynch syndrome patient carries a VUS, all first-degree relatives enroll in 
lifelong periodic screening, irrespective of their mutation status. Screening poses a physical 
and psychological burden on these families, but also a burden on the preventive health care 
apparatus. For these reasons it is of great relevance to develop widely applicable, validated, 
and standardized approaches for the diagnostic assessment of VUS in MMR genes.
This thesis focuses on the development of in vitro and in vivo functional assays to enable 
diagnosis of VUS in MMR genes. Chapter 1 introduces the field of MMR by reviewing recent 
work on the biochemistry and the genetics of MMR. Furthermore, the genetics, phenotype, 
diagnosis and the implications of LS are reviewed. The thesis then continues with a discussion 
of recent advances in functional analysis of VUS in MMR genes (Chapter 2).
In Chapter 3, an in vitro assay is presented that functionally analyzes missense variants in 
MSH2 and MSH6. Missense variants found in patients suspected of LS are recreated as variant 
cDNAs in two sequential PCR reactions. The amplicons are then used as templates to produce 
variant proteins in an in vitro transcription/translation reaction. The variant protein is dimerized 
with its partner to create a heterodimer, and this dimer is used to complement a cell extract 
deficient for that heterodimer. This recombinant heterodimer and cell extract mixture are then 
supplemented with an MMR substrate: a plasmid containing a single, defined G∙T mismatch 
that disrupts a HinDIII restriction site. After the in vitro MMR reaction repair of the mismatch 
to A·T can be assessed by HinDIII digestion. Since the plasmid substrate is fluorescently labeled, 
accurate quantification of repair products can be performed on a fragment analyzer. 
The assay is technically validated by showing its reproducibility, by showing that the 
relevant proteins are present in (near) stoichiometric quantities and by showing that the 
assay has sufficient resolution to distinguish known pathogenic variants from polymorphic 
variants. The in vitro expressed variant proteins are not in excess, which should allow the 
detection of subtle repair defects. In the future, this may allow the diagnosis of variants with 
intermediate penetrance. The assay does not require molecular cloning, cell culture and use 
of bacteria. In addition, due to its relative simplicity, the ability to generate reagents in large 
quantities and due to its relatively high speed, this assay may be suited for integration into 
clinical diagnostic labs, which would be unique in the field of diagnosis of variants in cancer 
predisposition genes. We have adapted this assay for the functional analysis of VUS in the 









Due to the cell-free nature of the assay described above this assay may have some pitfalls. Thus, 
defects in splicing, in protein stability or nuclear localization are not detected. These drawbacks 
could lead to false negatives (variants that are repair proficient in the assay, while they are actually 
pathogenic). To circumvent these issues, we have established an additional protocol to classify 
VUS in MMR genes. We reasoned that the comprehensive knowledge of residues in MMR proteins 
that are essential for in vivo function could aid in classifying MMR gene VUS. Such knowledge 
would enable the a priori classification of VUS without the need for further functional analysis. 
To acquire such knowledge we have taken a genetic screen-based approach (Chapter 6). Cells, 
heterozygous for Msh2 due to targeted disruption of one of the alleles, are treated with a point 
mutation-inducing mutagen. After this, clones that have acquired an inactivating substitution 
at the Msh2 gene are selected for and the complete Msh2 open reading frame in these clones is 
sequenced to identify the causal mutation, and thereby the essential residue.
In this chapter we describe the generation and analysis of 26 of the above-mentioned 
cell lines, all carrying unique amino acid substitutions in Msh2. These substitutions affect 
23 residues. We show that 10 of these residues have previously been reported as mutated in 
humans, and 6 substitutions are identical at the protein level. This supports the applicability 
of this protocol for the identification of pathogenic missense variants identified in 
humans. We have further validated this approach by showing that these cell lines have all 
phenotypes of MMR deficiency including microsatellite instability, a spontaneous mutator 
phenotype and strong tolerance to SN1-methylating drugs. Furthermore, we show that these 
phenotypes are caused by a genuine MMR defect, as extracts from these cell lines cannot 
repair a mismatch on an artificial substrate. Since this phenotype can be rescued by addition 
of recombinant wild type Msh2/Msh6, this defect is indeed due to defects in Msh2/Msh6 
and not due to defects in other genes/proteins. In addition, the mutations found inactivate 
MMR in an in vitro MMR assay and are therefore causative for the phenotype. Moreover, 
we describe dominant-negative effects for two substitutions. Such a phenotype could be 
of particular relevance since in patients these substitutions may already confer cancer 
predisposition in a heterozygous state. This is corroborated by the phenotype of a carrier of 
one of these substitutions who shows an extended tumour spectrum (colon, ovary, breast, 
oesophagus) and a young average age of onset of cancer. Another finding in this work is 
that in a number of the MMR-deficient variants protein stability is not affected. This is of 
relevance since genetic testing in LS patients is often preceded by an immunohistochemical 
analysis of protein expression in the tumor. In case normal protein expression is found, no 
further genetic screening is performed. Our data suggest that this is not warranted.
In Chapter 7, we apply the genetic screening technique described in Chapter 6 to the 
MMR gene Msh6. We have generated 51 cell lines that carry unique amino acid substitutions 
in Msh6, affecting 45 residues. Similar to Chapter 6, we show that several of these substitutions 
are also identified in humans, which suggests pathogenicity for these alleles and supports 
applicability of this assay to identify pathogenic variants in MSH6.  A selection of these cell 
lines has been further validated and these lines display an MMR deficient phenotype, apparent 
from their elevated spontaneous mutation frequency and microsatellite instability. 
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To gain insights into the mechanism of loss of MMR in these lines we first investigated Msh6 
protein expression by Western blotting and found that ~40% of all substitutions destabilize 
Msh6. The lines that retained normal Msh6 protein expression were tested for their ability to 
perform mismatch binding. This revealed that, of the 29 mutants tested, 21 have lost the ability 
to bind mismatched DNA, suggesting that defective mismatch binding is a major mechanism 
of loss of activity. These mutants included substitutions at residues that have previously been 
implicated in mismatch binding in crystallographic studies, but also substitutions that have not 
been implicated in this process. The proteins that do bind mismatches generally are proficient 
in sliding clamp formation, with the exception of substitution T1217I. This suggests that these 
substitutions have an MMR defect downstream of sliding clamp formation, such as in MutLα 
recruitment. We propose a model in which mutations hinder (minor) conformational changes 
that may be required during or before mismatch binding.
The thesis ends with a summarizing discussion and a reflection on future perspectives 
(Chapter 8). This thesis describes multiple methods that allow a functional analysis of 
MMR gene VUS. These methods allow to determine pathogenicity of such variants and may 
be instrumental in facilitating diagnosis in the upcoming age of personalized medicine, 
helping to shape the future of clinical molecular diagnostics. In addition, these methods 











Lynch syndroom (LS) is een erfelijk syndroom dat aanleg veroorzaakt voor het ontwikkelen 
van verschillende soorten kanker, waaronder dikke darm-, endometrium-, maag-, hersen- 
en urologische kankers. Het syndroom wordt veroorzaakt door heterozygositeit voor een 
mutatie die één van de DNA mismatch herstel (MMH) genen MSH2, MSH6, MLH1 of PMS2 
inactiveert. In een significante fractie van individuen die worden verdacht van LS wordt een 
missense mutatie of een kleine in-frame deletie in een MMH gen geïdentificeerd. Omdat 
de causaliteit van zulke genetische varianten moeilijk te bepalen is wordt er vaak naar deze 
varianten verwezen als “varianten met onzekere significantie” (VOS). Het uitblijven van 
classificatie van VOS verhindert LS diagnose. Als gevolg kan er geen gerichte chemopreventie 
en chemotherapie worden toegepast. Daarnaast zorgt de detectie van een VOS in een LS-
verdachte ervoor dat al zijn/haar familieleden in levenslange periodieke screeningsprogramma’s 
terecht komen, ongeacht hun mutatiestatus. Dergelijke screenings vormen een lichamelijke 
en psychische last voor die families, maar ook voor de preventieve gezondheidszorg. Om 
deze redenen is het zeer relevant om breed toepasbare, gevalideerde en gestandaardiseerde 
toepassingen te ontwikkelen om VOS in MMH genen diagnostisch te kunnen onderzoeken.
Dit proefschrift richt zich op het ontwikkelen van in vitro en in vivo functionele assays 
om VOS in MMH genen te kunnen diagnosticeren. Hoofdstuk 1 introduceert het MMH veld 
door recent gepubliceerd werk over de biochemie en de genetica van MMH te bespreken. 
Daarnaast wordt de genetica, het fenotype, de diagnose en de implicaties van LS besproken. 
Het proefschrift gaat dan verder met een bespreking van de recente ontwikkelingen in de 
functionele analyse van VOS in MMH genen (Hoofdstuk 2).
In Hoofdstuk 3 wordt een in vitro assay gepresenteerd voor de functionele analyse 
van missense varianten in MSH2 en MSH6. Missense varianten die zijn gevonden in 
patiënten verdacht van LS worden gerecreëerd als variante cDNAs in twee opvolgende PCR 
reacties. De PCR producten worden dan gebruikt als template in een in vitro transcriptie/
translatie reactie. De hieruit resulterende eiwitten worden gedimeriseerd met hun partner 
om een heterodimeer te creëren, en deze dimeer wordt gebruikt om een cel extract te 
complementeren dat deficiënt is voor die bewuste heterodimeer. Deze mix van cel extract 
en (variante) heterodimeer wordt gesupplementeerd met een MMH substraat: een plasmide 
dat een enkele, gedefinieerde G·T mismatch bevat die een HinDIII restrictiesite verstoort. 
Na de in vitro MMH reactie kan reparatie van de mismatch naar A·T worden bepaald door 
HinDIII digestie. Omdat het plasmide substraat fluorescent  is gelabeld kunnen herstel 
producten nauwkeurig worden gekwantificeerd door middel van fragment analyse.
De assay is technisch gevalideerd door aan te tonen dat de assay reproduceerbaar is, dat 
de relevante eiwitten in vrijwel stoichiometrische hoeveelheden aanwezig zijn en door aan 
te tonen dat de assay voldoende resolutie heeft om bekende, pathogene varianten te kunnen 
onderscheiden van bekende polymorfismen. Het in vitro tot expressie gebrachte eiwit is 
niet in overmaat, wat het detecteren van subtiele herstel defecten mogelijk moet maken. 









penetrantie te kunnen diagnosticeren. De assay vereist geen kloneerwerk, geen celkweek 
en geen bacteriewerk. Door de relatieve eenvoud van de assay, de mogelijkheid de reagentia 
in grote hoeveelheden te produceren en door de relatieve hoge doorvoersnelheid, voldoet 
de assay aan de eisen om geïntegreerd te worden in klinisch diagnostische laboratoria, wat 
uniek zou zijn in het veld van diagnose van varianten in kanker predispositie genen. We 
hebben de assay tevens aangepast voor de functionele analyse van VOS in de MMH genen 
MLH1 (Hoofdstuk 4) en PMS2 (Hoofdstuk 5).
Door de cel-vrije aard van de assay die hierboven is beschreven, heeft de assay mogelijke 
nadelen. Defecten in pre-mRNA splicing, in eiwit stabiliteit of nucleaire eiwitlokalisatie 
worden niet gedetecteerd. Dit kan leiden tot vals negatieven (varianten die herstel proficient 
zijn in de assay, terwijl ze werkelijk pathogeen zijn). Om deze problemen te omzeilen hebben 
we een tweede protocol ontwikkeld om VOS in MMH genen te classificeren. We redeneerden 
dat de allesomvattende kennis van residuen in MMH eiwitten die essentieel zijn voor in vivo 
eiwitfunctie zou kunnen helpen bij het classificeren van VOS in MMH genen. Dergelijke 
kennis zou een a priori classificatie van VOS mogelijk maken, zonder verdere noodzaak 
voor functionele analyses. Om die kennis te verwerven hebben we voor een genetische 
screen als aanpak gekozen (Hoofdstuk 6). Cellen, heterozygoot voor Msh2 door een gerichte 
verstoring van één van de allelen, worden behandeld met een puntmutatie-inducerende stof. 
Vervolgens wordt er geselecteerd voor kloons die een inactiverende mutatie in Msh2 hebben 
opgelopen, het volledige open leesraam van Msh2 wordt gesequenced om de causale mutatie 
te identificeren, en hierbij ook het essentiële residu.
In dit hoofdstuk beschrijven we de generatie en analyse van 26 van de eerder beschreven 
cel lijnen, die allen unieke aminozuur substituties dragen in Msh2. Deze substituties hebben 
betrekking op 23 residuen. We laten zien dat 10 van deze residuen als gemuteerd zijn 
gerapporteerd in mensen, waarvan 6 substituties identiek zijn op eiwitniveau. Dit ondersteunt 
de toepasbaarheid van dit protocol op de identificatie van pathogene missense substituties 
in mensen. We hebben de aanpak verder gevalideerd door aan te tonen dat de gegenereerde 
cellijnen alle fenotypes hebben die passen bij MMH deficiëntie, waaronder microsatelliet 
instabiliteit, een spontaan mutator fenotype en sterke tolerantie jegens SN1-methylerende 
stoffen. Daarnaast tonen we aan dat dit fenotype wordt veroorzaakt door een echt MMH 
defect, omdat extracten van deze cellijnen een mismatch op een kunstmatig substraat niet 
kunnen herstellen. Dit defect kan weer gered worden door wild type Msh2/Msh6 aan het 
extract toe te voegen, wat aangeeft dat het MMH defect wordt veroorzaakt door defecten 
in Msh2/Msh6 en niet door defecten in andere eiwitten. Omdat de mutaties die we in de 
lijnen aantonen MMH inactiveren in een in vitro assay, zijn deze causatief voor het fenotype. 
Bovendien beschrijven we dominant-negatieve effecten voor twee substituties. Een dergelijk 
fenotype zou zeer relevant kunnen zijn, omdat deze substituties in dragers al voor kanker 
predispositie zou kunnen zorgen in een heterozygote staat. Dit wordt ondersteund door het 
fenotype van een drager van één van deze mutaties, die een verlengd tumor spectrum vertoont 
(dikke darm-, eierstok-, borst- en slokdarmkanker) en een jonge leeftijd waarop deze kankers 
zich manifesteren. Een andere vinding in dit werk is, dat enkele MMH-deficiënte varianten 
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eiwitstabiliteit behouden. Dit is relevant omdat het genetisch diagnosticeren van LS patiënten 
vaak vooraf wordt gegaan door een immunohistochemische kleuring van de tumor van de 
patiënt. Wanneer er normale eiwitexpressie wordt gevonden, wordt er geen verdere genetische 
test uitgevoerd. Onze data suggereert dat dit ongegrond is.
In Hoofdstuk 7 passen we de genetische screen beschreven in Hoofdstuk 6 toe op het 
MMH gen Msh6. We hebben 51 cel lijnen gegenereerd die unieke aminozuur substituties 
bevatten in Msh6, die 45 residuen aantasten. Gelijk aan Hoofdstuk 6 laten we zien dat 
enkele van deze substituties in mensen zijn geïdentificeerd, wat pathogeniciteit voor deze 
allelen suggereert en de toepasbaarheid van deze assay voor de identificatie van pathogene 
varianten in MSH6 ondersteunt. Een selectie van deze cellijnen is verder gevalideerd en 
deze lijnen vertonen een MMH deficiënt fenotype, wat duidelijk wordt door de verhoogde 
spontane mutatie frequentie en microsatelliet instabiliteit.
Om inzichten te verkrijgen in het mechanisme van MMH verlies in deze lijnen, hebben we 
allereest Msh6 eiwitexpressie onderzocht door middel van Western blotting. Hieruit blijkt dat 
~40% van alle substituties Msh6 destabiliseren. Cel extracten van de lijnen met stabiele Msh6 
expressie zijn vervolgens getest op het vermogen om mismatches te binden. Dit toonde aan 
dat, van de 29 mutante extracten die zijn getest, 21 extracten niet in staat zijn om mismatches 
te binden. Dit suggereert dat een defect in mismatch binding een vooraanstaand mechanisme 
is voor verlies van MMH activiteit. Het verlies van mismatch binding werd aangetoond voor 
mutanten met substituties op residuen die eerder zijn geïmpliceerd in mismatch binding in 
kristallografische studies, maar ook voor residuen waarvan de implicaties in dit proces niet 
eerder zijn aangetoond. De eiwitten die nog mismatches binden zijn, over het algemeen, 
proficient in het vormen van een “sliding clamp”, substitutie T1217I uitgezonderd. Dit 
suggereert dat deze substituties een MMH defect hebben na sliding clamp formatie, zoals in 
het rekruteren van MutLα. We stellen een model voor, waarin mutaties op residuen (kleine) 
conformatie veranderingen verhinderen die noodzakelijk zijn vóór mismatch binding.
Dit proefschrift eindigt met een discussie en een reflectie op toekomstige perspectieven 
(Hoofdstuk 8). Het proefschrift beschrijft verschillende methoden om VOS in MMH genen 
functioneel te kunnen analyseren. Deze methodes stellen ons in staat de pathogeniciteit 
van zulke varianten te bepalen, kunnen diagnose faciliteren in het opkomende tijdperk 
van gepersonaliseerde gezondheidszorg, en helpen de toekomst te vormen in de klinisch 
moleculaire diagnostiek. Daarnaast leveren deze methoden het gereedschap om inzichten 
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